Antigen-binding molecules that bind to AAV particles and uses thereof

Abstract

Provided herein are anti-adeno-associated virus (AAV) antibodies and antigenic fragments thereof, as well as multispecific antibodies (e.g., bispecific antibodies) that bind to both the capsid of an AAV particle and molecules on a cell surface, related molecular complexes, affinity matrices, and pharmaceutical compositions, and methods for using them. Generally, the present disclosure provides antibodies that bind to the capsid of an adeno-associated virus (AAV) particle, as well as multispecific antibodies, such as bispecific antibodies, that can bind to both the capsid of an AAV particle and molecules on a cell surface (i.e., target molecules), and methods for using them.

Description

[Technical Field]

[0001] (CROSS-REFERENCE TO RELATED APPLICATIONS) CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application Nos. 63 / 387,876, filed December 16, 2023, 63 / 494,203, filed April 4, 2022, 63 / 520,508, filed August 18, 2023, and 63 / 578,925, filed August 25, 2023, the disclosures of each of which are incorporated herein by reference in their entirety.

[0002] (Sequence Listing) This application contains a Sequence Listing that has been submitted electronically in XML file format, which is incorporated herein by reference in its entirety. The XML copy, created on December 11, 2023, is named 250298_000568_SL and is 328,800 bytes in size.

[0003] FIELD OF THE INVENTION The present disclosure relates to antigen-binding molecules, including antibodies or antigen-binding fragments thereof, that bind to the capsid of adeno-associated virus (AAV) particles. In particular, the present disclosure provides multispecific antigen-binding molecules, such as multispecific antibodies, e.g., bispecific antibodies, or antigen-binding fragments thereof, that bind to molecules on the capsid and / or cell surface of AAV, as well as related molecular conjugates and pharmaceutical compositions. Methods for using the antibodies (e.g., multispecific antibodies), molecular conjugates, and / or pharmaceutical compositions disclosed herein are also provided. [Background technology]

[0004] Viral particles have emerged as vectors for gene therapy and disease treatment. Viral vectors, such as those based on the adeno-associated virus (AAV) genome, offer a promising platform for gene delivery. Despite advances in directing AAV infection, retargeting AAV as a gene delivery vehicle remains less than ideal, at least in part due to limited success in efforts to redirect vector tropism. The efficiency of AAV vector-mediated gene delivery to different cell types also varies greatly. One possible mechanism for inefficient AAV transduction of certain cells may be the lack of cellular receptor(s) that mediate viral binding and entry. There remains a need for selective and restricted targeting of AAV with enhanced cell binding and transduction capabilities. Summary of the Invention [Means for solving the problem]

[0005] In general, the present disclosure provides antibodies that bind to the capsid of adeno-associated virus (AAV) particles, as well as multispecific antibodies, e.g., bispecific antibodies, that can bind to both the capsid of AAV particles and molecules on cell surfaces (i.e., target molecules), and methods for their use. By binding to both the capsid of AAV particles and target cell surface molecules, the antibodies described herein can crosslink the virus to target cell surfaces not naturally targeted by the virus, thereby redirecting viral delivery and transduction.

[0006] In one aspect, provided herein is an antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof binds to the capsid of an adeno-associated virus (AAV) particle, and the antibody or antigen-binding fragment thereof is a) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 2, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, b) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 22, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, c) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 32, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, d) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 42, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; e) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 52 or SEQ ID NO: 1159, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157, f) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 62, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; g) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 71, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; h) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 81, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, i) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 91, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, or j) comprising a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 101, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10.

[0007] In some embodiments, the antibody or antigen-binding fragment thereof comprises: a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 8, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; b) HCDR1 comprising the amino acid sequence of SEQ ID NO: 24, HCDR2 comprising the amino acid sequence of SEQ ID NO: 26, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 28, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; c) HCDR1 comprising the amino acid sequence of SEQ ID NO: 34, HCDR2 comprising the amino acid sequence of SEQ ID NO: 36, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 38, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; d) HCDR1 comprising the amino acid sequence of SEQ ID NO: 44, HCDR2 comprising the amino acid sequence of SEQ ID NO: 46, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 48, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; e) HCDR1 comprising the amino acid sequence of SEQ ID NO: 54, HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; f) HCDR1 comprising the amino acid sequence of SEQ ID NO: 64, HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 67, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; g) HCDR1 comprising the amino acid sequence of SEQ ID NO: 73, HCDR2 comprising the amino acid sequence of SEQ ID NO: 75, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 77, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; h) HCDR1 comprising the amino acid sequence of SEQ ID NO: 83, HCDR2 comprising the amino acid sequence of SEQ ID NO: 85, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 87, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; i) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 93, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 95, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 97, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16, or j) Comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 103, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 105, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 107, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

[0008] In some embodiments, the antibody or antigen-binding fragment thereof comprises: a) an HCVR comprising the amino acid sequence of SEQ ID NO: 2 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; b) an HCVR comprising the amino acid sequence of SEQ ID NO: 22 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; c) an HCVR comprising the amino acid sequence of SEQ ID NO: 32 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; d) an HCVR comprising the amino acid sequence of SEQ ID NO: 42 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; e) an HCVR comprising the amino acid sequence of SEQ ID NO: 52 or SEQ ID NO: 1159, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157; f) HCVR comprising the amino acid sequence of SEQ ID NO: 62 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 10; g) HCVR comprising the amino acid sequence of SEQ ID NO: 71 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 10; h) an HCVR comprising the amino acid sequence of SEQ ID NO: 81 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; i) an HCVR comprising the amino acid sequence of SEQ ID NO: 91 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10, or j) Contains an HCVR comprising the amino acid sequence of SEQ ID NO: 101 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0009] In another aspect, provided herein are antibodies or antigen-binding fragments thereof, wherein the antibodies or antigen-binding fragments thereof bind to the capsid of an adeno-associated virus (AAV) particle, and the antibodies or antigen-binding fragments thereof bind to one or more residues in one or more viral protein 3 (VP3) polypeptides in the capsid, wherein the one or more residues are selected from those listed in Tables 18-26.

[0010] In some embodiments, the antibody or antigen-binding fragment thereof binds to a capsid of an AAV2 particle comprising the amino acid substitutions R585A and R588A, wherein the one or more residues are the following residues in the VP3 polypeptide (according to VP1 numbering): a) S264, A266, N268, H271, N382, S384, Q385, G512, R487, D494, K527, D529, K532, L538, D533, E555, N705, K706, V708, T450, Q457, and R459; b) S264, G265, A266, S267, N268, H271, N382, G383, S384, R487, K527, D528, E530, E574, Q575, K706, and S707; c) N254, L256, K258, I260, S261, Q263, Y272, E322, V323, T324, Q325, A655, A667, S668, F669, I670, T671, I332, Q545, G546, S547, E548, K556, N717, V719, T660, and F661; and / or d) selected from N254, L256, Q263, S264, V323, T324, Q325, S655, A667, S668, F669, I670, T671, G328, G546, E548, T716, and N717.

[0011] In some embodiments, the antibody or antigen-binding fragment thereof binds to the capsid of an AAV8 particle, and the one or more residues are identical to the following residues in the VP3 polypeptide (according to VP1 numbering): a) N255, L257, K259, 1261, S262, N263, S266, A269, Y275, E325, V326, T327, Q328, A658, N670, S671, F672, I673, T674, Q548, N549, A550, A551, D559, E720, and T663, and / or b) selected from N255, L257, S266, E325, V326, T327, Q328, N670, S671, F672, I673, T674, N549, T719, and E720.

[0012] In some embodiments, the antibody or antigen-binding fragment thereof binds to the capsid of an AAV9 particle, and the one or more residues are the following residues in the VP3 polypeptide (according to VP1 numbering): a) N254, I260, N262, Y274, E324, V325, T326, D327, N328, R550, D665, N668, S669, F670, 1671, T672, Q546, G547, G549, E718, and A661, and / or b) selected from N254, L256, I260, N262, E324, V325, T326, D551, N668, S669, F670, T672, G330, and E718.

[0013] In some embodiments, the antibody or antigen-binding fragment thereof comprises: 1) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 32, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, 2) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 52 or SEQ ID NO: 1159, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157, 3) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 71, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, or 4) A heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 81, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10.

[0014] In some embodiments, the antibody or antigen-binding fragment thereof comprises: 1) HCDR1 comprising the amino acid sequence of SEQ ID NO: 34, HCDR2 comprising the amino acid sequence of SEQ ID NO: 36, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 38, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; 2) HCDR1 comprising the amino acid sequence of SEQ ID NO: 54, HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; 3) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 73, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 75, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 77, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16, or 4) Comprises HCDR1 having the amino acid sequence of SEQ ID NO: 83, HCDR2 having the amino acid sequence of SEQ ID NO: 85, and HCDR3 having the amino acid sequence of SEQ ID NO: 87, and / or LCDR1 having the amino acid sequence of SEQ ID NO: 12, LCDR2 having the amino acid sequence of SEQ ID NO: 14, and LCDR3 having the amino acid sequence of SEQ ID NO: 16.

[0015] In some embodiments, the antibody or antigen-binding fragment thereof comprises: 1) an HCVR comprising the amino acid sequence of SEQ ID NO: 32 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; 2) an HCVR comprising the amino acid sequence of SEQ ID NO: 52 or SEQ ID NO: 1159, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157; 3) an HCVR comprising the amino acid sequence of SEQ ID NO: 71 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10, or 4) Contains an HCVR comprising the amino acid sequence of SEQ ID NO: 81 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0016] In some embodiments of any of the above antibodies or antigen-binding fragments, the antibody, or the antigen-binding fragment thereof, is a humanized antibody or antigen-binding fragment thereof, a human antibody or antigen-binding fragment thereof, a murine antibody or antigen-binding fragment thereof, a chimeric antibody or antigen-binding fragment thereof, a Fab fragment, a F(ab')2 fragment, a F(ab)'3 fragment, a single-chain fragment variable (scFv), a bis-scFv, an (scFv)2, a diabody, a minibody, a nanobody, a triabody, a tetrabody, a disulfide-stabilized Fv protein (dsFv), a single domain antibody (sdAb), an Ig NAR, a single heavy chain antibody, a bispecific antibody, a triabody, or a chemically modified derivative thereof.

[0017] In some embodiments, the antibody or antigen-binding fragment thereof comprises an IgG1, IgG2, IgG3, or IgG4 constant region, or a variant thereof.

[0018] In some embodiments, the antibody or antigen-binding fragment thereof comprises an IgG1 constant region or a variant thereof.

[0019] In some embodiments, the IgG1 constant region comprises the amino acid sequence of SEQ ID NO: 259 or 1164.

[0020] In some embodiments, the antibody or antigen-binding fragment thereof comprises an IgG4 constant region or a variant thereof.

[0021] In some embodiments, the IgG4 variants comprise a hinge domain that has been modified to reduce binding to Fcγ receptors.

[0022] In some embodiments, the IgG4 constant region comprises the amino acid sequence of SEQ ID NO:261.

[0023] In some embodiments, the antigen-binding fragment is a Fab fragment.

[0024] In some embodiments, the antigen-binding fragment is an scFv fragment.

[0025] In some embodiments of any of the above antibodies or antigen-binding fragments, the antibody, or antigen-binding fragment thereof, has a denaturing activity of about 1.5 x 10 as measured in a surface plasmon resonance assay. -6 It binds to AAV2 with a dissociation constant (KD) less than M.

[0026] In some embodiments, the antibody, or antigen-binding fragment thereof, has a dissociation constant (K) of less than about 20 nM as measured in a surface plasmon resonance assay. D ) binds to AAV2.

[0027] In some embodiments, the capsid comprises one or more wild-type AAV capsid polypeptides.

[0028] In some embodiments, the capsid comprises one or more non-wild-type AAV capsid polypeptides.

[0029] In some embodiments, binding of the antibody or antigen-binding fragment thereof to the AAV particle capsid does not neutralize the AAV particle.

[0030] In another aspect, provided herein is an antibody or antigen-binding fragment thereof that binds to the same epitope(s) as any of the above antibodies or antigen-binding fragments.

[0031] In another aspect, provided herein is an antibody or antigen-binding fragment thereof that competes with any of the above antibodies or antigen-binding fragments for binding to the capsid of an adeno-associated virus (AAV) particle.

[0032] In another aspect, provided herein is a pharmaceutical composition comprising any of the antibodies or antigen-binding fragments described above and a pharmaceutically acceptable carrier or excipient.

[0033] In another aspect, provided herein is a multispecific antibody, or multispecific antigen-binding fragment thereof, comprising: i) a first antigen-binding domain that binds to the capsid of an adeno-associated virus (AAV) particle; and ii) a second antigen-binding arm that binds to a molecule on a cell surface, wherein the first antigen-binding domain comprises: a) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 2, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, b) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 22, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, c) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 32, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, d) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 42, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; e) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 52 or SEQ ID NO: 1159, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157, f) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 62, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; g) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 71, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; h) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 81, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, i) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 91, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, or j) A multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 101, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10.

[0034] In some embodiments, the first antigen-binding domain that binds to the capsid of the AAV particle is a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 8, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; b) HCDR1 comprising the amino acid sequence of SEQ ID NO: 24, HCDR2 comprising the amino acid sequence of SEQ ID NO: 26, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 28, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; c) HCDR1 comprising the amino acid sequence of SEQ ID NO: 34, HCDR2 comprising the amino acid sequence of SEQ ID NO: 36, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 38, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; d) HCDR1 comprising the amino acid sequence of SEQ ID NO: 44, HCDR2 comprising the amino acid sequence of SEQ ID NO: 46, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 48, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; e) HCDR1 comprising the amino acid sequence of SEQ ID NO: 54, HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; f) HCDR1 comprising the amino acid sequence of SEQ ID NO: 64, HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 67, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; g) HCDR1 comprising the amino acid sequence of SEQ ID NO: 73, HCDR2 comprising the amino acid sequence of SEQ ID NO: 75, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 77, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; h) HCDR1 comprising the amino acid sequence of SEQ ID NO: 83, HCDR2 comprising the amino acid sequence of SEQ ID NO: 85, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 87, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; i) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 93, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 95, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 97, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16, or j) Comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 103, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 105, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 107, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

[0035] In some embodiments, the first antigen-binding domain that binds to the capsid of the AAV particle is a) an HCVR comprising the amino acid sequence of SEQ ID NO: 2 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; b) an HCVR comprising the amino acid sequence of SEQ ID NO: 22 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; c) an HCVR comprising the amino acid sequence of SEQ ID NO: 32 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; d) an HCVR comprising the amino acid sequence of SEQ ID NO: 42 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; e) an HCVR comprising the amino acid sequence of SEQ ID NO: 52 or SEQ ID NO: 1159, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157; f) HCVR comprising the amino acid sequence of SEQ ID NO: 62 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 10; g) HCVR comprising the amino acid sequence of SEQ ID NO: 71 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 10; h) an HCVR comprising the amino acid sequence of SEQ ID NO: 81 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; i) an HCVR comprising the amino acid sequence of SEQ ID NO: 91 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10, or j) Contains an HCVR comprising the amino acid sequence of SEQ ID NO: 101 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0036] In another aspect, provided herein is a multispecific antibody, or multispecific antigen-binding fragment thereof, comprising: i) a first antigen-binding domain that binds to the capsid of an adeno-associated virus (AAV) particle; and ii) A multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising a second antigen-binding domain that binds to a molecule on a cell surface, wherein the first antigen-binding domain binds to one or more residues in one or more viral protein 3 (VP3) polypeptides in the capsid, and the one or more residues are selected from the residues listed in Tables 18 to 26.

[0037] In some embodiments, the first antigen-binding domain binds to the capsid of an AAV2 particle comprising the amino acid substitutions R585A and R588A, wherein the one or more residues are the following residues in the VP3 polypeptide (according to VP1 numbering): a) S264, A266, N268, H271, N382, S384, Q385, G512, R487, D494, K527, K529, K532, L538, D533, E555, N705, K706, V708, T450, Q457, and R459; b) S264, G265, A266, S267, N268, H271, N382, G383, S384, R487, K527, D528, E530, Q574, Q575, K706, and S707; c) N254, L256, K258, I260, S261, Q263, Y272, E322, V323, T324, Q325, A655, A667, S668, F669, I670, T671, I332, Q545, G546, S547, E548, K556, N717, V719, T660, and F661; and / or d) selected from N254, L256, Q263, S264, V323, T324, Q325, S655, A667, S668, F669, I670, T671, G328, G546, E548, T716, and N717.

[0038] In some embodiments, the first antigen-binding domain binds to the capsid of an AAV8 particle, and the one or more residues are the following residues in the VP3 polypeptide (according to VP1 numbering): e) N255, L257, K259, 1261, S262, N263, S266, A269, Y275, E325, V326, T327, Q328, A658, N670, S671, F672, I673, T674, Q548, N549, A550, A551, D559, E720, and T663, and / or f) selected from N255, L257, S266, E325, V326, T327, Q328, N670, S671, F672, I673, T674, N549, T719, and E720.

[0039] In some embodiments, the first antigen-binding domain binds to the capsid of an AAV9 particle, and the one or more residues are the following residues in the VP3 polypeptide (according to VP1 numbering): g) N254, I260, N262, Y274, E324, V325, T326, D327, N328, R550, D665, N668, S669, F670, 1671, T672, Q546, G547, G549, E718, and A661, and / or h) selected from N254, L256, I260, N262, E324, V325, T326, D551, N668, S669, F670, T672, G330, and E718.

[0040] In some embodiments, the first antigen-binding domain that binds to the capsid of an AAV particle comprises: 1) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 32, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, 2) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 52 or SEQ ID NO: 1159, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157, 3) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 71, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, or 4) A heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 81, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10.

[0041] In some embodiments, the first antigen-binding domain that binds to the capsid of an AAV particle comprises: 1) HCDR1 comprising the amino acid sequence of SEQ ID NO: 34, HCDR2 comprising the amino acid sequence of SEQ ID NO: 36, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 38, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; 2) HCDR1 comprising the amino acid sequence of SEQ ID NO: 54, HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; 3) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 73, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 75, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 77, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16, or 4) Comprises HCDR1 having the amino acid sequence of SEQ ID NO: 83, HCDR2 having the amino acid sequence of SEQ ID NO: 85, and HCDR3 having the amino acid sequence of SEQ ID NO: 87, and / or LCDR1 having the amino acid sequence of SEQ ID NO: 12, LCDR2 having the amino acid sequence of SEQ ID NO: 14, and LCDR3 having the amino acid sequence of SEQ ID NO: 16.

[0042] In some embodiments, the first antigen-binding domain that binds to the capsid of an AAV particle comprises: 1) an HCVR comprising the amino acid sequence of SEQ ID NO: 32 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; 2) an HCVR comprising the amino acid sequence of SEQ ID NO: 52 or SEQ ID NO: 1159, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157; 3) an HCVR comprising the amino acid sequence of SEQ ID NO: 71 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10, or 4) Contains an HCVR comprising the amino acid sequence of SEQ ID NO: 81 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0043] In some embodiments of any of the above multispecific antibodies or multispecific antigen-binding fragments, the molecule on the cell surface is asialoglycoprotein receptor 1 (ASGR1), transferrin receptor (TfR), or calcium voltage-gated channel accessory subunit γ1 (CACNG1).

[0044] In some embodiments, the molecule on the cell surface is ASGR1.

[0045] In some embodiments, the second antigen-binding domain that binds to ASGR1 is: a) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 220 or SEQ ID NO: 1239, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157, or b) Comprises an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 230, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0046] In some embodiments, the second antigen-binding domain that binds to ASGR1 comprises: a) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 222, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 224, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 226, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16, or b) HCDR1 comprising the amino acid sequence of SEQ ID NO: 232, HCDR2 comprising the amino acid sequence of SEQ ID NO: 234, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 236, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

[0047] In some embodiments, the second antigen-binding domain that binds to ASGR1 comprises: a) an HCVR comprising the amino acid sequence of SEQ ID NO: 220 or SEQ ID NO: 1239, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157, or b) comprises an HCVR comprising the amino acid sequence of SEQ ID NO: 230 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0048] In some embodiments, the molecule on the cell surface is TfR.

[0049] In some embodiments, the second antigen-binding domain that binds to TfR is 1) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 270 or SEQ ID NO: 271, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 276; 2) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 281 or SEQ ID NO: 282, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 287; 3) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 292 or SEQ ID NO: 293, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 298; 4) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 303, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 308 or SEQ ID NO: 309; 5) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 314, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 319 or SEQ ID NO: 320; 6) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 325 or SEQ ID NO: 326, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 331 or SEQ ID NO: 332; 7) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 337 or SEQ ID NO: 338, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 343 or SEQ ID NO: 344; 8) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 349 or SEQ ID NO: 350, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 355 or SEQ ID NO: 356; 9) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 361, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 366; 10) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 371 or SEQ ID NO: 372, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 377; 11) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 382, ​​and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 387; 12) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 392 or SEQ ID NO: 393, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 398 or SEQ ID NO: 399; 13) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 404, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 409; 14) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 414, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 419; 15) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 424 or SEQ ID NO: 425, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 430 or SEQ ID NO: 431; 16) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 436, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 441; 17) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 446 or SEQ ID NO: 447, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 452; 18) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 457, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 462; 19) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 467 or SEQ ID NO: 468, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 473 or SEQ ID NO: 474; 20) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 479 or SEQ ID NO: 480, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 485; 21) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 490 or SEQ ID NO: 491, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 496; 22) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 501, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 506; 23) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 511, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 516; 24) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 521, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 526; 25) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 531, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 536; 26) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 541 or SEQ ID NO: 542, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 547; 27) An HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 552, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 557; 28) An HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 562, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 567; 29) An HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 572, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 577; 30) An HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 582, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 587; 31) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 592 or SEQ ID NO: 593, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 598 or SEQ ID NO: 599; 32) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 604, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 609 or SEQ ID NO: 610, or 33) Comprises an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1119, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 1127.

[0050] In some embodiments, the second antigen-binding domain that binds to TfR comprises: 1) HCDR1 comprising the amino acid sequence of SEQ ID NO: 272, HCDR2 comprising the amino acid sequence of SEQ ID NO: 273, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 274, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 277, LCDR2 comprising the amino acid sequence of SEQ ID NO: 278, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 279; 2) HCDR1 comprising the amino acid sequence of SEQ ID NO: 283, HCDR2 comprising the amino acid sequence of SEQ ID NO: 284, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 285, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 288, LCDR2 comprising the amino acid sequence of SEQ ID NO: 289, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 290; 3) HCDR1 comprising the amino acid sequence of SEQ ID NO: 294, HCDR2 comprising the amino acid sequence of SEQ ID NO: 295, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 296, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 299, LCDR2 comprising the amino acid sequence of SEQ ID NO: 300, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 301; 4) HCDR1 comprising the amino acid sequence of SEQ ID NO: 304, HCDR2 comprising the amino acid sequence of SEQ ID NO: 305, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 306, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 310, LCDR2 comprising the amino acid sequence of SEQ ID NO: 311, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 312; 5) HCDR1 comprising the amino acid sequence of SEQ ID NO: 315, HCDR2 comprising the amino acid sequence of SEQ ID NO: 316, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 317, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 321, LCDR2 comprising the amino acid sequence of SEQ ID NO: 322, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 323; 6) HCDR1 comprising the amino acid sequence of SEQ ID NO: 327, HCDR2 comprising the amino acid sequence of SEQ ID NO: 328, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 329, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 333, LCDR2 comprising the amino acid sequence of SEQ ID NO: 334, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 335; 7) HCDR1 comprising the amino acid sequence of SEQ ID NO: 339, HCDR2 comprising the amino acid sequence of SEQ ID NO: 340, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 341, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 345, LCDR2 comprising the amino acid sequence of SEQ ID NO: 346, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 347; 8) HCDR1 comprising the amino acid sequence of SEQ ID NO: 351, HCDR2 comprising the amino acid sequence of SEQ ID NO: 352, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 353, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 357, LCDR2 comprising the amino acid sequence of SEQ ID NO: 358, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 359; 9) HCDR1 comprising the amino acid sequence of SEQ ID NO: 362, HCDR2 comprising the amino acid sequence of SEQ ID NO: 363, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 364, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 367, LCDR2 comprising the amino acid sequence of SEQ ID NO: 368, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 369; 10) HCDR1 comprising the amino acid sequence of SEQ ID NO: 373, HCDR2 comprising the amino acid sequence of SEQ ID NO: 374, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 375, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 378, LCDR2 comprising the amino acid sequence of SEQ ID NO: 379, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 380; 11) HCDR1 comprising the amino acid sequence of SEQ ID NO: 383, HCDR2 comprising the amino acid sequence of SEQ ID NO: 384, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 385, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 388, LCDR2 comprising the amino acid sequence of SEQ ID NO: 389, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 390; 12) HCDR1 comprising the amino acid sequence of SEQ ID NO: 394, HCDR2 comprising the amino acid sequence of SEQ ID NO: 395, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 396, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 400, LCDR2 comprising the amino acid sequence of SEQ ID NO: 401, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 402; 13) HCDR1 comprising the amino acid sequence of SEQ ID NO: 405, HCDR2 comprising the amino acid sequence of SEQ ID NO: 406, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 407, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 410, LCDR2 comprising the amino acid sequence of SEQ ID NO: 411, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 412; 14) HCDR1 comprising the amino acid sequence of SEQ ID NO: 415, HCDR2 comprising the amino acid sequence of SEQ ID NO: 416, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 417, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 420, LCDR2 comprising the amino acid sequence of SEQ ID NO: 421, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 422; 15) HCDR1 comprising the amino acid sequence of SEQ ID NO: 426, HCDR2 comprising the amino acid sequence of SEQ ID NO: 427, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 428, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 432, LCDR2 comprising the amino acid sequence of SEQ ID NO: 433, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 434; 16) HCDR1 comprising the amino acid sequence of SEQ ID NO: 437, HCDR2 comprising the amino acid sequence of SEQ ID NO: 438, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 439, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 442, LCDR2 comprising the amino acid sequence of SEQ ID NO: 443, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 444; 17) HCDR1 comprising the amino acid sequence of SEQ ID NO: 448, HCDR2 comprising the amino acid sequence of SEQ ID NO: 449, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 450, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 453, LCDR2 comprising the amino acid sequence of SEQ ID NO: 454, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 455; 18) HCDR1 comprising the amino acid sequence of SEQ ID NO: 458, HCDR2 comprising the amino acid sequence of SEQ ID NO: 459, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 460, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 463, LCDR2 comprising the amino acid sequence of SEQ ID NO: 464, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 465; 19) HCDR1 comprising the amino acid sequence of SEQ ID NO: 469, HCDR2 comprising the amino acid sequence of SEQ ID NO: 470, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 471, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 475, LCDR2 comprising the amino acid sequence of SEQ ID NO: 476, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 477; 20) HCDR1 comprising the amino acid sequence of SEQ ID NO: 481, HCDR2 comprising the amino acid sequence of SEQ ID NO: 482, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 483, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 486, LCDR2 comprising the amino acid sequence of SEQ ID NO: 487, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 488; 21) HCDR1 comprising the amino acid sequence of SEQ ID NO: 492, HCDR2 comprising the amino acid sequence of SEQ ID NO: 493, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 494, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 497, LCDR2 comprising the amino acid sequence of SEQ ID NO: 498, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 499; 22) HCDR1 comprising the amino acid sequence of SEQ ID NO: 502, HCDR2 comprising the amino acid sequence of SEQ ID NO: 503, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 504, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 507, LCDR2 comprising the amino acid sequence of SEQ ID NO: 508, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 509; 23) HCDR1 comprising the amino acid sequence of SEQ ID NO: 512, HCDR2 comprising the amino acid sequence of SEQ ID NO: 513, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 514, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 517, LCDR2 comprising the amino acid sequence of SEQ ID NO: 518, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 519; 24) HCDR1 comprising the amino acid sequence of SEQ ID NO: 522, HCDR2 comprising the amino acid sequence of SEQ ID NO: 523, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 524, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 527, LCDR2 comprising the amino acid sequence of SEQ ID NO: 528, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 529; 25) HCDR1 comprising the amino acid sequence of SEQ ID NO: 532, HCDR2 comprising the amino acid sequence of SEQ ID NO: 533, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 534, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 537, LCDR2 comprising the amino acid sequence of SEQ ID NO: 538, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 539; 26) HCDR1 comprising the amino acid sequence of SEQ ID NO: 543, HCDR2 comprising the amino acid sequence of SEQ ID NO: 544, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 545, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 548, LCDR2 comprising the amino acid sequence of SEQ ID NO: 549, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 550; 27) HCDR1 comprising the amino acid sequence of SEQ ID NO: 553, HCDR2 comprising the amino acid sequence of SEQ ID NO: 554, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 555, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 558, LCDR2 comprising the amino acid sequence of SEQ ID NO: 559, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 560; 28) HCDR1 comprising the amino acid sequence of SEQ ID NO: 563, HCDR2 comprising the amino acid sequence of SEQ ID NO: 564, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 565, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 568, LCDR2 comprising the amino acid sequence of SEQ ID NO: 569, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 570; 29) HCDR1 comprising the amino acid sequence of SEQ ID NO: 573, HCDR2 comprising the amino acid sequence of SEQ ID NO: 574, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 575, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 578, LCDR2 comprising the amino acid sequence of SEQ ID NO: 579, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 580; 30) HCDR1 comprising the amino acid sequence of SEQ ID NO: 583, HCDR2 comprising the amino acid sequence of SEQ ID NO: 584, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 585, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 588, LCDR2 comprising the amino acid sequence of SEQ ID NO: 589, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 590; 31) HCDR1 comprising the amino acid sequence of SEQ ID NO: 594, HCDR2 comprising the amino acid sequence of SEQ ID NO: 595, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 596, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 600, LCDR2 comprising the amino acid sequence of SEQ ID NO: 601, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 602; 32) HCDR1 comprising the amino acid sequence of SEQ ID NO: 605, HCDR2 comprising the amino acid sequence of SEQ ID NO: 606, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 607, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 611, LCDR2 comprising the amino acid sequence of SEQ ID NO: 612, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 613, or 33) Comprises HCDR1 having the amino acid sequence of SEQ ID NO: 1121, HCDR2 having the amino acid sequence of SEQ ID NO: 1123, and HCDR3 having the amino acid sequence of SEQ ID NO: 1125, and / or LCDR1 having the amino acid sequence of SEQ ID NO: 1129, LCDR2 having the amino acid sequence of SEQ ID NO: 1131, and LCDR3 having the amino acid sequence of SEQ ID NO: 1133.

[0051] In some embodiments, the second antigen-binding domain that binds to TfR is 1) an HCVR comprising the amino acid sequence of SEQ ID NO: 270 or SEQ ID NO: 271, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 276; 2) an HCVR comprising the amino acid sequence of SEQ ID NO: 281 or SEQ ID NO: 282, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 287; 3) an HCVR comprising the amino acid sequence of SEQ ID NO: 292 or SEQ ID NO: 293, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 298; 4) an HCVR comprising the amino acid sequence of SEQ ID NO: 303, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 308 or SEQ ID NO: 309; 5) an HCVR comprising the amino acid sequence of SEQ ID NO: 314, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 319 or SEQ ID NO: 320; 6) an HCVR comprising the amino acid sequence of SEQ ID NO: 325 or SEQ ID NO: 326, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 331 or SEQ ID NO: 332; 7) an HCVR comprising the amino acid sequence of SEQ ID NO: 337 or SEQ ID NO: 338, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 343 or SEQ ID NO: 344; 8) an HCVR comprising the amino acid sequence of SEQ ID NO: 349 or SEQ ID NO: 350, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 355 or SEQ ID NO: 356; 9) an HCVR comprising the amino acid sequence of SEQ ID NO: 361 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 366; 10) an HCVR comprising the amino acid sequence of SEQ ID NO: 371 or SEQ ID NO: 372, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 377; 11) HCVR comprising the amino acid sequence of SEQ ID NO: 382 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 387; 12) an HCVR comprising the amino acid sequence of SEQ ID NO: 392 or SEQ ID NO: 393, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 398 or SEQ ID NO: 399; 13) HCVR comprising the amino acid sequence of SEQ ID NO: 404 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 409; 14) HCVR comprising the amino acid sequence of SEQ ID NO: 414 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 419; 15) HCVR comprising the amino acid sequence of SEQ ID NO: 424 or SEQ ID NO: 425, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 430 or SEQ ID NO: 431; 16) HCVR comprising the amino acid sequence of SEQ ID NO: 436 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 441; 17) HCVR comprising the amino acid sequence of SEQ ID NO: 446 or SEQ ID NO: 447, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 452; 18) HCVR comprising the amino acid sequence of SEQ ID NO: 457 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 462; 19) HCVR comprising the amino acid sequence of SEQ ID NO: 467 or SEQ ID NO: 468, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 473 or SEQ ID NO: 474; 20) HCVR comprising the amino acid sequence of SEQ ID NO: 479 or SEQ ID NO: 480, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 485; 21) HCVR comprising the amino acid sequence of SEQ ID NO: 490 or SEQ ID NO: 491, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 496; 22) HCVR comprising the amino acid sequence of SEQ ID NO: 501 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 506; 23) HCVR comprising the amino acid sequence of SEQ ID NO: 511 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 516; 24) HCVR comprising the amino acid sequence of SEQ ID NO: 521 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 526; 25) HCVR comprising the amino acid sequence of SEQ ID NO: 531 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 536; 26) HCVR comprising the amino acid sequence of SEQ ID NO: 541 or SEQ ID NO: 542, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 547; 27) HCVR comprising the amino acid sequence of SEQ ID NO: 552 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 557; 28) HCVR comprising the amino acid sequence of SEQ ID NO: 562 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 567; 29) HCVR comprising the amino acid sequence of SEQ ID NO: 572 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 577; 30) HCVR comprising the amino acid sequence of SEQ ID NO: 582 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 587; 31) HCVR comprising the amino acid sequence of SEQ ID NO: 592 or SEQ ID NO: 593, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 598 or SEQ ID NO: 599; 32) an HCVR comprising the amino acid sequence of SEQ ID NO: 604, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 609 or SEQ ID NO: 610, or 33) Contains an HCVR comprising the amino acid sequence of SEQ ID NO: 1119 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 1127.

[0052] In some embodiments, the molecule on the cell surface is CACNG1.

[0053] In some embodiments, the antigen binding domain that binds to CACNG1 is 1) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 615, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 623; 2) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 635, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 643; 3) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 655, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 663; 4) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 675, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 683; 5) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 695, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 703; 6) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 715, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 723; 7) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 735, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 743; 8) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 755, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 763; 9) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 775, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 783; 10) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 795, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 803; 11) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 815, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 823; 12) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 835, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 843; 13) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 855, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 863; 14) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 875, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 883; 15) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 895, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 903; 16) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 915, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 923; 17) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 935, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 943; 18) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 955, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 963; 19) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1181, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 1189, or 20) Comprises an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1205, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 1213.

[0054] In some embodiments, the second antigen-binding domain that binds to CACNG1 is: 1) HCDR1 comprising the amino acid sequence of SEQ ID NO: 617, HCDR2 comprising the amino acid sequence of SEQ ID NO: 619, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 621, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 625, LCDR2 comprising the amino acid sequence of SEQ ID NO: 627, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 629; 2) HCDR1 comprising the amino acid sequence of SEQ ID NO: 637, HCDR2 comprising the amino acid sequence of SEQ ID NO: 639, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 641, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 645, LCDR2 comprising the amino acid sequence of SEQ ID NO: 647, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 649; 3) HCDR1 comprising the amino acid sequence of SEQ ID NO: 657, HCDR2 comprising the amino acid sequence of SEQ ID NO: 659, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 661, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 665, LCDR2 comprising the amino acid sequence of SEQ ID NO: 667, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 669; 4) HCDR1 comprising the amino acid sequence of SEQ ID NO: 677, HCDR2 comprising the amino acid sequence of SEQ ID NO: 679, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 681, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 685, LCDR2 comprising the amino acid sequence of SEQ ID NO: 687, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 689; 5) HCDR1 comprising the amino acid sequence of SEQ ID NO: 697, HCDR2 comprising the amino acid sequence of SEQ ID NO: 699, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 701, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 705, LCDR2 comprising the amino acid sequence of SEQ ID NO: 707, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 709; 6) HCDR1 comprising the amino acid sequence of SEQ ID NO: 717, HCDR2 comprising the amino acid sequence of SEQ ID NO: 719, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 721, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 725, LCDR2 comprising the amino acid sequence of SEQ ID NO: 727, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 729; 7) HCDR1 comprising the amino acid sequence of SEQ ID NO: 737, HCDR2 comprising the amino acid sequence of SEQ ID NO: 739, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 741, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 745, LCDR2 comprising the amino acid sequence of SEQ ID NO: 747, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 749; 8) HCDR1 comprising the amino acid sequence of SEQ ID NO: 757, HCDR2 comprising the amino acid sequence of SEQ ID NO: 759, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 761, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 765, LCDR2 comprising the amino acid sequence of SEQ ID NO: 767, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 769; 9) HCDR1 comprising the amino acid sequence of SEQ ID NO: 777, HCDR2 comprising the amino acid sequence of SEQ ID NO: 779, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 781, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 785, LCDR2 comprising the amino acid sequence of SEQ ID NO: 787, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 789; 10) HCDR1 comprising the amino acid sequence of SEQ ID NO: 797, HCDR2 comprising the amino acid sequence of SEQ ID NO: 799, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 801, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 805, LCDR2 comprising the amino acid sequence of SEQ ID NO: 807, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 809; 11) HCDR1 comprising the amino acid sequence of SEQ ID NO: 817, HCDR2 comprising the amino acid sequence of SEQ ID NO: 819, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 821, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 825, LCDR2 comprising the amino acid sequence of SEQ ID NO: 827, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 829; 12) HCDR1 comprising the amino acid sequence of SEQ ID NO: 837, HCDR2 comprising the amino acid sequence of SEQ ID NO: 839, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 841, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 845, LCDR2 comprising the amino acid sequence of SEQ ID NO: 847, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 849; 13) HCDR1 comprising the amino acid sequence of SEQ ID NO: 857, HCDR2 comprising the amino acid sequence of SEQ ID NO: 859, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 861, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 865, LCDR2 comprising the amino acid sequence of SEQ ID NO: 867, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 869; 14) HCDR1 comprising the amino acid sequence of SEQ ID NO: 877, HCDR2 comprising the amino acid sequence of SEQ ID NO: 879, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 881, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 885, LCDR2 comprising the amino acid sequence of SEQ ID NO: 887, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 889; 15) HCDR1 comprising the amino acid sequence of SEQ ID NO: 897, HCDR2 comprising the amino acid sequence of SEQ ID NO: 899, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 901, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 905, LCDR2 comprising the amino acid sequence of SEQ ID NO: 907, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 909; 16) HCDR1 comprising the amino acid sequence of SEQ ID NO: 917, HCDR2 comprising the amino acid sequence of SEQ ID NO: 919, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 921, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 925, LCDR2 comprising the amino acid sequence of SEQ ID NO: 927, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 929; 17) HCDR1 comprising the amino acid sequence of SEQ ID NO: 937, HCDR2 comprising the amino acid sequence of SEQ ID NO: 939, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 941, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 945, LCDR2 comprising the amino acid sequence of SEQ ID NO: 947, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 949; 18) HCDR1 comprising the amino acid sequence of SEQ ID NO: 957, HCDR2 comprising the amino acid sequence of SEQ ID NO: 959, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 961, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 965, LCDR2 comprising the amino acid sequence of SEQ ID NO: 967, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 969; 19) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1183, HCDR2 comprising the amino acid sequence of SEQ ID NO: 1185, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 1187, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1191, LCDR2 comprising the amino acid sequence of SEQ ID NO: 1193, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 1195, or 20) Comprises HCDR1 having the amino acid sequence of SEQ ID NO: 1207, HCDR2 having the amino acid sequence of SEQ ID NO: 1209, and HCDR3 having the amino acid sequence of SEQ ID NO: 1211, and / or LCDR1 having the amino acid sequence of SEQ ID NO: 1215, LCDR2 having the amino acid sequence of SEQ ID NO: 1217, and LCDR3 having the amino acid sequence of SEQ ID NO: 1219.

[0055] In some embodiments, the second antigen-binding domain that binds to CACNG1 is: 1) an HCVR comprising the amino acid sequence of SEQ ID NO: 615 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 623; 2) an HCVR comprising the amino acid sequence of SEQ ID NO: 635 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 643; 3) an HCVR comprising the amino acid sequence of SEQ ID NO: 655 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 663; 4) an HCVR comprising the amino acid sequence of SEQ ID NO: 675 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 683; 5) an HCVR comprising the amino acid sequence of SEQ ID NO: 695 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 703; 6) an HCVR comprising the amino acid sequence of SEQ ID NO: 715 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 723; 7) an HCVR comprising the amino acid sequence of SEQ ID NO: 735 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 743; 8) an HCVR comprising the amino acid sequence of SEQ ID NO: 755 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 763; 9) an HCVR comprising the amino acid sequence of SEQ ID NO: 775 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 783; 10) an HCVR comprising the amino acid sequence of SEQ ID NO: 795 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 803; 11) HCVR comprising the amino acid sequence of SEQ ID NO: 815 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 823; 12) an HCVR comprising the amino acid sequence of SEQ ID NO: 835 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 843; 13) HCVR comprising the amino acid sequence of SEQ ID NO: 855 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 863; 14) HCVR comprising the amino acid sequence of SEQ ID NO: 875 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 883; 15) HCVR comprising the amino acid sequence of SEQ ID NO: 895 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 903; 16) HCVR comprising the amino acid sequence of SEQ ID NO: 915 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 923; 17) HCVR comprising the amino acid sequence of SEQ ID NO: 935 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 943; 18) HCVR comprising the amino acid sequence of SEQ ID NO: 955 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 963; 19) HCVR comprising the amino acid sequence of SEQ ID NO: 1181 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 1189, or 20) Contains an HCVR comprising the amino acid sequence of SEQ ID NO: 1205 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 1213.

[0056] In another aspect, provided herein is a multispecific antibody, or multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, from N-terminal to C-terminal, (i) a first heavy chain region of a first Fab ("Fab1") operably linked to (ii) a second heavy chain region of a second Fab ("Fab2"); b) a second polypeptide chain comprising a first light chain that pairs with a first heavy chain region to form Fab1, wherein Fab1 comprises a first antigen-binding domain (“ABD1”); and c) a third polypeptide chain comprising a second light chain that pairs with a second heavy chain region to form Fab2, wherein Fab2 comprises a second antigen-binding domain ("ABD2"), wherein ABD1 or ABD2 binds to the capsid of an adeno-associated virus (AAV) particle, and the other of ABD1 or ABD2 binds to a molecule on the surface of a cell, or a multispecific antigen-binding fragment thereof.

[0057] In some embodiments, ABD1 binds to the capsid of an adeno-associated virus (AAV) particle and ABD2 binds to a molecule on the cell surface.

[0058] In some embodiments, ABD2 binds to the capsid of an adeno-associated virus (AAV) particle and ABD1 binds to a molecule on the cell surface.

[0059] In some embodiments, the first heavy chain region is linked to the second heavy chain region via a linker.

[0060] In another aspect, provided herein is a multispecific antibody, or multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, in an N-terminal to C-terminal direction, a first scFv comprising: (i) a first antigen-binding domain (“ABD1”) operably linked to (ii) an Fc domain; b) a second polypeptide chain, in an N-terminal to C-terminal direction, of (i) a first heavy chain region of a first Fab (“Fab1”) operably linked to (ii) an Fc domain; and c) a third polypeptide chain comprising a first light chain that pairs with a first heavy chain region to form Fab1, wherein Fab1 comprises a second antigen-binding domain ("ABD2"), wherein ABD1 or ABD2 binds to the capsid of an adeno-associated virus (AAV) particle, and the other of ABD1 or ABD2 binds to a molecule on the surface of a cell, or a multispecific antigen-binding fragment thereof.

[0061] In some embodiments, ABD1 binds to the capsid of an adeno-associated virus (AAV) particle and ABD2 binds to a molecule on the cell surface.

[0062] In some embodiments, ABD2 binds to the capsid of an adeno-associated virus (AAV) particle and ABD1 binds to a molecule on the cell surface.

[0063] In some embodiments, the first scFv and / or the first heavy chain region is linked to the Fc domain via a linker.

[0064] In some embodiments, ABD1 or ABD2 that binds to the capsid of an AAV particle is a) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 2, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, b) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 22, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, c) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 32, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, d) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 42, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; e) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 52 or SEQ ID NO: 1159, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157, f) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 62, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; g) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 71, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; h) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 81, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, i) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3, and contained within a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 91, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3, and contained within a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 10, and / or j) A heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3, contained within a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 101, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3, contained within a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 10.

[0065] In some embodiments, ABD1 or ABD2 that binds to the capsid of an AAV particle is a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 8, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; b) HCDR1 comprising the amino acid sequence of SEQ ID NO: 24, HCDR2 comprising the amino acid sequence of SEQ ID NO: 26, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 28, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; c) HCDR1 comprising the amino acid sequence of SEQ ID NO: 34, HCDR2 comprising the amino acid sequence of SEQ ID NO: 36, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 38, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; d) HCDR1 comprising the amino acid sequence of SEQ ID NO: 44, HCDR2 comprising the amino acid sequence of SEQ ID NO: 46, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 48, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; e) HCDR1 comprising the amino acid sequence of SEQ ID NO: 54, HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; f) HCDR1 comprising the amino acid sequence of SEQ ID NO: 64, HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 67, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; g) HCDR1 comprising the amino acid sequence of SEQ ID NO: 73, HCDR2 comprising the amino acid sequence of SEQ ID NO: 75, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 77, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; h) HCDR1 comprising the amino acid sequence of SEQ ID NO: 83, HCDR2 comprising the amino acid sequence of SEQ ID NO: 85, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 87, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; i) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 93, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 95, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 97, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16, and / or j) Comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 103, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 105, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 107, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

[0066] In some embodiments, ABD1 or ABD2 that binds to the capsid of an AAV particle is a) an HCVR comprising the amino acid sequence of SEQ ID NO: 2 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; b) an HCVR comprising the amino acid sequence of SEQ ID NO: 22 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; c) an HCVR comprising the amino acid sequence of SEQ ID NO: 32 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; d) an HCVR comprising the amino acid sequence of SEQ ID NO: 42 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; e) an HCVR comprising the amino acid sequence of SEQ ID NO: 52 or SEQ ID NO: 1159, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157; f) HCVR comprising the amino acid sequence of SEQ ID NO: 62 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 10; g) HCVR comprising the amino acid sequence of SEQ ID NO: 71 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 10; h) an HCVR comprising the amino acid sequence of SEQ ID NO: 81 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; i) an HCVR comprising the amino acid sequence of SEQ ID NO: 91, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10, and / or j) Contains an HCVR comprising the amino acid sequence of SEQ ID NO: 101 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0067] In some embodiments, the molecule on the cell surface is asialoglycoprotein receptor 1 (ASGR1), transferrin receptor (TfR), or calcium voltage-gated channel accessory subunit gamma 1 (CACNG1).

[0068] In some embodiments, the molecule on the cell surface is ASGR1.

[0069] In some embodiments, the other of ABD1 or ABD2 that binds to ASGR1 is a) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 220 or SEQ ID NO: 1239, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157, or b) Comprises an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 230, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0070] In some embodiments, the other of ABD1 or ABD2 that binds to ASGR1 is a) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 222, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 224, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 226, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16, or b) HCDR1 comprising the amino acid sequence of SEQ ID NO: 232, HCDR2 comprising the amino acid sequence of SEQ ID NO: 234, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 236, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

[0071] In some embodiments, the other of ABD1 or ABD2 that binds to ASGR1 is a) an HCVR comprising the amino acid sequence of SEQ ID NO: 220 or SEQ ID NO: 1239, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157, or b) comprises an HCVR comprising the amino acid sequence of SEQ ID NO: 230 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0072] In some embodiments, the molecule on the cell surface is TfR.

[0073] In some embodiments, the other of ABD1 or ABD2 that binds to TfR is 1) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 270 or SEQ ID NO: 271, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 276; 2) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 281 or SEQ ID NO: 282, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 287; 3) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 292 or SEQ ID NO: 293, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 298; 4) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 303, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 308 or SEQ ID NO: 309; 5) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 314, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 319 or SEQ ID NO: 320; 6) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 325 or SEQ ID NO: 326, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 331 or SEQ ID NO: 332; 7) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 337 or SEQ ID NO: 338, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 343 or SEQ ID NO: 344; 8) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 349 or SEQ ID NO: 350, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 355 or SEQ ID NO: 356; 9) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 361, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 366; 10) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 371 or SEQ ID NO: 372, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 377; 11) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 382, ​​and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 387; 12) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 392 or SEQ ID NO: 393, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 398 or SEQ ID NO: 399; 13) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 404, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 409; 14) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 414, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 419; 15) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 424 or SEQ ID NO: 425, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 430 or SEQ ID NO: 431; 16) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 436, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 441; 17) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 446 or SEQ ID NO: 447, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 452; 18) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 457, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 462; 19) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 467 or SEQ ID NO: 468, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 473 or SEQ ID NO: 474; 20) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 479 or SEQ ID NO: 480, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 485; 21) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 490 or SEQ ID NO: 491, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 496; 22) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 501, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 506; 23) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 511, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 516; 24) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 521, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 526; 25) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 531, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 536; 26) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 541 or SEQ ID NO: 542, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 547; 27) An HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 552, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 557; 28) An HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 562, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 567; 29) An HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 572, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 577; 30) An HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 582, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 587; 31) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 592 or SEQ ID NO: 593, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 598 or SEQ ID NO: 599; 32) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 604, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 609 or SEQ ID NO: 610, or 33) Comprises an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1119, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 1127.

[0074] In some embodiments, the other of ABD1 or ABD2 that binds to TfR is 1) HCDR1 comprising the amino acid sequence of SEQ ID NO: 272, HCDR2 comprising the amino acid sequence of SEQ ID NO: 273, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 274, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 277, LCDR2 comprising the amino acid sequence of SEQ ID NO: 278, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 279; 2) HCDR1 comprising the amino acid sequence of SEQ ID NO: 283, HCDR2 comprising the amino acid sequence of SEQ ID NO: 284, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 285, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 288, LCDR2 comprising the amino acid sequence of SEQ ID NO: 289, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 290; 3) HCDR1 comprising the amino acid sequence of SEQ ID NO: 294, HCDR2 comprising the amino acid sequence of SEQ ID NO: 295, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 296, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 299, LCDR2 comprising the amino acid sequence of SEQ ID NO: 300, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 301; 4) HCDR1 comprising the amino acid sequence of SEQ ID NO: 304, HCDR2 comprising the amino acid sequence of SEQ ID NO: 305, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 306, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 310, LCDR2 comprising the amino acid sequence of SEQ ID NO: 311, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 312; 5) HCDR1 comprising the amino acid sequence of SEQ ID NO: 315, HCDR2 comprising the amino acid sequence of SEQ ID NO: 316, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 317, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 321, LCDR2 comprising the amino acid sequence of SEQ ID NO: 322, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 323; 6) HCDR1 comprising the amino acid sequence of SEQ ID NO: 327, HCDR2 comprising the amino acid sequence of SEQ ID NO: 328, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 329, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 333, LCDR2 comprising the amino acid sequence of SEQ ID NO: 334, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 335; 7) HCDR1 comprising the amino acid sequence of SEQ ID NO: 339, HCDR2 comprising the amino acid sequence of SEQ ID NO: 340, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 341, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 345, LCDR2 comprising the amino acid sequence of SEQ ID NO: 346, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 347; 8) HCDR1 comprising the amino acid sequence of SEQ ID NO: 351, HCDR2 comprising the amino acid sequence of SEQ ID NO: 352, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 353, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 357, LCDR2 comprising the amino acid sequence of SEQ ID NO: 358, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 359; 9) HCDR1 comprising the amino acid sequence of SEQ ID NO: 362, HCDR2 comprising the amino acid sequence of SEQ ID NO: 363, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 364, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 367, LCDR2 comprising the amino acid sequence of SEQ ID NO: 368, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 369; 10) HCDR1 comprising the amino acid sequence of SEQ ID NO: 373, HCDR2 comprising the amino acid sequence of SEQ ID NO: 374, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 375, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 378, LCDR2 comprising the amino acid sequence of SEQ ID NO: 379, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 380; 11) HCDR1 comprising the amino acid sequence of SEQ ID NO: 383, HCDR2 comprising the amino acid sequence of SEQ ID NO: 384, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 385, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 388, LCDR2 comprising the amino acid sequence of SEQ ID NO: 389, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 390; 12) HCDR1 comprising the amino acid sequence of SEQ ID NO: 394, HCDR2 comprising the amino acid sequence of SEQ ID NO: 395, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 396, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 400, LCDR2 comprising the amino acid sequence of SEQ ID NO: 401, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 402; 13) HCDR1 comprising the amino acid sequence of SEQ ID NO: 405, HCDR2 comprising the amino acid sequence of SEQ ID NO: 406, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 407, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 410, LCDR2 comprising the amino acid sequence of SEQ ID NO: 411, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 412; 14) HCDR1 comprising the amino acid sequence of SEQ ID NO: 415, HCDR2 comprising the amino acid sequence of SEQ ID NO: 416, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 417, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 420, LCDR2 comprising the amino acid sequence of SEQ ID NO: 421, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 422; 15) HCDR1 comprising the amino acid sequence of SEQ ID NO: 426, HCDR2 comprising the amino acid sequence of SEQ ID NO: 427, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 428, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 432, LCDR2 comprising the amino acid sequence of SEQ ID NO: 433, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 434; 16) HCDR1 comprising the amino acid sequence of SEQ ID NO: 437, HCDR2 comprising the amino acid sequence of SEQ ID NO: 438, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 439, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 442, LCDR2 comprising the amino acid sequence of SEQ ID NO: 443, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 444; 17) HCDR1 comprising the amino acid sequence of SEQ ID NO: 448, HCDR2 comprising the amino acid sequence of SEQ ID NO: 449, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 450, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 453, LCDR2 comprising the amino acid sequence of SEQ ID NO: 454, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 455; 18) HCDR1 comprising the amino acid sequence of SEQ ID NO: 458, HCDR2 comprising the amino acid sequence of SEQ ID NO: 459, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 460, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 463, LCDR2 comprising the amino acid sequence of SEQ ID NO: 464, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 465; 19) HCDR1 comprising the amino acid sequence of SEQ ID NO: 469, HCDR2 comprising the amino acid sequence of SEQ ID NO: 470, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 471, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 475, LCDR2 comprising the amino acid sequence of SEQ ID NO: 476, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 477; 20) HCDR1 comprising the amino acid sequence of SEQ ID NO: 481, HCDR2 comprising the amino acid sequence of SEQ ID NO: 482, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 483, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 486, LCDR2 comprising the amino acid sequence of SEQ ID NO: 487, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 488; 21) HCDR1 comprising the amino acid sequence of SEQ ID NO: 492, HCDR2 comprising the amino acid sequence of SEQ ID NO: 493, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 494, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 497, LCDR2 comprising the amino acid sequence of SEQ ID NO: 498, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 499; 22) HCDR1 comprising the amino acid sequence of SEQ ID NO: 502, HCDR2 comprising the amino acid sequence of SEQ ID NO: 503, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 504, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 507, LCDR2 comprising the amino acid sequence of SEQ ID NO: 508, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 509; 23) HCDR1 comprising the amino acid sequence of SEQ ID NO: 512, HCDR2 comprising the amino acid sequence of SEQ ID NO: 513, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 514, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 517, LCDR2 comprising the amino acid sequence of SEQ ID NO: 518, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 519; 24) HCDR1 comprising the amino acid sequence of SEQ ID NO: 522, HCDR2 comprising the amino acid sequence of SEQ ID NO: 523, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 524, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 527, LCDR2 comprising the amino acid sequence of SEQ ID NO: 528, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 529; 25) HCDR1 comprising the amino acid sequence of SEQ ID NO: 532, HCDR2 comprising the amino acid sequence of SEQ ID NO: 533, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 534, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 537, LCDR2 comprising the amino acid sequence of SEQ ID NO: 538, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 539; 26) HCDR1 comprising the amino acid sequence of SEQ ID NO: 543, HCDR2 comprising the amino acid sequence of SEQ ID NO: 544, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 545, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 548, LCDR2 comprising the amino acid sequence of SEQ ID NO: 549, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 550; 27) HCDR1 comprising the amino acid sequence of SEQ ID NO: 553, HCDR2 comprising the amino acid sequence of SEQ ID NO: 554, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 555, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 558, LCDR2 comprising the amino acid sequence of SEQ ID NO: 559, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 560; 28) HCDR1 comprising the amino acid sequence of SEQ ID NO: 563, HCDR2 comprising the amino acid sequence of SEQ ID NO: 564, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 565, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 568, LCDR2 comprising the amino acid sequence of SEQ ID NO: 569, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 570; 29) HCDR1 comprising the amino acid sequence of SEQ ID NO: 573, HCDR2 comprising the amino acid sequence of SEQ ID NO: 574, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 575, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 578, LCDR2 comprising the amino acid sequence of SEQ ID NO: 579, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 580; 30) HCDR1 comprising the amino acid sequence of SEQ ID NO: 583, HCDR2 comprising the amino acid sequence of SEQ ID NO: 584, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 585, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 588, LCDR2 comprising the amino acid sequence of SEQ ID NO: 589, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 590; 31) HCDR1 comprising the amino acid sequence of SEQ ID NO: 594, HCDR2 comprising the amino acid sequence of SEQ ID NO: 595, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 596, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 600, LCDR2 comprising the amino acid sequence of SEQ ID NO: 601, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 602; 32) HCDR1 comprising the amino acid sequence of SEQ ID NO: 605, HCDR2 comprising the amino acid sequence of SEQ ID NO: 606, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 607, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 611, LCDR2 comprising the amino acid sequence of SEQ ID NO: 612, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 613, or 33) Comprises HCDR1 having the amino acid sequence of SEQ ID NO: 1121, HCDR2 having the amino acid sequence of SEQ ID NO: 1123, and HCDR3 having the amino acid sequence of SEQ ID NO: 1125, and / or LCDR1 having the amino acid sequence of SEQ ID NO: 1129, LCDR2 having the amino acid sequence of SEQ ID NO: 1131, and LCDR3 having the amino acid sequence of SEQ ID NO: 1133.

[0075] In some embodiments, the other of ABD1 or ABD2 that binds to TfR is 1) an HCVR comprising the amino acid sequence of SEQ ID NO: 270 or SEQ ID NO: 271, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 276; 2) an HCVR comprising the amino acid sequence of SEQ ID NO: 281 or SEQ ID NO: 282, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 287; 3) an HCVR comprising the amino acid sequence of SEQ ID NO: 292 or SEQ ID NO: 293, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 298; 4) an HCVR comprising the amino acid sequence of SEQ ID NO: 303, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 308 or SEQ ID NO: 309; 5) an HCVR comprising the amino acid sequence of SEQ ID NO: 314, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 319 or SEQ ID NO: 320; 6) an HCVR comprising the amino acid sequence of SEQ ID NO: 325 or SEQ ID NO: 326, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 331 or SEQ ID NO: 332; 7) an HCVR comprising the amino acid sequence of SEQ ID NO: 337 or SEQ ID NO: 338, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 343 or SEQ ID NO: 344; 8) an HCVR comprising the amino acid sequence of SEQ ID NO: 349 or SEQ ID NO: 350, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 355 or SEQ ID NO: 356; 9) an HCVR comprising the amino acid sequence of SEQ ID NO: 361 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 366; 10) an HCVR comprising the amino acid sequence of SEQ ID NO: 371 or SEQ ID NO: 372, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 377; 11) HCVR comprising the amino acid sequence of SEQ ID NO: 382 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 387; 12) an HCVR comprising the amino acid sequence of SEQ ID NO: 392 or SEQ ID NO: 393, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 398 or SEQ ID NO: 399; 13) HCVR comprising the amino acid sequence of SEQ ID NO: 404 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 409; 14) HCVR comprising the amino acid sequence of SEQ ID NO: 414 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 419; 15) HCVR comprising the amino acid sequence of SEQ ID NO: 424 or SEQ ID NO: 425, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 430 or SEQ ID NO: 431; 16) HCVR comprising the amino acid sequence of SEQ ID NO: 436 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 441; 17) HCVR comprising the amino acid sequence of SEQ ID NO: 446 or SEQ ID NO: 447, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 452; 18) HCVR comprising the amino acid sequence of SEQ ID NO: 457 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 462; 19) HCVR comprising the amino acid sequence of SEQ ID NO: 467 or SEQ ID NO: 468, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 473 or SEQ ID NO: 474; 20) HCVR comprising the amino acid sequence of SEQ ID NO: 479 or SEQ ID NO: 480, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 485; 21) HCVR comprising the amino acid sequence of SEQ ID NO: 490 or SEQ ID NO: 491, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 496; 22) HCVR comprising the amino acid sequence of SEQ ID NO: 501 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 506; 23) HCVR comprising the amino acid sequence of SEQ ID NO: 511 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 516; 24) HCVR comprising the amino acid sequence of SEQ ID NO: 521 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 526; 25) HCVR comprising the amino acid sequence of SEQ ID NO: 531 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 536; 26) HCVR comprising the amino acid sequence of SEQ ID NO: 541 or SEQ ID NO: 542, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 547; 27) HCVR comprising the amino acid sequence of SEQ ID NO: 552 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 557; 28) HCVR comprising the amino acid sequence of SEQ ID NO: 562 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 567; 29) HCVR comprising the amino acid sequence of SEQ ID NO: 572 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 577; 30) HCVR comprising the amino acid sequence of SEQ ID NO: 582 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 587; 31) HCVR comprising the amino acid sequence of SEQ ID NO: 592 or SEQ ID NO: 593, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 598 or SEQ ID NO: 599; 32) an HCVR comprising the amino acid sequence of SEQ ID NO: 604, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 609 or SEQ ID NO: 610, or 33) Contains an HCVR comprising the amino acid sequence of SEQ ID NO: 1119 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 1127.

[0076] In some embodiments, the molecule on the cell surface is CACNG1.

[0077] In some embodiments, the other of ABD1 or ABD2 that binds to CACNG1 is 1) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 615, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 623; 2) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 635, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 643; 3) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 655, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 663; 4) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 675, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 683; 5) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 695, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 703; 6) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 715, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 723; 7) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 735, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 743; 8) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 755, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 763; 9) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 775, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 783; 10) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 795, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 803; 11) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 815, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 823; 12) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 835, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 843; 13) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 855, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 863; 14) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 875, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 883; 15) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 895, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 903; 16) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 915, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 923; 17) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 935, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 943; 18) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 955, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 963; 19) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1181, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 1189, or 20) Comprises an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1205, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 1213.

[0078] In some embodiments, the other of ABD1 or ABD2 that binds to CACNG1 is 1) HCDR1 comprising the amino acid sequence of SEQ ID NO: 617, HCDR2 comprising the amino acid sequence of SEQ ID NO: 619, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 621, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 625, LCDR2 comprising the amino acid sequence of SEQ ID NO: 627, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 629; 2) HCDR1 comprising the amino acid sequence of SEQ ID NO: 637, HCDR2 comprising the amino acid sequence of SEQ ID NO: 639, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 641, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 645, LCDR2 comprising the amino acid sequence of SEQ ID NO: 647, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 649; 3) HCDR1 comprising the amino acid sequence of SEQ ID NO: 657, HCDR2 comprising the amino acid sequence of SEQ ID NO: 659, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 661, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 665, LCDR2 comprising the amino acid sequence of SEQ ID NO: 667, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 669; 4) HCDR1 comprising the amino acid sequence of SEQ ID NO: 677, HCDR2 comprising the amino acid sequence of SEQ ID NO: 679, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 681, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 685, LCDR2 comprising the amino acid sequence of SEQ ID NO: 687, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 689; 5) HCDR1 comprising the amino acid sequence of SEQ ID NO: 697, HCDR2 comprising the amino acid sequence of SEQ ID NO: 699, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 701, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 705, LCDR2 comprising the amino acid sequence of SEQ ID NO: 707, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 709; 6) HCDR1 comprising the amino acid sequence of SEQ ID NO: 717, HCDR2 comprising the amino acid sequence of SEQ ID NO: 719, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 721, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 725, LCDR2 comprising the amino acid sequence of SEQ ID NO: 727, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 729; 7) HCDR1 comprising the amino acid sequence of SEQ ID NO: 737, HCDR2 comprising the amino acid sequence of SEQ ID NO: 739, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 741, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 745, LCDR2 comprising the amino acid sequence of SEQ ID NO: 747, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 749; 8) HCDR1 comprising the amino acid sequence of SEQ ID NO: 757, HCDR2 comprising the amino acid sequence of SEQ ID NO: 759, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 761, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 765, LCDR2 comprising the amino acid sequence of SEQ ID NO: 767, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 769; 9) HCDR1 comprising the amino acid sequence of SEQ ID NO: 777, HCDR2 comprising the amino acid sequence of SEQ ID NO: 779, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 781, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 785, LCDR2 comprising the amino acid sequence of SEQ ID NO: 787, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 789; 10) HCDR1 comprising the amino acid sequence of SEQ ID NO: 797, HCDR2 comprising the amino acid sequence of SEQ ID NO: 799, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 801, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 805, LCDR2 comprising the amino acid sequence of SEQ ID NO: 807, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 809; 11) HCDR1 comprising the amino acid sequence of SEQ ID NO: 817, HCDR2 comprising the amino acid sequence of SEQ ID NO: 819, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 821, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 825, LCDR2 comprising the amino acid sequence of SEQ ID NO: 827, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 829; 12) HCDR1 comprising the amino acid sequence of SEQ ID NO: 837, HCDR2 comprising the amino acid sequence of SEQ ID NO: 839, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 841, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 845, LCDR2 comprising the amino acid sequence of SEQ ID NO: 847, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 849; 13) HCDR1 comprising the amino acid sequence of SEQ ID NO: 857, HCDR2 comprising the amino acid sequence of SEQ ID NO: 859, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 861, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 865, LCDR2 comprising the amino acid sequence of SEQ ID NO: 867, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 869; 14) HCDR1 comprising the amino acid sequence of SEQ ID NO: 877, HCDR2 comprising the amino acid sequence of SEQ ID NO: 879, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 881, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 885, LCDR2 comprising the amino acid sequence of SEQ ID NO: 887, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 889; 15) HCDR1 comprising the amino acid sequence of SEQ ID NO: 897, HCDR2 comprising the amino acid sequence of SEQ ID NO: 899, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 901, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 905, LCDR2 comprising the amino acid sequence of SEQ ID NO: 907, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 909; 16) HCDR1 comprising the amino acid sequence of SEQ ID NO: 917, HCDR2 comprising the amino acid sequence of SEQ ID NO: 919, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 921, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 925, LCDR2 comprising the amino acid sequence of SEQ ID NO: 927, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 929; 17) HCDR1 comprising the amino acid sequence of SEQ ID NO: 937, HCDR2 comprising the amino acid sequence of SEQ ID NO: 939, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 941, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 945, LCDR2 comprising the amino acid sequence of SEQ ID NO: 947, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 949; 18) HCDR1 comprising the amino acid sequence of SEQ ID NO: 957, HCDR2 comprising the amino acid sequence of SEQ ID NO: 959, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 961, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 965, LCDR2 comprising the amino acid sequence of SEQ ID NO: 967, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 969; 19) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1183, HCDR2 comprising the amino acid sequence of SEQ ID NO: 1185, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 1187, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1191, LCDR2 comprising the amino acid sequence of SEQ ID NO: 1193, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 1195, or 20) Comprises HCDR1 having the amino acid sequence of SEQ ID NO: 1207, HCDR2 having the amino acid sequence of SEQ ID NO: 1209, and HCDR3 having the amino acid sequence of SEQ ID NO: 1211, and / or LCDR1 having the amino acid sequence of SEQ ID NO: 1215, LCDR2 having the amino acid sequence of SEQ ID NO: 1217, and LCDR3 having the amino acid sequence of SEQ ID NO: 1219.

[0079] In some embodiments, the other of ABD1 or ABD2 that binds to CACNG1 is 1) an HCVR comprising the amino acid sequence of SEQ ID NO: 615 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 623; 2) an HCVR comprising the amino acid sequence of SEQ ID NO: 635 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 643; 3) an HCVR comprising the amino acid sequence of SEQ ID NO: 655 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 663; 4) an HCVR comprising the amino acid sequence of SEQ ID NO: 675 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 683; 5) an HCVR comprising the amino acid sequence of SEQ ID NO: 695 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 703; 6) an HCVR comprising the amino acid sequence of SEQ ID NO: 715 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 723; 7) an HCVR comprising the amino acid sequence of SEQ ID NO: 735 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 743; 8) an HCVR comprising the amino acid sequence of SEQ ID NO: 755 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 763; 9) an HCVR comprising the amino acid sequence of SEQ ID NO: 775 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 783; 10) an HCVR comprising the amino acid sequence of SEQ ID NO: 795 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 803; 11) HCVR comprising the amino acid sequence of SEQ ID NO: 815 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 823; 12) an HCVR comprising the amino acid sequence of SEQ ID NO: 835 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 843; 13) HCVR comprising the amino acid sequence of SEQ ID NO: 855 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 863; 14) HCVR comprising the amino acid sequence of SEQ ID NO: 875 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 883; 15) HCVR comprising the amino acid sequence of SEQ ID NO: 895 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 903; 16) HCVR comprising the amino acid sequence of SEQ ID NO: 915 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 923; 17) HCVR comprising the amino acid sequence of SEQ ID NO: 935 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 943; 18) HCVR comprising the amino acid sequence of SEQ ID NO: 955 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 963; 19) HCVR comprising the amino acid sequence of SEQ ID NO: 1181 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 1189, or 20) Contains an HCVR comprising the amino acid sequence of SEQ ID NO: 1205 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 1213.

[0080] In another aspect, provided herein is a multispecific antibody, or multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, from N-terminal to C-terminal, (i) an scFv comprising a first antigen binding domain (“ABD1”) operably linked to (ii) a first heavy chain region of a first Fab (“Fab1”), said first heavy chain region being operably linked to (iii) an Fc domain; b) a second polypeptide chain comprising, in an N-terminal to C-terminal direction: (i) a second heavy chain region of a second Fab (“Fab2”) operably linked to (ii) an Fc domain; c) a third polypeptide chain comprising a first light chain that pairs with a first heavy chain region to form Fab1, wherein Fab1 comprises a second antigen-binding domain (“ABD2”); and d) a fourth polypeptide chain comprising a second light chain that pairs with a second heavy chain region to form Fab2, wherein Fab2 comprises a third antigen-binding domain ("ABD3"); At least one of ABD1, ABD2, and ABD3 binds to the capsid of an adeno-associated virus (AAV) particle, and the other(s) of ABD1, ABD2, and ABD3 bind to a molecule on the cell surface, or a multispecific antigen-binding fragment thereof.

[0081] In some embodiments, two of ABD1, ABD2, and ABD3 bind to the capsid of an AAV particle, and one of ABD1, ABD2, and ABD3 binds to a molecule on the cell surface.

[0082] In some embodiments, ABD2 and ABD3 bind to the capsid of an AAV particle, and ABD1 binds to a molecule on the cell surface.

[0083] In some embodiments, ABD1 and ABD3 bind to the capsid of an AAV particle, and ABD2 binds to a molecule on the cell surface.

[0084] In some embodiments, the scFv is linked to the first heavy chain region via a linker.

[0085] In another aspect, provided herein is a multispecific antibody, or multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, from N-terminal to C-terminal, (i) a first heavy chain region of a first Fab ("Fab1") operably linked to (ii) an Fc domain, said Fc domain being operably linked to (iii) an scFv comprising a first antigen binding domain ("ABD1"); b) a second polypeptide chain comprising, in an N-terminal to C-terminal direction: (i) a second heavy chain region of a second Fab (“Fab2”) operably linked to (ii) an Fc domain; c) a third polypeptide chain comprising a first light chain that pairs with a first heavy chain region to form Fab1, wherein Fab1 comprises a second antigen-binding domain (“ABD2”); and d) a fourth polypeptide chain comprising a second light chain that pairs with a second heavy chain region to form Fab2, wherein Fab2 comprises a third antigen-binding domain ("ABD3"); At least one of ABD1, ABD2, and ABD3 binds to the capsid of an adeno-associated virus (AAV) particle, and the other(s) of ABD1, ABD2, and ABD3 bind to a molecule on the cell surface, or a multispecific antigen-binding fragment thereof.

[0086] In some embodiments, two of ABD1, ABD2, and ABD3 bind to the capsid of an AAV particle, and one of ABD1, ABD2, and ABD3 binds to a molecule on the cell surface.

[0087] In some embodiments, ABD2 and ABD3 bind to the capsid of an AAV particle, and ABD1 binds to a molecule on the cell surface.

[0088] In some embodiments, ABD1 and ABD2 bind to the capsid of an AAV particle, and ABD3 binds to a molecule on the cell surface.

[0089] In some embodiments, the scFv is linked to the Fc domain via a linker.

[0090] In another aspect, provided herein is a multispecific antibody, or multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, from N-terminal to C-terminal, (i) a first heavy chain region of a first Fab ("Fab1") operably linked to (ii) a second heavy chain region of a second Fab ("Fab2"), wherein the second heavy chain region of Fab2 is operably linked to (iii) an Fc domain; b) a second polypeptide chain comprising, in N-terminal to C-terminal direction: (i) a third heavy chain region of a third Fab (“Fab3”) operably linked to (ii) an Fc domain; c) a third polypeptide chain comprising a first light chain that pairs with a first heavy chain region to form Fab1, wherein Fab1 comprises a first antigen-binding domain ("ABD1"); d) a fourth polypeptide chain comprising a second light chain that pairs with a second heavy chain region to form Fab2, wherein Fab2 comprises a second antigen-binding domain (“ABD2”); and e) a fifth polypeptide chain comprising a third light chain that pairs with a third heavy chain region to form Fab3, wherein Fab3 comprises a third antigen-binding domain ("ABD3"), wherein at least one of ABD1, ABD2, and ABD3 binds to the capsid of an adeno-associated virus (AAV) particle, and the other(s) of ABD1, ABD2, and ABD3 bind to a molecule on a cell surface.

[0091] In some embodiments, two of ABD1, ABD2, and ABD3 bind to the capsid of an AAV particle, and one of ABD1, ABD2, and ABD3 binds to a molecule on the cell surface.

[0092] In some embodiments, ABD2 and ABD3 bind to the capsid of an AAV particle, and ABD1 binds to a molecule on the cell surface.

[0093] In some embodiments, ABD1 and ABD3 bind to the capsid of an AAV particle, and ABD2 binds to a molecule on the cell surface.

[0094] In some embodiments, the first heavy chain region is linked to the second heavy chain region via a linker.

[0095] In another aspect, provided herein is a multispecific antibody, or multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, from N-terminal to C-terminal, (i) a first heavy chain region of a first Fab ("Fab1") operably linked to (ii) an Fc domain, said Fc domain being operably linked to (iii) a second heavy chain region of a second Fab ("Fab2"); b) a second polypeptide chain comprising, in N-terminal to C-terminal direction: (i) a third heavy chain region of a third Fab (“Fab3”) operably linked to (ii) an Fc domain; c) a third polypeptide chain comprising a first light chain that pairs with a first heavy chain region to form Fab1, wherein Fab1 comprises a first antigen-binding domain ("ABD1"); d) a fourth polypeptide chain comprising a second light chain that pairs with a second heavy chain region to form Fab2, wherein Fab2 comprises a second antigen-binding domain (“ABD2”); and e) a fifth polypeptide chain comprising a third light chain that pairs with a third heavy chain region to form Fab3, wherein Fab3 comprises a third antigen-binding domain ("ABD3"), wherein at least one of ABD1, ABD2, and ABD3 binds to the capsid of an adeno-associated virus (AAV) particle, and the other(s) of ABD1, ABD2, and ABD3 bind to a molecule on a cell surface.

[0096] In some embodiments, two of ABD1, ABD2, and ABD3 bind to the capsid of an AAV particle, and one of ABD1, ABD2, and ABD3 binds to a molecule on the cell surface.

[0097] In some embodiments, ABD1 and ABD3 bind to the capsid of an AAV particle, and ABD2 binds to a molecule on the cell surface.

[0098] In some embodiments, ABD1 and ABD2 bind to the capsid of an AAV particle, and ABD3 binds to a molecule on the cell surface.

[0099] In some embodiments, the second heavy chain region is linked to the Fc domain via a linker.

[0100] In another aspect, provided herein is a multispecific antibody, or multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, from N-terminal to C-terminal, (i) a first heavy chain region of a first Fab ("Fab1"), operably linked to (ii) an scFv comprising a first antigen binding domain ("ABD1"), which scFv is operably linked to (iii) an Fc domain; b) a second polypeptide chain comprising, in an N-terminal to C-terminal direction: (i) a second heavy chain region of a second Fab (“Fab2”) operably linked to (ii) an Fc domain; c) a third polypeptide chain comprising a first light chain that pairs with a first heavy chain region to form Fab1, wherein Fab1 comprises a second antigen-binding domain (“ABD2”); and d) a fourth polypeptide chain comprising a second light chain that pairs with a second heavy chain region to form Fab2, wherein Fab2 comprises a third antigen-binding domain ("ABD3"); At least one of ABD1, ABD2, and ABD3 binds to the capsid of an adeno-associated virus (AAV) particle, and the other(s) of ABD1, ABD2, and ABD3 bind to a molecule on the cell surface, or a multispecific antigen-binding fragment thereof.

[0101] In some embodiments, two of ABD1, ABD2, and ABD3 bind to the capsid of an AAV particle, and one of ABD1, ABD2, and ABD3 binds to a molecule on the cell surface.

[0102] In some embodiments, ABD2 and ABD3 bind to the capsid of an AAV particle, and ABD1 binds to a molecule on the cell surface.

[0103] In some embodiments, ABD1 and ABD2 bind to the capsid of an AAV particle, and ABD3 binds to a molecule on the cell surface.

[0104] In some embodiments, the scFv is linked to the first heavy chain region via a linker.

[0105] In another aspect, provided herein is a multispecific antibody, or multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, from N-terminal to C-terminal, (i) a first heavy chain region of a first Fab ("Fab1") operably linked to (ii) an Fc domain, said Fc domain being operably linked to (iii) a second heavy chain region of a second Fab ("Fab2"); b) a second polypeptide chain comprising, in an N-terminal to C-terminal direction, an scFv comprising: (i) a first antigen-binding domain (“ABD1”) operably linked to (ii) an Fc domain; c) a third polypeptide chain comprising a first light chain that pairs with a first heavy chain region to form Fab1, wherein Fab1 comprises a second antigen-binding domain (“ABD2”); and d) a fourth polypeptide chain comprising a second light chain that pairs with a second heavy chain region to form Fab2, wherein Fab2 comprises a third antigen-binding domain ("ABD3"); At least one of ABD1, ABD2, and ABD3 binds to the capsid of an adeno-associated virus (AAV) particle, and the other(s) of ABD1, ABD2, and ABD3 bind to a molecule on the cell surface, or a multispecific antigen-binding fragment thereof.

[0106] In some embodiments, two of ABD1, ABD2, and ABD3 bind to the capsid of an AAV particle, and one of ABD1, ABD2, and ABD3 binds to a molecule on the cell surface.

[0107] In some embodiments, ABD2 and ABD3 bind to the capsid of an AAV particle, and ABD1 binds to a molecule on the cell surface.

[0108] In some embodiments, ABD1 and ABD2 bind to the capsid of an AAV particle, and ABD3 binds to a molecule on the cell surface.

[0109] In some embodiments, the second heavy chain region is linked to the Fc domain via a linker.

[0110] In another aspect, provided herein is a multispecific antibody, or multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, from N-terminal to C-terminal, (i) a first heavy chain region of a first Fab ("Fab1"), operably linked to (ii) a second heavy chain region of a second Fab ("Fab2"), which second heavy chain region is operably linked to (iii) a third heavy chain region of a third Fab ("Fab3"); b) a second polypeptide chain comprising a first light chain that pairs with a first heavy chain region to form Fab1, wherein Fab1 comprises a first antigen-binding domain (“ABD1”); and c) a third polypeptide chain comprising a second light chain that pairs with a second heavy chain region to form Fab2, wherein Fab2 comprises a second antigen-binding domain ("ABD2"); d) a fourth polypeptide chain comprising a fifth polypeptide chain comprising a third light chain that pairs with a third heavy chain region to form Fab3, wherein Fab3 comprises a third antigen-binding domain ("ABD3"), wherein at least one of ABD1, ABD2, and ABD3 binds to the capsid of an adeno-associated virus (AAV) particle, and the other(s) of ABD1, ABD2, and ABD3 bind to a molecule on a cell surface.

[0111] In some embodiments, two of ABD1, ABD2, and ABD3 bind to the capsid of an AAV particle, and one of ABD1, ABD2, and ABD3 binds to a molecule on the cell surface.

[0112] In some embodiments, ABD2 and ABD3 bind to the capsid of an AAV particle, and ABD1 binds to a molecule on the cell surface.

[0113] In some embodiments, ABD1 and ABD3 bind to the capsid of an AAV particle, and ABD2 binds to a molecule on the cell surface.

[0114] In some embodiments, the first heavy chain region is operably linked to the second heavy chain region, and / or the second heavy chain region is operably linked to the third heavy chain region via a linker.

[0115] In some embodiments, at least one of ABD1, ABD2, and ABD3 that binds to the capsid of an AAV particle is a) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 2, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, b) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 22, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, c) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 32, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, d) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 42, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; e) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 52 or SEQ ID NO: 1159, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157, f) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 62, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; g) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 71, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; h) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 81, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, i) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3, and contained within a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 91, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3, and contained within a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 10, and / or j) A heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3, contained within a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 101, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3, contained within a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 10.

[0116] In some embodiments, at least one of ABD1, ABD2, and ABD3 that binds to the capsid of an AAV particle is a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 8, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; b) HCDR1 comprising the amino acid sequence of SEQ ID NO: 24, HCDR2 comprising the amino acid sequence of SEQ ID NO: 26, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 28, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; c) HCDR1 comprising the amino acid sequence of SEQ ID NO: 34, HCDR2 comprising the amino acid sequence of SEQ ID NO: 36, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 38, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; d) HCDR1 comprising the amino acid sequence of SEQ ID NO: 44, HCDR2 comprising the amino acid sequence of SEQ ID NO: 46, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 48, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; e) HCDR1 comprising the amino acid sequence of SEQ ID NO: 54, HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; f) HCDR1 comprising the amino acid sequence of SEQ ID NO: 64, HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 67, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; g) HCDR1 comprising the amino acid sequence of SEQ ID NO: 73, HCDR2 comprising the amino acid sequence of SEQ ID NO: 75, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 77, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; h) HCDR1 comprising the amino acid sequence of SEQ ID NO: 83, HCDR2 comprising the amino acid sequence of SEQ ID NO: 85, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 87, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; i) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 93, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 95, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 97, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16, and / or j) Comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 103, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 105, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 107, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

[0117] In some embodiments, at least one of ABD1, ABD2, and ABD3 that binds to the capsid of an AAV particle is a) an HCVR comprising the amino acid sequence of SEQ ID NO: 2 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; b) an HCVR comprising the amino acid sequence of SEQ ID NO: 22 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; c) an HCVR comprising the amino acid sequence of SEQ ID NO: 32 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; d) an HCVR comprising the amino acid sequence of SEQ ID NO: 42 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; e) an HCVR comprising the amino acid sequence of SEQ ID NO: 52 or SEQ ID NO: 1159, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157; f) HCVR comprising the amino acid sequence of SEQ ID NO: 62 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 10; g) HCVR comprising the amino acid sequence of SEQ ID NO: 71 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 10; h) an HCVR comprising the amino acid sequence of SEQ ID NO: 81 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; i) an HCVR comprising the amino acid sequence of SEQ ID NO: 91, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10, and / or j) Contains an HCVR comprising the amino acid sequence of SEQ ID NO: 101 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0118] In some embodiments, the molecule on the cell surface is asialoglycoprotein receptor 1 (ASGR1), transferrin receptor (TfR), or calcium voltage-gated channel accessory subunit γ1 (CACNG1).

[0119] In some embodiments, the molecule on the cell surface is ASGR1.

[0120] In some embodiments, the other(s) of ABD1, ABD2, and ABD3 that binds to ASGR1 is / are: a) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 220 or SEQ ID NO: 1239, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157, or b) Comprises an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 230, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0121] In some embodiments, the other(s) of ABD1, ABD2, and ABD3 that binds to ASGR1 is / are: a) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 222, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 224, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 226, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16, or b) HCDR1 comprising the amino acid sequence of SEQ ID NO: 232, HCDR2 comprising the amino acid sequence of SEQ ID NO: 234, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 236, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

[0122] In some embodiments, the other(s) of ABD1, ABD2, and ABD3 that binds to ASGR1 is / are: a) an HCVR comprising the amino acid sequence of SEQ ID NO: 220 or SEQ ID NO: 1239, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157, or b) comprises an HCVR comprising the amino acid sequence of SEQ ID NO: 230 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0123] In some embodiments, the molecule on the cell surface is TfR.

[0124] In some embodiments, the other(s) of ABD1, ABD2, and ABD3 that bind to TfR is / are: 1) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 270 or SEQ ID NO: 271, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 276; 2) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 281 or SEQ ID NO: 282, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 287; 3) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 292 or SEQ ID NO: 293, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 298; 4) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 303, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 308 or SEQ ID NO: 309; 5) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 314, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 319 or SEQ ID NO: 320; 6) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 325 or SEQ ID NO: 326, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 331 or SEQ ID NO: 332; 7) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 337 or SEQ ID NO: 338, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 343 or SEQ ID NO: 344; 8) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 349 or SEQ ID NO: 350, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 355 or SEQ ID NO: 356; 9) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 361, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 366; 10) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 371 or SEQ ID NO: 372, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 377; 11) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 382, ​​and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 387; 12) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 392 or SEQ ID NO: 393, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 398 or SEQ ID NO: 399; 13) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 404, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 409; 14) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 414, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 419; 15) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 424 or SEQ ID NO: 425, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 430 or SEQ ID NO: 431; 16) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 436, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 441; 17) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 446 or SEQ ID NO: 447, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 452; 18) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 457, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 462; 19) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 467 or SEQ ID NO: 468, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 473 or SEQ ID NO: 474; 20) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 479 or SEQ ID NO: 480, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 485; 21) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 490 or SEQ ID NO: 491, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 496; 22) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 501, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 506; 23) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 511, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 516; 24) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 521, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 526; 25) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 531, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 536; 26) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 541 or SEQ ID NO: 542, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 547; 27) An HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 552, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 557; 28) An HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 562, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 567; 29) An HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 572, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 577; 30) An HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 582, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 587; 31) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 592 or SEQ ID NO: 593, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 598 or SEQ ID NO: 599; 32) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 604, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 609 or SEQ ID NO: 610, or 33) Comprises an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1119, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 1127.

[0125] In some embodiments, the other(s) of ABD1, ABD2, and ABD3 that bind to TfR is / are: 1) HCDR1 comprising the amino acid sequence of SEQ ID NO: 272, HCDR2 comprising the amino acid sequence of SEQ ID NO: 273, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 274, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 277, LCDR2 comprising the amino acid sequence of SEQ ID NO: 278, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 279; 2) HCDR1 comprising the amino acid sequence of SEQ ID NO: 283, HCDR2 comprising the amino acid sequence of SEQ ID NO: 284, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 285, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 288, LCDR2 comprising the amino acid sequence of SEQ ID NO: 289, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 290; 3) HCDR1 comprising the amino acid sequence of SEQ ID NO: 294, HCDR2 comprising the amino acid sequence of SEQ ID NO: 295, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 296, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 299, LCDR2 comprising the amino acid sequence of SEQ ID NO: 300, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 301; 4) HCDR1 comprising the amino acid sequence of SEQ ID NO: 304, HCDR2 comprising the amino acid sequence of SEQ ID NO: 305, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 306, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 310, LCDR2 comprising the amino acid sequence of SEQ ID NO: 311, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 312; 5) HCDR1 comprising the amino acid sequence of SEQ ID NO: 315, HCDR2 comprising the amino acid sequence of SEQ ID NO: 316, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 317, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 321, LCDR2 comprising the amino acid sequence of SEQ ID NO: 322, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 323; 6) HCDR1 comprising the amino acid sequence of SEQ ID NO: 327, HCDR2 comprising the amino acid sequence of SEQ ID NO: 328, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 329, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 333, LCDR2 comprising the amino acid sequence of SEQ ID NO: 334, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 335; 7) HCDR1 comprising the amino acid sequence of SEQ ID NO: 339, HCDR2 comprising the amino acid sequence of SEQ ID NO: 340, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 341, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 345, LCDR2 comprising the amino acid sequence of SEQ ID NO: 346, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 347; 8) HCDR1 comprising the amino acid sequence of SEQ ID NO: 351, HCDR2 comprising the amino acid sequence of SEQ ID NO: 352, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 353, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 357, LCDR2 comprising the amino acid sequence of SEQ ID NO: 358, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 359; 9) HCDR1 comprising the amino acid sequence of SEQ ID NO: 362, HCDR2 comprising the amino acid sequence of SEQ ID NO: 363, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 364, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 367, LCDR2 comprising the amino acid sequence of SEQ ID NO: 368, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 369; 10) HCDR1 comprising the amino acid sequence of SEQ ID NO: 373, HCDR2 comprising the amino acid sequence of SEQ ID NO: 374, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 375, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 378, LCDR2 comprising the amino acid sequence of SEQ ID NO: 379, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 380; 11) HCDR1 comprising the amino acid sequence of SEQ ID NO: 383, HCDR2 comprising the amino acid sequence of SEQ ID NO: 384, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 385, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 388, LCDR2 comprising the amino acid sequence of SEQ ID NO: 389, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 390; 12) HCDR1 comprising the amino acid sequence of SEQ ID NO: 394, HCDR2 comprising the amino acid sequence of SEQ ID NO: 395, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 396, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 400, LCDR2 comprising the amino acid sequence of SEQ ID NO: 401, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 402; 13) HCDR1 comprising the amino acid sequence of SEQ ID NO: 405, HCDR2 comprising the amino acid sequence of SEQ ID NO: 406, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 407, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 410, LCDR2 comprising the amino acid sequence of SEQ ID NO: 411, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 412; 14) HCDR1 comprising the amino acid sequence of SEQ ID NO: 415, HCDR2 comprising the amino acid sequence of SEQ ID NO: 416, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 417, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 420, LCDR2 comprising the amino acid sequence of SEQ ID NO: 421, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 422; 15) HCDR1 comprising the amino acid sequence of SEQ ID NO: 426, HCDR2 comprising the amino acid sequence of SEQ ID NO: 427, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 428, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 432, LCDR2 comprising the amino acid sequence of SEQ ID NO: 433, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 434; 16) HCDR1 comprising the amino acid sequence of SEQ ID NO: 437, HCDR2 comprising the amino acid sequence of SEQ ID NO: 438, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 439, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 442, LCDR2 comprising the amino acid sequence of SEQ ID NO: 443, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 444; 17) HCDR1 comprising the amino acid sequence of SEQ ID NO: 448, HCDR2 comprising the amino acid sequence of SEQ ID NO: 449, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 450, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 453, LCDR2 comprising the amino acid sequence of SEQ ID NO: 454, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 455; 18) HCDR1 comprising the amino acid sequence of SEQ ID NO: 458, HCDR2 comprising the amino acid sequence of SEQ ID NO: 459, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 460, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 463, LCDR2 comprising the amino acid sequence of SEQ ID NO: 464, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 465; 19) HCDR1 comprising the amino acid sequence of SEQ ID NO: 469, HCDR2 comprising the amino acid sequence of SEQ ID NO: 470, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 471, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 475, LCDR2 comprising the amino acid sequence of SEQ ID NO: 476, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 477; 20) HCDR1 comprising the amino acid sequence of SEQ ID NO: 481, HCDR2 comprising the amino acid sequence of SEQ ID NO: 482, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 483, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 486, LCDR2 comprising the amino acid sequence of SEQ ID NO: 487, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 488; 21) HCDR1 comprising the amino acid sequence of SEQ ID NO: 492, HCDR2 comprising the amino acid sequence of SEQ ID NO: 493, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 494, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 497, LCDR2 comprising the amino acid sequence of SEQ ID NO: 498, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 499; 22) HCDR1 comprising the amino acid sequence of SEQ ID NO: 502, HCDR2 comprising the amino acid sequence of SEQ ID NO: 503, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 504, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 507, LCDR2 comprising the amino acid sequence of SEQ ID NO: 508, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 509; 23) HCDR1 comprising the amino acid sequence of SEQ ID NO: 512, HCDR2 comprising the amino acid sequence of SEQ ID NO: 513, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 514, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 517, LCDR2 comprising the amino acid sequence of SEQ ID NO: 518, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 519; 24) HCDR1 comprising the amino acid sequence of SEQ ID NO: 522, HCDR2 comprising the amino acid sequence of SEQ ID NO: 523, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 524, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 527, LCDR2 comprising the amino acid sequence of SEQ ID NO: 528, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 529; 25) HCDR1 comprising the amino acid sequence of SEQ ID NO: 532, HCDR2 comprising the amino acid sequence of SEQ ID NO: 533, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 534, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 537, LCDR2 comprising the amino acid sequence of SEQ ID NO: 538, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 539; 26) HCDR1 comprising the amino acid sequence of SEQ ID NO: 543, HCDR2 comprising the amino acid sequence of SEQ ID NO: 544, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 545, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 548, LCDR2 comprising the amino acid sequence of SEQ ID NO: 549, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 550; 27) HCDR1 comprising the amino acid sequence of SEQ ID NO: 553, HCDR2 comprising the amino acid sequence of SEQ ID NO: 554, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 555, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 558, LCDR2 comprising the amino acid sequence of SEQ ID NO: 559, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 560; 28) HCDR1 comprising the amino acid sequence of SEQ ID NO: 563, HCDR2 comprising the amino acid sequence of SEQ ID NO: 564, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 565, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 568, LCDR2 comprising the amino acid sequence of SEQ ID NO: 569, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 570; 29) HCDR1 comprising the amino acid sequence of SEQ ID NO: 573, HCDR2 comprising the amino acid sequence of SEQ ID NO: 574, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 575, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 578, LCDR2 comprising the amino acid sequence of SEQ ID NO: 579, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 580; 30) HCDR1 comprising the amino acid sequence of SEQ ID NO: 583, HCDR2 comprising the amino acid sequence of SEQ ID NO: 584, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 585, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 588, LCDR2 comprising the amino acid sequence of SEQ ID NO: 589, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 590; 31) HCDR1 comprising the amino acid sequence of SEQ ID NO: 594, HCDR2 comprising the amino acid sequence of SEQ ID NO: 595, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 596, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 600, LCDR2 comprising the amino acid sequence of SEQ ID NO: 601, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 602; 32) HCDR1 comprising the amino acid sequence of SEQ ID NO: 605, HCDR2 comprising the amino acid sequence of SEQ ID NO: 606, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 607, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 611, LCDR2 comprising the amino acid sequence of SEQ ID NO: 612, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 613, or 33) Comprises HCDR1 having the amino acid sequence of SEQ ID NO: 1121, HCDR2 having the amino acid sequence of SEQ ID NO: 1123, and HCDR3 having the amino acid sequence of SEQ ID NO: 1125, and / or LCDR1 having the amino acid sequence of SEQ ID NO: 1129, LCDR2 having the amino acid sequence of SEQ ID NO: 1131, and LCDR3 having the amino acid sequence of SEQ ID NO: 1133.

[0126] In some embodiments, the other(s) of ABD1, ABD2, and ABD3 that bind to TfR is / are: 1) an HCVR comprising the amino acid sequence of SEQ ID NO: 270 or SEQ ID NO: 271, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 276; 2) an HCVR comprising the amino acid sequence of SEQ ID NO: 281 or SEQ ID NO: 282, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 287; 3) an HCVR comprising the amino acid sequence of SEQ ID NO: 292 or SEQ ID NO: 293, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 298; 4) an HCVR comprising the amino acid sequence of SEQ ID NO: 303, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 308 or SEQ ID NO: 309; 5) an HCVR comprising the amino acid sequence of SEQ ID NO: 314, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 319 or SEQ ID NO: 320; 6) an HCVR comprising the amino acid sequence of SEQ ID NO: 325 or SEQ ID NO: 326, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 331 or SEQ ID NO: 332; 7) an HCVR comprising the amino acid sequence of SEQ ID NO: 337 or SEQ ID NO: 338, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 343 or SEQ ID NO: 344; 8) an HCVR comprising the amino acid sequence of SEQ ID NO: 349 or SEQ ID NO: 350, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 355 or SEQ ID NO: 356; 9) an HCVR comprising the amino acid sequence of SEQ ID NO: 361 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 366; 10) an HCVR comprising the amino acid sequence of SEQ ID NO: 371 or SEQ ID NO: 372, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 377; 11) HCVR comprising the amino acid sequence of SEQ ID NO: 382 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 387; 12) an HCVR comprising the amino acid sequence of SEQ ID NO: 392 or SEQ ID NO: 393, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 398 or SEQ ID NO: 399; 13) HCVR comprising the amino acid sequence of SEQ ID NO: 404 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 409; 14) HCVR comprising the amino acid sequence of SEQ ID NO: 414 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 419; 15) HCVR comprising the amino acid sequence of SEQ ID NO: 424 or SEQ ID NO: 425, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 430 or SEQ ID NO: 431; 16) HCVR comprising the amino acid sequence of SEQ ID NO: 436 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 441; 17) HCVR comprising the amino acid sequence of SEQ ID NO: 446 or SEQ ID NO: 447, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 452; 18) HCVR comprising the amino acid sequence of SEQ ID NO: 457 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 462; 19) HCVR comprising the amino acid sequence of SEQ ID NO: 467 or SEQ ID NO: 468, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 473 or SEQ ID NO: 474; 20) HCVR comprising the amino acid sequence of SEQ ID NO: 479 or SEQ ID NO: 480, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 485; 21) HCVR comprising the amino acid sequence of SEQ ID NO: 490 or SEQ ID NO: 491, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 496; 22) HCVR comprising the amino acid sequence of SEQ ID NO: 501 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 506; 23) HCVR comprising the amino acid sequence of SEQ ID NO: 511 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 516; 24) HCVR comprising the amino acid sequence of SEQ ID NO: 521 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 526; 25) HCVR comprising the amino acid sequence of SEQ ID NO: 531 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 536; 26) HCVR comprising the amino acid sequence of SEQ ID NO: 541 or SEQ ID NO: 542, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 547; 27) HCVR comprising the amino acid sequence of SEQ ID NO: 552 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 557; 28) HCVR comprising the amino acid sequence of SEQ ID NO: 562 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 567; 29) HCVR comprising the amino acid sequence of SEQ ID NO: 572 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 577; 30) HCVR comprising the amino acid sequence of SEQ ID NO: 582 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 587; 31) HCVR comprising the amino acid sequence of SEQ ID NO: 592 or SEQ ID NO: 593, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 598 or SEQ ID NO: 599; 32) an HCVR comprising the amino acid sequence of SEQ ID NO: 604, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 609 or SEQ ID NO: 610, or 33) Contains an HCVR comprising the amino acid sequence of SEQ ID NO: 1119 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 1127.

[0127] In some embodiments, the molecule on the cell surface is CACNG1.

[0128] In some embodiments, the other(s) of ABD1, ABD2, and ABD3 that binds to CACNG1 is / are: 1) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 615, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 623; 2) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 635, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 643; 3) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 655, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 663; 4) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 675, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 683; 5) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 695, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 703; 6) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 715, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 723; 7) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 735, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 743; 8) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 755, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 763; 9) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 775, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 783; 10) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 795, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 803; 11) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 815, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 823; 12) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 835, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 843; 13) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 855, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 863; 14) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 875, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 883; 15) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 895, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 903; 16) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 915, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 923; 17) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 935, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 943; 18) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 955, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 963; 19) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1181, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 1189, or 20) Comprises an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1205, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 1213.

[0129] In some embodiments, the other(s) of ABD1, ABD2, and ABD3 that binds to CACNG1 is / are: 1) HCDR1 comprising the amino acid sequence of SEQ ID NO: 617, HCDR2 comprising the amino acid sequence of SEQ ID NO: 619, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 621, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 625, LCDR2 comprising the amino acid sequence of SEQ ID NO: 627, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 629; 2) HCDR1 comprising the amino acid sequence of SEQ ID NO: 637, HCDR2 comprising the amino acid sequence of SEQ ID NO: 639, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 641, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 645, LCDR2 comprising the amino acid sequence of SEQ ID NO: 647, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 649; 3) HCDR1 comprising the amino acid sequence of SEQ ID NO: 657, HCDR2 comprising the amino acid sequence of SEQ ID NO: 659, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 661, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 665, LCDR2 comprising the amino acid sequence of SEQ ID NO: 667, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 669; 4) HCDR1 comprising the amino acid sequence of SEQ ID NO: 677, HCDR2 comprising the amino acid sequence of SEQ ID NO: 679, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 681, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 685, LCDR2 comprising the amino acid sequence of SEQ ID NO: 687, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 689; 5) HCDR1 comprising the amino acid sequence of SEQ ID NO: 697, HCDR2 comprising the amino acid sequence of SEQ ID NO: 699, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 701, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 705, LCDR2 comprising the amino acid sequence of SEQ ID NO: 707, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 709; 6) HCDR1 comprising the amino acid sequence of SEQ ID NO: 717, HCDR2 comprising the amino acid sequence of SEQ ID NO: 719, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 721, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 725, LCDR2 comprising the amino acid sequence of SEQ ID NO: 727, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 729; 7) HCDR1 comprising the amino acid sequence of SEQ ID NO: 737, HCDR2 comprising the amino acid sequence of SEQ ID NO: 739, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 741, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 745, LCDR2 comprising the amino acid sequence of SEQ ID NO: 747, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 749; 8) HCDR1 comprising the amino acid sequence of SEQ ID NO: 757, HCDR2 comprising the amino acid sequence of SEQ ID NO: 759, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 761, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 765, LCDR2 comprising the amino acid sequence of SEQ ID NO: 767, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 769; 9) HCDR1 comprising the amino acid sequence of SEQ ID NO: 777, HCDR2 comprising the amino acid sequence of SEQ ID NO: 779, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 781, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 785, LCDR2 comprising the amino acid sequence of SEQ ID NO: 787, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 789; 10) HCDR1 comprising the amino acid sequence of SEQ ID NO: 797, HCDR2 comprising the amino acid sequence of SEQ ID NO: 799, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 801, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 805, LCDR2 comprising the amino acid sequence of SEQ ID NO: 807, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 809; 11) HCDR1 comprising the amino acid sequence of SEQ ID NO: 817, HCDR2 comprising the amino acid sequence of SEQ ID NO: 819, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 821, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 825, LCDR2 comprising the amino acid sequence of SEQ ID NO: 827, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 829; 12) HCDR1 comprising the amino acid sequence of SEQ ID NO: 837, HCDR2 comprising the amino acid sequence of SEQ ID NO: 839, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 841, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 845, LCDR2 comprising the amino acid sequence of SEQ ID NO: 847, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 849; 13) HCDR1 comprising the amino acid sequence of SEQ ID NO: 857, HCDR2 comprising the amino acid sequence of SEQ ID NO: 859, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 861, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 865, LCDR2 comprising the amino acid sequence of SEQ ID NO: 867, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 869; 14) HCDR1 comprising the amino acid sequence of SEQ ID NO: 877, HCDR2 comprising the amino acid sequence of SEQ ID NO: 879, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 881, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 885, LCDR2 comprising the amino acid sequence of SEQ ID NO: 887, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 889; 15) HCDR1 comprising the amino acid sequence of SEQ ID NO: 897, HCDR2 comprising the amino acid sequence of SEQ ID NO: 899, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 901, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 905, LCDR2 comprising the amino acid sequence of SEQ ID NO: 907, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 909; 16) HCDR1 comprising the amino acid sequence of SEQ ID NO: 917, HCDR2 comprising the amino acid sequence of SEQ ID NO: 919, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 921, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 925, LCDR2 comprising the amino acid sequence of SEQ ID NO: 927, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 929; 17) HCDR1 comprising the amino acid sequence of SEQ ID NO: 937, HCDR2 comprising the amino acid sequence of SEQ ID NO: 939, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 941, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 945, LCDR2 comprising the amino acid sequence of SEQ ID NO: 947, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 949; 18) HCDR1 comprising the amino acid sequence of SEQ ID NO: 957, HCDR2 comprising the amino acid sequence of SEQ ID NO: 959, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 961, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 965, LCDR2 comprising the amino acid sequence of SEQ ID NO: 967, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 969; 19) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1183, HCDR2 comprising the amino acid sequence of SEQ ID NO: 1185, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 1187, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1191, LCDR2 comprising the amino acid sequence of SEQ ID NO: 1193, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 1195, or 20) Comprises HCDR1 having the amino acid sequence of SEQ ID NO: 1207, HCDR2 having the amino acid sequence of SEQ ID NO: 1209, and HCDR3 having the amino acid sequence of SEQ ID NO: 1211, and / or LCDR1 having the amino acid sequence of SEQ ID NO: 1215, LCDR2 having the amino acid sequence of SEQ ID NO: 1217, and LCDR3 having the amino acid sequence of SEQ ID NO: 1219.

[0130] In some embodiments, the other(s) of ABD1, ABD2, and ABD3 that binds to CACNG1 is / are: 1) an HCVR comprising the amino acid sequence of SEQ ID NO: 615 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 623; 2) an HCVR comprising the amino acid sequence of SEQ ID NO: 635 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 643; 3) an HCVR comprising the amino acid sequence of SEQ ID NO: 655 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 663; 4) an HCVR comprising the amino acid sequence of SEQ ID NO: 675 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 683; 5) an HCVR comprising the amino acid sequence of SEQ ID NO: 695 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 703; 6) an HCVR comprising the amino acid sequence of SEQ ID NO: 715 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 723; 7) an HCVR comprising the amino acid sequence of SEQ ID NO: 735 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 743; 8) an HCVR comprising the amino acid sequence of SEQ ID NO: 755 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 763; 9) an HCVR comprising the amino acid sequence of SEQ ID NO: 775 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 783; 10) an HCVR comprising the amino acid sequence of SEQ ID NO: 795 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 803; 11) HCVR comprising the amino acid sequence of SEQ ID NO: 815 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 823; 12) an HCVR comprising the amino acid sequence of SEQ ID NO: 835 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 843; 13) HCVR comprising the amino acid sequence of SEQ ID NO: 855 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 863; 14) HCVR comprising the amino acid sequence of SEQ ID NO: 875 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 883; 15) HCVR comprising the amino acid sequence of SEQ ID NO: 895 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 903; 16) HCVR comprising the amino acid sequence of SEQ ID NO: 915 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 923; 17) HCVR comprising the amino acid sequence of SEQ ID NO: 935 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 943; 18) HCVR comprising the amino acid sequence of SEQ ID NO: 955 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 963; 19) HCVR comprising the amino acid sequence of SEQ ID NO: 1181 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 1189, or 20) Contains an HCVR comprising the amino acid sequence of SEQ ID NO: 1205 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 1213.

[0131] In another aspect, provided herein is a multispecific antibody, or multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, from N-terminal to C-terminal, (i) a first scFv comprising a first antigen binding domain (“ABD1”) operably linked to (ii) a first heavy chain region of a first Fab (“Fab1”), wherein the first heavy chain region of Fab1 is operably linked to (iii) an Fc domain; b) a second polypeptide chain comprising, in N-terminal to C-terminal direction, (i) a second scFv comprising a second antigen binding domain (“ABD2”) operably linked to (ii) a second heavy chain region of a second Fab (“Fab2”), wherein the second heavy chain region of Fab2 is operably linked to (iii) an Fc domain; c) a third polypeptide chain comprising a first light chain paired with a first heavy chain region to form a Fab1, wherein the Fab1 comprises a third antigen-binding domain ("ABD3"); d) a fourth polypeptide chain comprising a second light chain that pairs with a second heavy chain region to form Fab2, wherein Fab2 comprises a fourth antigen-binding domain ("ABD4"); A multispecific antibody, or multispecific antigen-binding fragment thereof, wherein at least one of ABD1, ABD2, ABD3, and ABD4 binds to the capsid of an adeno-associated virus (AAV) particle, and the other(s) of ABD1, ABD2, ABD3, and ABD4 bind to a molecule on the cell surface.

[0132] In some embodiments, two of ABD1, ABD2, ABD3, and ABD4 bind to the capsid of an AAV particle, and two of ABD1, ABD2, ABD3, and ABD4 bind to a molecule on the cell surface.

[0133] In some embodiments, ABD1 and ABD2 bind to the capsid of an AAV particle, and ABD3 and ABD4 bind to a molecule on the cell surface.

[0134] In some embodiments, ABD3 and ABD4 bind to the capsid of an AAV particle, and ABD1 and ABD2 bind to a molecule on the cell surface.

[0135] In some embodiments, the first scFv is linked to a first heavy chain region and / or the second scFv is linked to a second heavy chain region via a linker.

[0136] In another aspect, provided herein is a multispecific antibody, or multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, from N-terminal to C-terminal, (i) a first heavy chain region of a first Fab (“Fab1”) operably linked to (ii) an Fc domain, said Fc domain being operably linked to (iii) a first scFv comprising a first antigen binding domain (“ABD1”); b) a second polypeptide chain comprising, in N-terminal to C-terminal direction, (i) a second heavy chain region of a second Fab ("Fab2") operably linked to (ii) an Fc domain, said Fc domain being operably linked to (iii) a second scFv comprising a second antigen binding domain ("ABD2"); c) a third polypeptide chain comprising a first light chain paired with a first heavy chain region to form a Fab1, wherein the Fab1 comprises a third antigen-binding domain ("ABD3"); d) a fourth polypeptide chain comprising a second light chain that pairs with a second heavy chain region to form Fab2, wherein Fab2 comprises a fourth antigen-binding domain ("ABD4"), wherein at least one of ABD1, ABD2, ABD3, and ABD4 binds to the capsid of an adeno-associated virus (AAV) particle, and the other(s) of ABD1, ABD2, ABD3, and ABD4 bind to a molecule on the cell surface.

[0137] In some embodiments, two of ABD1, ABD2, ABD3, and ABD4 bind to the capsid of an AAV particle, and two of ABD1, ABD2, ABD3, and ABD4 bind to a molecule on the cell surface.

[0138] In some embodiments, ABD1 and ABD2 bind to the capsid of an AAV particle, and ABD3 and ABD4 bind to a molecule on the cell surface.

[0139] In some embodiments, ABD3 and ABD4 bind to the capsid of an AAV particle, and ABD1 and ABD2 bind to a molecule on the cell surface.

[0140] In some embodiments, the first scFv and / or the second scFv are linked to the Fc domain via a linker.

[0141] In another aspect, provided herein is a multispecific antibody, or multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, from N-terminal to C-terminal, (i) a first heavy chain region of a first Fab ("Fab1"), (ii) a first heavy chain region operably linked to a second heavy chain region of a second Fab ("Fab2"), (iii) the first polypeptide chain operably linked to an Fc domain; b) a second polypeptide chain operably linked, in the N-terminal to C-terminal direction, (i) a third heavy chain region of a third Fab (Fab3) to (ii) a fourth heavy chain region of a fourth Fab ("Fab4"), and (iii) an Fc domain; c) a third polypeptide chain comprising a first light chain that pairs with a first heavy chain region to form Fab1, wherein Fab1 comprises a first antigen-binding domain ("ABD1"); d) a fourth polypeptide chain comprising a second light chain paired with a second heavy chain region to form Fab2, wherein Fab2 comprises a second antigen binding domain (“ADB2”); e) a fifth polypeptide chain comprising a third light chain region paired with a third heavy chain region to form Fab3, wherein Fab3 comprises a third antigen-binding domain (“ABD3”); and f) a sixth polypeptide chain comprising a fourth light chain that pairs with a fourth heavy chain region to form Fab4, wherein Fab4 comprises a fourth antigen-binding domain ("ABD4"), wherein at least one of ABD1, ABD2, ABD3, and ABD4 binds to the capsid of an adeno-associated virus (AAV) particle, and the other(s) of ABD1, ABD2, ABD3, and ABD4 bind to a molecule on the cell surface.

[0142] In some embodiments, two of ABD1, ABD2, ABD3, and ABD4 bind to the capsid of an AAV particle, and two of ABD1, ABD2, ABD3, and ABD4 bind to a molecule on the cell surface.

[0143] In some embodiments, ABD1 and ABD3 bind to the capsid of an AAV particle, and ABD2 and ABD4 bind to a molecule on the cell surface.

[0144] In some embodiments, ABD2 and ABD4 bind to the capsid of an AAV particle, and ABD1 and ABD3 bind to a molecule on the cell surface.

[0145] In some embodiments, the first heavy chain region is linked to the second heavy chain region and / or the third heavy chain region is linked to the fourth heavy chain region via a linker.

[0146] In some embodiments, at least one of ABD1, ABD2, ABD3, and ABD4 that binds to the capsid of an AAV particle is a) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 2, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, b) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 22, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, c) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 32, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, d) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 42, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; e) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 52 or SEQ ID NO: 1159, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157, f) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 62, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; g) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 71, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; h) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 81, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, i) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3, and contained within a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 91, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3, and contained within a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 10, and / or j) A heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3, contained within a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 101, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3, contained within a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 10.

[0147] In some embodiments, at least one of ABD1, ABD2, ABD3, and ABD4 that binds to the capsid of an AAV particle is a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 8, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; b) HCDR1 comprising the amino acid sequence of SEQ ID NO: 24, HCDR2 comprising the amino acid sequence of SEQ ID NO: 26, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 28, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; c) HCDR1 comprising the amino acid sequence of SEQ ID NO: 34, HCDR2 comprising the amino acid sequence of SEQ ID NO: 36, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 38, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; d) HCDR1 comprising the amino acid sequence of SEQ ID NO: 44, HCDR2 comprising the amino acid sequence of SEQ ID NO: 46, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 48, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; e) HCDR1 comprising the amino acid sequence of SEQ ID NO: 54, HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; f) HCDR1 comprising the amino acid sequence of SEQ ID NO: 64, HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 67, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; g) HCDR1 comprising the amino acid sequence of SEQ ID NO: 73, HCDR2 comprising the amino acid sequence of SEQ ID NO: 75, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 77, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; h) HCDR1 comprising the amino acid sequence of SEQ ID NO: 83, HCDR2 comprising the amino acid sequence of SEQ ID NO: 85, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 87, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; i) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 93, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 95, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 97, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16, and / or j) Comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 103, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 105, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 107, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

[0148] In some embodiments, at least one of ABD1, ABD2, ABD3, and ABD4 that binds to the capsid of an AAV particle is a) an HCVR comprising the amino acid sequence of SEQ ID NO: 2 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; b) an HCVR comprising the amino acid sequence of SEQ ID NO: 22 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; c) an HCVR comprising the amino acid sequence of SEQ ID NO: 32 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; d) an HCVR comprising the amino acid sequence of SEQ ID NO: 42 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; e) an HCVR comprising the amino acid sequence of SEQ ID NO: 52 or SEQ ID NO: 1159, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157; f) HCVR comprising the amino acid sequence of SEQ ID NO: 62 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 10; g) HCVR comprising the amino acid sequence of SEQ ID NO: 71 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 10; h) an HCVR comprising the amino acid sequence of SEQ ID NO: 81 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; i) an HCVR comprising the amino acid sequence of SEQ ID NO: 91, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10, and / or j) Contains an HCVR comprising the amino acid sequence of SEQ ID NO: 101 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0149] In some embodiments, the molecule on the cell surface is asialoglycoprotein receptor 1 (ASGR1), transferrin receptor (TfR), or calcium voltage-gated channel accessory subunit γ1 (CACNG1).

[0150] In some embodiments, the molecule on the cell surface is ASGR1.

[0151] In some embodiments, the other(s) of ABD1, ABD2, ABD3, and ABD4 that binds to ASGR1 is / are: a) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 220 or SEQ ID NO: 1239, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157, or b) Comprises an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 230, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0152] In some embodiments, the other(s) of ABD1, ABD2, ABD3, and ABD4 that binds to ASGR1 is / are: a) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 222, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 224, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 226, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16, or b) HCDR1 comprising the amino acid sequence of SEQ ID NO: 232, HCDR2 comprising the amino acid sequence of SEQ ID NO: 234, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 236, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

[0153] In some embodiments, the other(s) of ABD1, ABD2, ABD3, and ABD4 that binds to ASGR1 is / are: a) an HCVR comprising the amino acid sequence of SEQ ID NO: 220 or SEQ ID NO: 1239, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157, or b) comprises an HCVR comprising the amino acid sequence of SEQ ID NO: 230 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10.

[0154] In some embodiments, the molecule on the cell surface is TfR.

[0155] In some embodiments, the other(s) of ABD1, ABD2, ABD3, and ABD4 that bind to TfR are: 1) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 270 or SEQ ID NO: 271, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 276; 2) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 281 or SEQ ID NO: 282, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 287; 3) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 292 or SEQ ID NO: 293, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 298; 4) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 303, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 308 or SEQ ID NO: 309; 5) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 314, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 319 or SEQ ID NO: 320; 6) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 325 or SEQ ID NO: 326, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 331 or SEQ ID NO: 332; 7) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 337 or SEQ ID NO: 338, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 343 or SEQ ID NO: 344; 8) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 349 or SEQ ID NO: 350, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 355 or SEQ ID NO: 356; 9) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 361, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 366; 10) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 371 or SEQ ID NO: 372, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 377; 11) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 382, ​​and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 387; 12) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 392 or SEQ ID NO: 393, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 398 or SEQ ID NO: 399; 13) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 404, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 409; 14) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 414, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 419; 15) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 424 or SEQ ID NO: 425, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 430 or SEQ ID NO: 431; 16) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 436, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 441; 17) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 446 or SEQ ID NO: 447, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 452; 18) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 457, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 462; 19) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 467 or SEQ ID NO: 468, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 473 or SEQ ID NO: 474; 20) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 479 or SEQ ID NO: 480, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 485; 21) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 490 or SEQ ID NO: 491, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 496; 22) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 501, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 506; 23) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 511, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 516; 24) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 521, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 526; 25) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 531, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 536; 26) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 541 or SEQ ID NO: 542, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 547; 27) An HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 552, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 557; 28) An HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 562, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 567; 29) An HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 572, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 577; 30) An HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 582, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 587; 31) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 592 or SEQ ID NO: 593, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 598 or SEQ ID NO: 599; 32) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 604, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 609 or SEQ ID NO: 610, or 33) Comprises an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1119, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 1127.

[0156] In some embodiments, the other(s) of ABD1, ABD2, ABD3, and ABD4 that bind to TfR are: 1) HCDR1 comprising the amino acid sequence of SEQ ID NO: 272, HCDR2 comprising the amino acid sequence of SEQ ID NO: 273, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 274, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 277, LCDR2 comprising the amino acid sequence of SEQ ID NO: 278, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 279; 2) HCDR1 comprising the amino acid sequence of SEQ ID NO: 283, HCDR2 comprising the amino acid sequence of SEQ ID NO: 284, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 285, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 288, LCDR2 comprising the amino acid sequence of SEQ ID NO: 289, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 290; 3) HCDR1 comprising the amino acid sequence of SEQ ID NO: 294, HCDR2 comprising the amino acid sequence of SEQ ID NO: 295, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 296, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 299, LCDR2 comprising the amino acid sequence of SEQ ID NO: 300, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 301; 4) HCDR1 comprising the amino acid sequence of SEQ ID NO: 304, HCDR2 comprising the amino acid sequence of SEQ ID NO: 305, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 306, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 310, LCDR2 comprising the amino acid sequence of SEQ ID NO: 311, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 312; 5) HCDR1 comprising the amino acid sequence of SEQ ID NO: 315, HCDR2 comprising the amino acid sequence of SEQ ID NO: 316, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 317, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 321, LCDR2 comprising the amino acid sequence of SEQ ID NO: 322, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 323; 6) HCDR1 comprising the amino acid sequence of SEQ ID NO: 327, HCDR2 comprising the amino acid sequence of SEQ ID NO: 328, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 329, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 333, LCDR2 comprising the amino acid sequence of SEQ ID NO: 334, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 335; 7) HCDR1 comprising the amino acid sequence of SEQ ID NO: 339, HCDR2 comprising the amino acid sequence of SEQ ID NO: 340, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 341, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 345, LCDR2 comprising the amino acid sequence of SEQ ID NO: 346, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 347; 8) HCDR1 comprising the amino acid sequence of SEQ ID NO: 351, HCDR2 comprising the amino acid sequence of SEQ ID NO: 352, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 353, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 357, LCDR2 comprising the amino acid sequence of SEQ ID NO: 358, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 359; 9) HCDR1 comprising the amino acid sequence of SEQ ID NO: 362, HCDR2 comprising the amino acid sequence of SEQ ID NO: 363, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 364, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 367, LCDR2 comprising the amino acid sequence of SEQ ID NO: 368, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 369; 10) HCDR1 comprising the amino acid sequence of SEQ ID NO: 373, HCDR2 comprising the amino acid sequence of SEQ ID NO: 374, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 375, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 378, LCDR2 comprising the amino acid sequence of SEQ ID NO: 379, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 380; 11) HCDR1 comprising the amino acid sequence of SEQ ID NO: 383, HCDR2 comprising the amino acid sequence of SEQ ID NO: 384, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 385, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 388, LCDR2 comprising the amino acid sequence of SEQ ID NO: 389, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 390; 12) HCDR1 comprising the amino acid sequence of SEQ ID NO: 394, HCDR2 comprising the amino acid sequence of SEQ ID NO: 395, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 396, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 400, LCDR2 comprising the amino acid sequence of SEQ ID NO: 401, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 402; 13) HCDR1 comprising the amino acid sequence of SEQ ID NO: 405, HCDR2 comprising the amino acid sequence of SEQ ID NO: 406, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 407, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 410, LCDR2 comprising the amino acid sequence of SEQ ID NO: 411, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 412; 14) HCDR1 comprising the amino acid sequence of SEQ ID NO: 415, HCDR2 comprising the amino acid sequence of SEQ ID NO: 416, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 417, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 420, LCDR2 comprising the amino acid sequence of SEQ ID NO: 421, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 422; 15) HCDR1 comprising the amino acid sequence of SEQ ID NO: 426, HCDR2 comprising the amino acid sequence of SEQ ID NO: 427, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 428, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 432, LCDR2 comprising the amino acid sequence of SEQ ID NO: 433, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 434; 16) HCDR1 comprising the amino acid sequence of SEQ ID NO: 437, HCDR2 comprising the amino acid sequence of SEQ ID NO: 438, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 439, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 442, LCDR2 comprising the amino acid sequence of SEQ ID NO: 443, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 444; 17) HCDR1 comprising the amino acid sequence of SEQ ID NO: 448, HCDR2 comprising the amino acid sequence of SEQ ID NO: 449, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 450, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 453, LCDR2 comprising the amino acid sequence of SEQ ID NO: 454, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 455; 18) HCDR1 comprising the amino acid sequence of SEQ ID NO: 458, HCDR2 comprising the amino acid sequence of SEQ ID NO: 459, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 460, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 463, LCDR2 comprising the amino acid sequence of SEQ ID NO: 464, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 465; 19) HCDR1 comprising the amino acid sequence of SEQ ID NO: 469, HCDR2 comprising the amino acid sequence of SEQ ID NO: 470, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 471, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 475, LCDR2 comprising the amino acid sequence of SEQ ID NO: 476, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 477; 20) HCDR1 comprising the amino acid sequence of SEQ ID NO: 481, HCDR2 comprising the amino acid sequence of SEQ ID NO: 482, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 483, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 486, LCDR2 comprising the amino acid sequence of SEQ ID NO: 487, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 488; 21) HCDR1 comprising the amino acid sequence of SEQ ID NO: 492, HCDR2 comprising the amino acid sequence of SEQ ID NO: 493, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 494, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 497, LCDR2 comprising the amino acid sequence of SEQ ID NO: 498, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 499; 22) HCDR1 comprising the amino acid sequence of SEQ ID NO: 502, HCDR2 comprising the amino acid sequence of SEQ ID NO: 503, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 504, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 507, LCDR2 comprising the amino acid sequence of SEQ ID NO: 508, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 509; 23) HCDR1 comprising the amino acid sequence of SEQ ID NO: 512, HCDR2 comprising the amino acid sequence of SEQ ID NO: 513, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 514, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 517, LCDR2 comprising the amino acid sequence of SEQ ID NO: 518, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 519; 24) HCDR1 comprising the amino acid sequence of SEQ ID NO: 522, HCDR2 comprising the amino acid sequence of SEQ ID NO: 523, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 524, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 527, LCDR2 comprising the amino acid sequence of SEQ ID NO: 528, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 529; 25) HCDR1 comprising the amino acid sequence of SEQ ID NO: 532, HCDR2 comprising the amino acid sequence of SEQ ID NO: 533, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 534, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 537, LCDR2 comprising the amino acid sequence of SEQ ID NO: 538, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 539; 26) HCDR1 comprising the amino acid sequence of SEQ ID NO: 543, HCDR2 comprising the amino acid sequence of SEQ ID NO: 544, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 545, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 548, LCDR2 comprising the amino acid sequence of SEQ ID NO: 549, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 550; 27) HCDR1 comprising the amino acid sequence of SEQ ID NO: 553, HCDR2 comprising the amino acid sequence of SEQ ID NO: 554, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 555, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 558, LCDR2 comprising the amino acid sequence of SEQ ID NO: 559, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 560; 28) HCDR1 comprising the amino acid sequence of SEQ ID NO: 563, HCDR2 comprising the amino acid sequence of SEQ ID NO: 564, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 565, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 568, LCDR2 comprising the amino acid sequence of SEQ ID NO: 569, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 570; 29) HCDR1 comprising the amino acid sequence of SEQ ID NO: 573, HCDR2 comprising the amino acid sequence of SEQ ID NO: 574, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 575, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 578, LCDR2 comprising the amino acid sequence of SEQ ID NO: 579, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 580; 30) HCDR1 comprising the amino acid sequence of SEQ ID NO: 583, HCDR2 comprising the amino acid sequence of SEQ ID NO: 584, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 585, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 588, LCDR2 comprising the amino acid sequence of SEQ ID NO: 589, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 590; 31) HCDR1 comprising the amino acid sequence of SEQ ID NO: 594, HCDR2 comprising the amino acid sequence of SEQ ID NO: 595, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 596, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 600, LCDR2 comprising the amino acid sequence of SEQ ID NO: 601, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 602; 32) HCDR1 comprising the amino acid sequence of SEQ ID NO: 605, HCDR2 comprising the amino acid sequence of SEQ ID NO: 606, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 607, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 611, LCDR2 comprising the amino acid sequence of SEQ ID NO: 612, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 613, or 33) Comprises HCDR1 having the amino acid sequence of SEQ ID NO: 1121, HCDR2 having the amino acid sequence of SEQ ID NO: 1123, and HCDR3 having the amino acid sequence of SEQ ID NO: 1125, and / or LCDR1 having the amino acid sequence of SEQ ID NO: 1129, LCDR2 having the amino acid sequence of SEQ ID NO: 1131, and LCDR3 having the amino acid sequence of SEQ ID NO: 1133.

[0157] In some embodiments, the other(s) of ABD1, ABD2, ABD3, and ABD4 that bind to TfR are: 1) an HCVR comprising the amino acid sequence of SEQ ID NO: 270 or SEQ ID NO: 271, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 276; 2) an HCVR comprising the amino acid sequence of SEQ ID NO: 281 or SEQ ID NO: 282, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 287; 3) an HCVR comprising the amino acid sequence of SEQ ID NO: 292 or SEQ ID NO: 293, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 298; 4) an HCVR comprising the amino acid sequence of SEQ ID NO: 303, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 308 or SEQ ID NO: 309; 5) an HCVR comprising the amino acid sequence of SEQ ID NO: 314, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 319 or SEQ ID NO: 320; 6) an HCVR comprising the amino acid sequence of SEQ ID NO: 325 or SEQ ID NO: 326, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 331 or SEQ ID NO: 332; 7) an HCVR comprising the amino acid sequence of SEQ ID NO: 337 or SEQ ID NO: 338, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 343 or SEQ ID NO: 344; 8) an HCVR comprising the amino acid sequence of SEQ ID NO: 349 or SEQ ID NO: 350, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 355 or SEQ ID NO: 356; 9) an HCVR comprising the amino acid sequence of SEQ ID NO: 361 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 366; 10) an HCVR comprising the amino acid sequence of SEQ ID NO: 371 or SEQ ID NO: 372, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 377; 11) HCVR comprising the amino acid sequence of SEQ ID NO: 382 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 387; 12) an HCVR comprising the amino acid sequence of SEQ ID NO: 392 or SEQ ID NO: 393, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 398 or SEQ ID NO: 399; 13) HCVR comprising the amino acid sequence of SEQ ID NO: 404 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 409; 14) HCVR comprising the amino acid sequence of SEQ ID NO: 414 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 419; 15) HCVR comprising the amino acid sequence of SEQ ID NO: 424 or SEQ ID NO: 425, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 430 or SEQ ID NO: 431; 16) HCVR comprising the amino acid sequence of SEQ ID NO: 436 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 441; 17) HCVR comprising the amino acid sequence of SEQ ID NO: 446 or SEQ ID NO: 447, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 452; 18) HCVR comprising the amino acid sequence of SEQ ID NO: 457 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 462; 19) HCVR comprising the amino acid sequence of SEQ ID NO: 467 or SEQ ID NO: 468, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 473 or SEQ ID NO: 474; 20) HCVR comprising the amino acid sequence of SEQ ID NO: 479 or SEQ ID NO: 480, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 485; 21) HCVR comprising the amino acid sequence of SEQ ID NO: 490 or SEQ ID NO: 491, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 496; 22) HCVR comprising the amino acid sequence of SEQ ID NO: 501 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 506; 23) HCVR comprising the amino acid sequence of SEQ ID NO: 511 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 516; 24) HCVR comprising the amino acid sequence of SEQ ID NO: 521 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 526; 25) HCVR comprising the amino acid sequence of SEQ ID NO: 531 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 536; 26) HCVR comprising the amino acid sequence of SEQ ID NO: 541 or SEQ ID NO: 542, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 547; 27) HCVR comprising the amino acid sequence of SEQ ID NO: 552 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 557; 28) HCVR comprising the amino acid sequence of SEQ ID NO: 562 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 567; 29) HCVR comprising the amino acid sequence of SEQ ID NO: 572 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 577; 30) HCVR comprising the amino acid sequence of SEQ ID NO: 582 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 587; 31) HCVR comprising the amino acid sequence of SEQ ID NO: 592 or SEQ ID NO: 593, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 598 or SEQ ID NO: 599; 32) an HCVR comprising the amino acid sequence of SEQ ID NO: 604, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 609 or SEQ ID NO: 610, or 33) Contains an HCVR comprising the amino acid sequence of SEQ ID NO: 1119 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 1127.

[0158] In some embodiments, the molecule on the cell surface is CACNG1.

[0159] In some embodiments, the other(s) of ABD1, ABD2, ABD3, and ABD4 that binds to CACNG1 are: 1) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 615, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 623; 2) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 635, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 643; 3) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 655, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 663; 4) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 675, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 683; 5) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 695, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 703; 6) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 715, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 723; 7) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 735, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 743; 8) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 755, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 763; 9) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 775, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 783; 10) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 795, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 803; 11) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 815, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 823; 12) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 835, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 843; 13) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 855, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 863; 14) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 875, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 883; 15) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 895, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 903; 16) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 915, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 923; 17) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 935, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 943; 18) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 955, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 963; 19) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1181, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 1189, or 20) Comprises an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1205, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 1213.

[0160] In some embodiments, the other(s) of ABD1, ABD2, ABD3, and ABD4 that binds to CACNG1 are: 1) HCDR1 comprising the amino acid sequence of SEQ ID NO: 617, HCDR2 comprising the amino acid sequence of SEQ ID NO: 619, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 621, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 625, LCDR2 comprising the amino acid sequence of SEQ ID NO: 627, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 629; 2) HCDR1 comprising the amino acid sequence of SEQ ID NO: 637, HCDR2 comprising the amino acid sequence of SEQ ID NO: 639, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 641, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 645, LCDR2 comprising the amino acid sequence of SEQ ID NO: 647, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 649; 3) HCDR1 comprising the amino acid sequence of SEQ ID NO: 657, HCDR2 comprising the amino acid sequence of SEQ ID NO: 659, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 661, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 665, LCDR2 comprising the amino acid sequence of SEQ ID NO: 667, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 669; 4) HCDR1 comprising the amino acid sequence of SEQ ID NO: 677, HCDR2 comprising the amino acid sequence of SEQ ID NO: 679, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 681, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 685, LCDR2 comprising the amino acid sequence of SEQ ID NO: 687, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 689; 5) HCDR1 comprising the amino acid sequence of SEQ ID NO: 697, HCDR2 comprising the amino acid sequence of SEQ ID NO: 699, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 701, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 705, LCDR2 comprising the amino acid sequence of SEQ ID NO: 707, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 709; 6) HCDR1 comprising the amino acid sequence of SEQ ID NO: 717, HCDR2 comprising the amino acid sequence of SEQ ID NO: 719, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 721, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 725, LCDR2 comprising the amino acid sequence of SEQ ID NO: 727, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 729; 7) HCDR1 comprising the amino acid sequence of SEQ ID NO: 737, HCDR2 comprising the amino acid sequence of SEQ ID NO: 739, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 741, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 745, LCDR2 comprising the amino acid sequence of SEQ ID NO: 747, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 749; 8) HCDR1 comprising the amino acid sequence of SEQ ID NO: 757, HCDR2 comprising the amino acid sequence of SEQ ID NO: 759, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 761, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 765, LCDR2 comprising the amino acid sequence of SEQ ID NO: 767, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 769; 9) HCDR1 comprising the amino acid sequence of SEQ ID NO: 777, HCDR2 comprising the amino acid sequence of SEQ ID NO: 779, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 781, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 785, LCDR2 comprising the amino acid sequence of SEQ ID NO: 787, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 789; 10) HCDR1 comprising the amino acid sequence of SEQ ID NO: 797, HCDR2 comprising the amino acid sequence of SEQ ID NO: 799, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 801, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 805, LCDR2 comprising the amino acid sequence of SEQ ID NO: 807, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 809; 11) HCDR1 comprising the amino acid sequence of SEQ ID NO: 817, HCDR2 comprising the amino acid sequence of SEQ ID NO: 819, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 821, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 825, LCDR2 comprising the amino acid sequence of SEQ ID NO: 827, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 829; 12) HCDR1 comprising the amino acid sequence of SEQ ID NO: 837, HCDR2 comprising the amino acid sequence of SEQ ID NO: 839, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 841, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 845, LCDR2 comprising the amino acid sequence of SEQ ID NO: 847, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 849; 13) HCDR1 comprising the amino acid sequence of SEQ ID NO: 857, HCDR2 comprising the amino acid sequence of SEQ ID NO: 859, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 861, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 865, LCDR2 comprising the amino acid sequence of SEQ ID NO: 867, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 869; 14) HCDR1 comprising the amino acid sequence of SEQ ID NO: 877, HCDR2 comprising the amino acid sequence of SEQ ID NO: 879, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 881, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 885, LCDR2 comprising the amino acid sequence of SEQ ID NO: 887, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 889; 15) HCDR1 comprising the amino acid sequence of SEQ ID NO: 897, HCDR2 comprising the amino acid sequence of SEQ ID NO: 899, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 901, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 905, LCDR2 comprising the amino acid sequence of SEQ ID NO: 907, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 909; 16) HCDR1 comprising the amino acid sequence of SEQ ID NO: 917, HCDR2 comprising the amino acid sequence of SEQ ID NO: 919, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 921, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 925, LCDR2 comprising the amino acid sequence of SEQ ID NO: 927, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 929; 17) HCDR1 comprising the amino acid sequence of SEQ ID NO: 937, HCDR2 comprising the amino acid sequence of SEQ ID NO: 939, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 941, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 945, LCDR2 comprising the amino acid sequence of SEQ ID NO: 947, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 949; 18) HCDR1 comprising the amino acid sequence of SEQ ID NO: 957, HCDR2 comprising the amino acid sequence of SEQ ID NO: 959, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 961, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 965, LCDR2 comprising the amino acid sequence of SEQ ID NO: 967, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 969; 19) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1183, HCDR2 comprising the amino acid sequence of SEQ ID NO: 1185, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 1187, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1191, LCDR2 comprising the amino acid sequence of SEQ ID NO: 1193, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 1195, or 20) Comprises HCDR1 having the amino acid sequence of SEQ ID NO: 1207, HCDR2 having the amino acid sequence of SEQ ID NO: 1209, and HCDR3 having the amino acid sequence of SEQ ID NO: 1211, and / or LCDR1 having the amino acid sequence of SEQ ID NO: 1215, LCDR2 having the amino acid sequence of SEQ ID NO: 1217, and LCDR3 having the amino acid sequence of SEQ ID NO: 1219.

[0161] In some embodiments, the other(s) of ABD1, ABD2, ABD3, and ABD4 that binds to CACNG1 are: 1) an HCVR comprising the amino acid sequence of SEQ ID NO: 615 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 623; 2) an HCVR comprising the amino acid sequence of SEQ ID NO: 635 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 643; 3) an HCVR comprising the amino acid sequence of SEQ ID NO: 655 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 663; 4) an HCVR comprising the amino acid sequence of SEQ ID NO: 675 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 683; 5) an HCVR comprising the amino acid sequence of SEQ ID NO: 695 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 703; 6) an HCVR comprising the amino acid sequence of SEQ ID NO: 715 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 723; 7) an HCVR comprising the amino acid sequence of SEQ ID NO: 735 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 743; 8) an HCVR comprising the amino acid sequence of SEQ ID NO: 755 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 763; 9) an HCVR comprising the amino acid sequence of SEQ ID NO: 775 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 783; 10) an HCVR comprising the amino acid sequence of SEQ ID NO: 795 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 803; 11) HCVR comprising the amino acid sequence of SEQ ID NO: 815 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 823; 12) an HCVR comprising the amino acid sequence of SEQ ID NO: 835 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 843; 13) HCVR comprising the amino acid sequence of SEQ ID NO: 855 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 863; 14) HCVR comprising the amino acid sequence of SEQ ID NO: 875 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 883; 15) HCVR comprising the amino acid sequence of SEQ ID NO: 895 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 903; 16) HCVR comprising the amino acid sequence of SEQ ID NO: 915 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 923; 17) HCVR comprising the amino acid sequence of SEQ ID NO: 935 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 943; 18) HCVR comprising the amino acid sequence of SEQ ID NO: 955 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 963; 19) HCVR comprising the amino acid sequence of SEQ ID NO: 1181 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 1189, or 20) Contains an HCVR comprising the amino acid sequence of SEQ ID NO: 1205 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 1213.

[0162] In some embodiments, the linker is (a) at least 5 amino acids in length, at least 6 amino acids in length, or at least 7 amino acids in length, and optionally (b) is at most 30 amino acids in length, at most 40 amino acids in length, at most 50 amino acids in length, or at most 60 amino acids in length.

[0163] In some embodiments, the linker is (a) 5 amino acids to 50 amino acids in length, (b) 5 amino acids to 45 amino acids in length; (c) 5 amino acids to 40 amino acids in length; (d) 5 amino acids to 35 amino acids in length; (e) 5 amino acids to 30 amino acids in length, (f) 5 to 25 amino acids in length, or (g) 5 to 20 amino acids in length.

[0164] In some embodiments, the linker is (a) 6 amino acids to 50 amino acids in length, (b) 6 amino acids to 45 amino acids in length; (c) 6 amino acids to 40 amino acids in length; (d) 6 amino acids to 35 amino acids in length; (e) 6 amino acids to 30 amino acids in length, (f) 6 to 25 amino acids in length, or (g) 6 to 20 amino acids in length.

[0165] In some embodiments, the linker is (a) 7 amino acids to 40 amino acids in length, (b) 7 amino acids to 35 amino acids in length; (c) 7 amino acids to 30 amino acids in length; (d) 7 amino acids to 25 amino acids in length; (e) 7 to 20 amino acids in length.

[0166] In some embodiments, the linker is between 5 and 25 amino acids in length.

[0167] In some embodiments, the linker is between 10 and 60 amino acids in length.

[0168] In some embodiments, the linker is between 20 and 50 amino acids in length.

[0169] In some embodiments, the linker is between 25 and 35 amino acids in length.

[0170] In some embodiments, the linker is G n S(sequence number 239) or SGn (SEQ ID NO: 240) (wherein n is an integer from 1 to 10).

[0171] In some embodiments, the linker is or comprises a multimer of G4S (SEQ ID NO: 242).

[0172] In some embodiments, the linker is or comprises two consecutive glycines (2Gly), three consecutive glycines (3Gly), four consecutive glycines (4Gly (SEQ ID NO: 243)), five consecutive glycines (5Gly (SEQ ID NO: 244)), six consecutive glycines (6Gly (SEQ ID NO: 245)), seven consecutive glycines (7Gly (SEQ ID NO: 246)), eight consecutive glycines (8Gly (SEQ ID NO: 247)), or nine consecutive glycines (9Gly (SEQ ID NO: 248)).

[0173] In some embodiments, one or more of the light chains is a universal light chain.

[0174] In some embodiments, the light chain constant region (CL) and the first heavy chain constant region (CH1) of one or more Fabs are in a CrossmAb configuration.

[0175] In some embodiments of any of the above multispecific antibodies or multispecific antigen-binding fragments, the multispecific antibody or multispecific antigen-binding fragment comprises an Fc heterodimer.

[0176] In some embodiments, the Fc domain in the Fc heterodimer comprises a knobs-in-holes mutation compared to the wild-type Fc domain.

[0177] In some embodiments, one Fc domain in the Fc heterodimer comprises the amino acid substitutions S354C and T366W (according to EU numbering) compared to the wild-type Fc domain, and the other Fc domain in the Fc heterodimer comprises the amino acid substitutions Y349C, T366S, L368A, and Y407V (according to EU numbering) compared to the wild-type Fc domain.

[0178] In some embodiments, at least one Fc domain in the Fc heterodimer comprises a star mutation compared to the wild-type Fc domain.

[0179] In some embodiments, one Fc domain in the Fc heterodimer comprises the amino acid mutations H435R and / or Y436F (according to EU numbering) compared to the wild-type Fc domain.

[0180] In some embodiments, the capsid comprises one or more wild-type AAV capsid polypeptides.

[0181] In some embodiments, the capsid comprises one or more non-wild-type AAV capsid polypeptides.

[0182] In some embodiments of any of the above multispecific antibodies or multispecific antibody fragments, the multispecific antibody or multispecific antigen-binding fragment may be a bispecific antibody or bispecific antigen-binding fragment thereof.

[0183] In another aspect, provided herein is a pharmaceutical composition comprising a multispecific antibody or multispecific antigen-binding fragment described herein and a pharmaceutically acceptable carrier or excipient.

[0184] In another aspect, provided herein is a molecular complex comprising an AAV particle bound to one or more antibodies and / or antigen-binding fragments described herein.

[0185] In some embodiments, the AAV particles comprise one or more mutations in one or more AAV capsid proteins that inhibit the natural tropism of the AAV particle.

[0186] In another aspect, provided herein is a pharmaceutical composition comprising a molecular conjugate described herein and a pharmaceutically acceptable carrier or excipient.

[0187] In another aspect, provided herein is a method of preparing a molecular complex described herein, the method comprising incubating the AAV particle in the presence of the one or more antibodies and / or antigen-binding fragments under conditions that allow specific binding of the one or more antibodies and / or antigen-binding fragments to the AAV particle capsid.

[0188] In another aspect, provided herein is a molecular complex comprising an AAV particle bound to one or more multispecific antibodies and / or multispecific antigen-binding fragments described herein.

[0189] In some embodiments, the AAV particles comprise one or more mutations in one or more AAV capsid proteins that inhibit the natural tropism of the AAV particle.

[0190] In another aspect, provided herein is a pharmaceutical composition comprising a molecular conjugate described herein and a pharmaceutically acceptable carrier or excipient.

[0191] In another aspect, provided herein is a method of preparing a molecular complex described herein, the method comprising incubating the AAV particles in the presence of the one or more multispecific antibodies and / or multispecific antigen-binding fragments under conditions that allow for specific binding of the one or more multispecific antibodies and / or multispecific antigen-binding fragments to the AAV particle capsid.

[0192] In another aspect, provided herein is a method for targeting AAV particles to a cell that expresses a molecule on its surface, comprising contacting the cell with a molecular conjugate described herein or a pharmaceutical composition described herein, wherein the molecular conjugate comprises one or more multispecific antibodies and / or multispecific antigen-binding fragments that bind to the molecule on the cell surface.

[0193] In another aspect, provided herein is a method for delivering a polynucleotide to a cell expressing a molecule on its surface, comprising contacting the cell with a molecular complex described herein or a pharmaceutical composition described herein, wherein the molecular complex comprises AAV particles comprising the polynucleotide and bound to one or more multispecific antibodies and / or multispecific antigen-binding fragments that bind to the molecule on the cell surface.

[0194] In some embodiments, the cells are in a subject and the molecular complex is administered to the subject.

[0195] In some embodiments, the AAV particles do not target the cells in the absence of the one or more multispecific antibodies and / or multispecific antigen-binding fragments.

[0196] In various embodiments, any of the features or components of the embodiments described above or discussed herein may be combined, and such combinations are encompassed within the scope of the present disclosure. Any particular value described above or discussed herein may be combined with another associated value described above or discussed herein to recite a range with the values ​​representing the upper and lower limits of the range, and such ranges are encompassed within the scope of the present disclosure.

[0197] Other embodiments will become apparent from consideration of the following detailed description. [Brief explanation of the drawings]

[0198] [Figure 1A] 1 shows a graph of the binding activity of anti-adeno-associated virus (AAV) antibodies described herein against various adeno-associated virus (AAV) serotypes. RLU, relative light units. [Figure 1B] 1 shows a graph of the binding activity of anti-adeno-associated virus (AAV) antibodies described herein against various adeno-associated virus (AAV) serotypes. RLU, relative light units. [Figure 1C] 1 shows a graph of the binding activity of anti-adeno-associated virus (AAV) antibodies described herein against various adeno-associated virus (AAV) serotypes. RLU, relative light units. [Figure 1D] 1 shows a graph of the binding activity of anti-adeno-associated virus (AAV) antibodies described herein against various adeno-associated virus (AAV) serotypes. RLU, relative light units. [Figure 1E] 1 shows a graph of the binding activity of anti-adeno-associated virus (AAV) antibodies described herein against various adeno-associated virus (AAV) serotypes. RLU, relative light units. [Figure 1F] 1 shows a graph of the binding activity of anti-adeno-associated virus (AAV) antibodies described herein against various adeno-associated virus (AAV) serotypes. RLU, relative light units. [Figure 1G]1 shows a graph of the binding activity of anti-adeno-associated virus (AAV) antibodies described herein against various adeno-associated virus (AAV) serotypes. RLU, relative light units. [Figure 1H] 1 shows a graph of the binding activity of anti-adeno-associated virus (AAV) antibodies described herein against various adeno-associated virus (AAV) serotypes. RLU, relative light units. [Figure 1I] 1 shows a graph of the binding activity of anti-adeno-associated virus (AAV) antibodies described herein against various adeno-associated virus (AAV) serotypes. RLU, relative light units. [Figure 1J] 1 shows a graph of the binding activity of anti-adeno-associated virus (AAV) antibodies described herein against various adeno-associated virus (AAV) serotypes. RLU, relative light units. [Figure 1K] 1 shows a graph of the binding activity of anti-adeno-associated virus (AAV) antibodies described herein against various adeno-associated virus (AAV) serotypes. RLU, relative light units. [Figure 1L] 1 shows a graph of the binding activity of anti-adeno-associated virus (AAV) antibodies described herein against various adeno-associated virus (AAV) serotypes. RLU, relative light units.

[0199] [Figure 2A] 2A-F are graphs showing immunoglobulin gamma Fc receptor I (FcGR-1) AAV retargeting by anti-AAV antibodies obtained using the next-generation sequencing (NGS) and mass spectrometry (MS) methods described herein for various AAV serotypes. [Figure 2B] 2A-F are graphs showing immunoglobulin gamma Fc receptor I (FcGR-1) AAV retargeting by anti-AAV antibodies obtained using the next-generation sequencing (NGS) and mass spectrometry (MS) methods described herein for various AAV serotypes. [Figure 2C]2A-F are graphs showing immunoglobulin gamma Fc receptor I (FcGR-1) AAV retargeting by anti-AAV antibodies obtained using the next-generation sequencing (NGS) and mass spectrometry (MS) methods described herein for various AAV serotypes. [Figure 2D] 2A-F are graphs showing immunoglobulin gamma Fc receptor I (FcGR-1) AAV retargeting by anti-AAV antibodies obtained using the next-generation sequencing (NGS) and mass spectrometry (MS) methods described herein for various AAV serotypes. [Figure 2E] 2A-F are graphs showing immunoglobulin gamma Fc receptor I (FcGR-1) AAV retargeting by anti-AAV antibodies obtained using the next-generation sequencing (NGS) and mass spectrometry (MS) methods described herein for various AAV serotypes. [Figure 2F] 2A-F are graphs showing immunoglobulin gamma Fc receptor I (FcGR-1) AAV retargeting by anti-AAV antibodies obtained using the next-generation sequencing (NGS) and mass spectrometry (MS) methods described herein for various AAV serotypes. [Figure 2G] 2A-2J are graphs showing immunoglobulin gamma Fc receptor I (FcGR-1) AAV retargeting by anti-AAV antibodies obtained from hybridomas described herein for various AAV serotypes (FIGS. 2G-2J). [Figure 2H] 2A-2J are graphs showing immunoglobulin gamma Fc receptor I (FcGR-1) AAV retargeting by anti-AAV antibodies obtained from hybridomas described herein for various AAV serotypes (FIGS. 2G-2J). [Figure 2I] 2A-2J are graphs showing immunoglobulin gamma Fc receptor I (FcGR-1) AAV retargeting by anti-AAV antibodies obtained from hybridomas described herein for various AAV serotypes (FIGS. 2G-2J). [Figure 2J]2A-2J are graphs showing immunoglobulin gamma Fc receptor I (FcGR-1) AAV retargeting by anti-AAV antibodies obtained from hybridomas described herein for various AAV serotypes (FIGS. 2G-2J).

[0200] [Figure 3] 1 shows a schematic diagram of an alternative format antibody design for the bispecific antibody of the present disclosure. An exemplary bispecific antibody targets AAV and asialoglycoprotein receptor 1 (ASGR1). Star mutations are indicated with an asterisk (*), and knob-in-hole (KiH) mutations are indicated with a triangle (e.g.,

number

[0201] [Figure 4-1] 1 shows a representation of an alternative format bispecific antibody molecule described herein. [Figure 4-2] 1 shows a representation of an alternative format bispecific antibody molecule described herein. [Figure 4-3] 1 shows a representation of an alternative format bispecific antibody molecule described herein.

[0202] [Figure 5] An example of the rationale for anti-AAV antibody selection is shown.

[0203] [Figure 6A]

[0023] Figure 1 shows a graph of the binding affinity of alternative format antibodies (e.g., anti-AAV-ASGR 1 bispecific antibodies) described herein to the AAV2 heparin-binding mutant (HBM) serotype. The AAV2-HBM serotype contains R585A R588A mutations. RLU, relative light units. [Figure 6B]

[0023] Figure 1 shows a graph of the binding affinity of alternative format antibodies (e.g., anti-AAV-ASGR 1 bispecific antibodies) described herein to the AAV2 heparin-binding mutant (HBM) serotype. The AAV2-HBM serotype contains R585A R588A mutations. RLU, relative light units. [Figure 6C]

[0023] Figure 1 shows a graph of the binding affinity of alternative format antibodies (e.g., anti-AAV-ASGR 1 bispecific antibodies) described herein to the AAV2 heparin-binding mutant (HBM) serotype. The AAV2-HBM serotype contains R585A R588A mutations. RLU, relative light units. [Figure 6D]

[0023] Figure 1 shows a graph of the binding affinity of alternative format antibodies (e.g., anti-AAV-ASGR 1 bispecific antibodies) described herein to the AAV2 heparin-binding mutant (HBM) serotype. The AAV2-HBM serotype contains R585A R588A mutations. RLU, relative light units. [Figure 6E]

[0023] Figure 1 shows a graph of the binding affinity of alternative format antibodies (e.g., anti-AAV-ASGR 1 bispecific antibodies) described herein to the AAV2 heparin-binding mutant (HBM) serotype. The AAV2-HBM serotype contains R585A R588A mutations. RLU, relative light units. [Figure 6F]

[0023] Figure 1 shows a graph of the binding affinity of alternative format antibodies (e.g., anti-AAV-ASGR 1 bispecific antibodies) described herein to the AAV2 heparin-binding mutant (HBM) serotype. The AAV2-HBM serotype contains R585A R588A mutations. RLU, relative light units. [Figure 6G]

[0023] Figure 1 shows a graph of the binding affinity of alternative format antibodies (e.g., anti-AAV-ASGR 1 bispecific antibodies) described herein to the AAV2 heparin-binding mutant (HBM) serotype. The AAV2-HBM serotype contains R585A R588A mutations. RLU, relative light units. [Figure 6H]

[0023] Figure 1 shows a graph of the binding affinity of alternative format antibodies (e.g., anti-AAV-ASGR 1 bispecific antibodies) described herein to the AAV2 heparin-binding mutant (HBM) serotype. The AAV2-HBM serotype contains R585A R588A mutations. RLU, relative light units. [Figure 6I]

[0023] Figure 1 shows a graph of the binding affinity of alternative format antibodies (e.g., anti-AAV-ASGR 1 bispecific antibodies) described herein to the AAV2 heparin-binding mutant (HBM) serotype. The AAV2-HBM serotype contains R585A R588A mutations. RLU, relative light units. [Figure 6J]

[0023] Figure 1 shows a graph of the binding affinity of alternative format antibodies (e.g., anti-AAV-ASGR 1 bispecific antibodies) described herein to the AAV2 heparin-binding mutant (HBM) serotype. The AAV2-HBM serotype contains R585A R588A mutations. RLU, relative light units.

[0204] [Figure 7A] We demonstrate that bispecific antibodies can effectively retarget adeno-associated virus (AAV) to the central nervous system (CNS). A schematic diagram of AAV retargeting to the CNS by anti-transferrin receptor (TfR) x anti-AAV bispecific antibodies is shown in Figure 7A. BBB, blood-brain barrier. [Figure 7B] We demonstrate that bispecific antibodies can effectively retarget adeno-associated virus (AAV) to the central nervous system (CNS). A comparison of wild-type (WT) AAV9, a covalent platform control, and the bispecific platform retargeting of AAV to the cerebellum, cortex, and hippocampus is shown in Figure 7B. BBB, blood-brain barrier.

[0205] [Figure 8A] We demonstrate that liver detargeting can be controlled by adjusting antibody concentration [Ab] and / or by using detargeted capsids. A comparison of transduction efficiency between the covalent and bispecific platforms, assessed using cDNA quantification, is shown in Figure 8A. IHC, immunohistochemistry. [Figure 8B]We demonstrate that liver detargeting can be controlled by adjusting antibody concentration [Ab] and / or by using detargeted capsids. A comparison between detargeted AAV9 and WT AA9 using the bispecific platform in the cerebellum and liver is shown in Figure 8B. IHC, immunohistochemistry.

[0206] [Figure 9] Schematic diagram of AAV×CACNG1 alternative format (AF) antibodies AF70 and AF71. AF70 contains an anti-AAV#70 scFv fused to the N-terminus of the anti-CACNG1 REGN10717 hIgG1 N297G antibody. AF71 contains an anti-AAV#70 scFv fused to the C-terminus of the anti-CACNG1 REGN10717 hIgG1 N297G antibody. Disulfide bonds are indicated by SS.

[0207] [Figure 10-1] Flow cytometry data show that co-incubation of AAV9 W503A with AF70 (top two rows) and AF71 (bottom two rows) resulted in improved transduction of HEK 293 cells overexpressing mouse CACNG1 (mCACNGI) compared with control AAV without antibody. Transduction efficiency, as assessed by percent (%) GFP-positive cells, was optimal between a molar ratio of 1 AAV to 1 antibody (AAV:Ab ratio 1:1) and a molar ratio of 1 AAV to 9 antibodies (AAV:Ab ratio 1:9). [Figure 10-2] Flow cytometry data show that co-incubation of AAV9 W503A with AF70 (top two rows) and AF71 (bottom two rows) resulted in improved transduction of HEK 293 cells overexpressing mouse CACNG1 (mCACNGI) compared with control AAV without antibody. Transduction efficiency, as assessed by percent (%) GFP-positive cells, was optimal between a molar ratio of 1 AAV to 1 antibody (AAV:Ab ratio 1:1) and a molar ratio of 1 AAV to 9 antibodies (AAV:Ab ratio 1:9). [Figure 10-3]Flow cytometry data show that co-incubation of AAV9 W503A with AF70 (top two rows) and AF71 (bottom two rows) resulted in improved transduction of HEK 293 cells overexpressing mouse CACNG1 (mCACNGI) compared with control AAV without antibody. Transduction efficiency, as assessed by percent (%) GFP-positive cells, was optimal between a molar ratio of 1 AAV to 1 antibody (AAV:Ab ratio 1:1) and a molar ratio of 1 AAV to 9 antibodies (AAV:Ab ratio 1:9). [Figure 10-4] Flow cytometry data show that co-incubation of AAV9 W503A with AF70 (top two rows) and AF71 (bottom two rows) resulted in improved transduction of HEK 293 cells overexpressing mouse CACNG1 (mCACNGI) compared with control AAV without antibody. Transduction efficiency, as assessed by percent (%) GFP-positive cells, was optimal between a molar ratio of 1 AAV to 1 antibody (AAV:Ab ratio 1:1) and a molar ratio of 1 AAV to 9 antibodies (AAV:Ab ratio 1:9). [Figure 10-5] Flow cytometry data show that co-incubation of AAV9 W503A with AF70 (top two rows) and AF71 (bottom two rows) resulted in improved transduction of HEK 293 cells overexpressing mouse CACNG1 (mCACNGI) compared with control AAV without antibody. Transduction efficiency, as assessed by percent (%) GFP-positive cells, was optimal between a molar ratio of 1 AAV to 1 antibody (AAV:Ab ratio 1:1) and a molar ratio of 1 AAV to 9 antibodies (AAV:Ab ratio 1:9). [Figure 10-6]Flow cytometry data show that co-incubation of AAV9 W503A with AF70 (top two rows) and AF71 (bottom two rows) resulted in improved transduction of HEK 293 cells overexpressing mouse CACNG1 (mCACNGI) compared with control AAV without antibody. Transduction efficiency, as assessed by percent (%) GFP-positive cells, was optimal between a molar ratio of 1 AAV to 1 antibody (AAV:Ab ratio 1:1) and a molar ratio of 1 AAV to 9 antibodies (AAV:Ab ratio 1:9).

[0208] [Figure 11] A line graph shows that co-incubation of AAV9 W503A with AF70 (top) and AF71 (bottom) resulted in improved transduction of HEK 293 cells overexpressing mouse CACNG1 (mCACNGI) compared with control AAV. Transduction efficiency, as assessed by mean fluorescence intensity (MFI), was optimal between a molar ratio of 1 AAV to 1 antibody (AAV:Ab ratio 1:1) and a molar ratio of 1 AAV to 9 antibodies (AAV:Ab ratio 1:9).

[0209] [Figure 12-1] Flow cytometry data show that co-incubation of AAV9 W503A with AF70 (top two rows) and AF71 (bottom two rows) resulted in improved AAV transduction efficacy in HEK 293 cells overexpressing human CACNG1 (hCACNGI) compared with control AAV without antibody. Transduction efficiency, as assessed by percent (%) GFP-positive cells, was optimal between a molar ratio of 1 AAV to 1 antibody (AAV:Ab ratio 1:1) and a molar ratio of 1 AAV to 9 antibodies (AAV:Ab ratio 1:9). [Figure 12-2]Flow cytometry data show that co-incubation of AAV9 W503A with AF70 (top two rows) and AF71 (bottom two rows) resulted in improved AAV transduction efficacy in HEK 293 cells overexpressing human CACNG1 (hCACNGI) compared with control AAV without antibody. Transduction efficiency, as assessed by percent (%) GFP-positive cells, was optimal between a molar ratio of 1 AAV to 1 antibody (AAV:Ab ratio 1:1) and a molar ratio of 1 AAV to 9 antibodies (AAV:Ab ratio 1:9). [Figure 12-3] Flow cytometry data show that co-incubation of AAV9 W503A with AF70 (top two rows) and AF71 (bottom two rows) resulted in improved AAV transduction efficacy in HEK 293 cells overexpressing human CACNG1 (hCACNGI) compared with control AAV without antibody. Transduction efficiency, as assessed by percent (%) GFP-positive cells, was optimal between a molar ratio of 1 AAV to 1 antibody (AAV:Ab ratio 1:1) and a molar ratio of 1 AAV to 9 antibodies (AAV:Ab ratio 1:9). [Figure 12-4] Flow cytometry data show that co-incubation of AAV9 W503A with AF70 (top two rows) and AF71 (bottom two rows) resulted in improved AAV transduction efficacy in HEK 293 cells overexpressing human CACNG1 (hCACNGI) compared with control AAV without antibody. Transduction efficiency, as assessed by percent (%) GFP-positive cells, was optimal between a molar ratio of 1 AAV to 1 antibody (AAV:Ab ratio 1:1) and a molar ratio of 1 AAV to 9 antibodies (AAV:Ab ratio 1:9). [Figure 12-5]Flow cytometry data show that co-incubation of AAV9 W503A with AF70 (top two rows) and AF71 (bottom two rows) resulted in improved AAV transduction efficacy in HEK 293 cells overexpressing human CACNG1 (hCACNGI) compared with control AAV without antibody. Transduction efficiency, as assessed by percent (%) GFP-positive cells, was optimal between a molar ratio of 1 AAV to 1 antibody (AAV:Ab ratio 1:1) and a molar ratio of 1 AAV to 9 antibodies (AAV:Ab ratio 1:9). [Figure 12-6] Flow cytometry data show that co-incubation of AAV9 W503A with AF70 (top two rows) and AF71 (bottom two rows) resulted in improved AAV transduction efficacy in HEK 293 cells overexpressing human CACNG1 (hCACNGI) compared with control AAV without antibody. Transduction efficiency, as assessed by percent (%) GFP-positive cells, was optimal between a molar ratio of 1 AAV to 1 antibody (AAV:Ab ratio 1:1) and a molar ratio of 1 AAV to 9 antibodies (AAV:Ab ratio 1:9).

[0210] [Figure 13] A line graph shows that co-incubation of AAV9 W503A with AF70 (top) and AF71 (bottom) resulted in improved AAV transduction efficiency in HEK 293 cells overexpressing human CACNG1 (hCACNGI) compared with control AAV without AAV. Transduction efficiency, as assessed by mean fluorescence intensity (MFI), was optimal between a molar ratio of 1 AAV to 1 antibody (AAV:Ab ratio 1:1) and a molar ratio of 1 AAV to 9 antibodies (AAV:Ab ratio 1:9).

[0211] [Figure 14] Shown is immunohistochemical staining of differentiated C2C12 myotubes for myosin heavy chain (MyHC) and a demonstration that incubation of AAV with AF70 and AF71 enhanced transduction of myotubes as determined by GFP fluorescence.

[0212] [Figure 15] This figure shows a demonstration that incubation of AAV with AF70 and AF71 enhanced myotube transduction, as determined by immunohistochemical staining of differentiated human myotubes for myosin heavy chain (MyHC) and GFP fluorescence. Human myotubes were most efficiently transduced with AAV complexed with AF71 at molar ratios of 1:3 and 1:9.

[0213] [Figure 16A] Figure 1 shows that incubation of AAV with AF70 and AF71 enhanced transduction of differentiated C2C12 myotubes as determined by quantification of GFP-positive cells. [Figure 16B] Figure 1 shows that incubation of AAV with AF70 and AF71 enhanced transduction of differentiated C2C12 myotubes as determined by quantification of GFP-positive cells. [Figure 16C] Figure 1 shows that incubation of AAV with AF70 and AF71 enhanced transduction of differentiated C2C12 myotubes as determined by quantification of GFP-positive cells. [Figure 16D] Figure 1 shows that incubation of AAV with AF70 and AF71 enhanced transduction of differentiated C2C12 myotubes as determined by quantification of GFP-positive cells.

[0214] [Figure 17A] We demonstrate that incubation of AAV with AF70 and AF71 enhanced transduction of differentiated human myotubes, as determined by quantification of GFP-positive cells. [Figure 17B] We demonstrate that incubation of AAV with AF70 and AF71 enhanced transduction of differentiated human myotubes, as determined by quantification of GFP-positive cells. [Figure 17C] We demonstrate that incubation of AAV with AF70 and AF71 enhanced transduction of differentiated human myotubes, as determined by quantification of GFP-positive cells. [Figure 17D] We demonstrate that incubation of AAV with AF70 and AF71 enhanced transduction of differentiated human myotubes, as determined by quantification of GFP-positive cells.

[0215] [Figure 18A] 1 shows non-limiting examples of AAVx mTfR surrogate format (AF) antibodies described herein. Star mutations are indicated with an asterisk (*), and knob-in-hole (KiH) mutations are indicated with a triangle (e.g.,

number

number

[0216] [Figure 19] An example of the experimental setup used to test alternative format antibody binding to AAV9W503A virus by ELISA is shown.

[0217] [Figure 20] ELISA data for AAV×mTfR surrogate format antibodies binding to AAV9W503A is shown.

[0218] [Figure 21] Figure 1 shows a schematic of the FLuc assay protocol used to test the retargeting of AAV9W503A with an mTfR surrogate format antibody to 293T cells expressing the mTfR receptor.

[0219] [Figure 22]1 shows a line graph of data generated in an experiment testing AAV9W503A retargeting using AAVxmTfR surrogate format antibodies against mTfR293T cells.

[0220] [Figure 23A-1] 1 shows a retargeting assay using AAV9 scCBH.eGFP. [Figure 23A-2] 1 shows a retargeting assay using AAV9 scCBH.eGFP. [Figure 23A-3] 1 shows a retargeting assay using AAV9 scCBH.eGFP. [Figure 23B-1] 1 shows a retargeting assay using AAV9 scCBH.eGFP. [Figure 23B-2] 1 shows a retargeting assay using AAV9 scCBH.eGFP. [Figure 23C] 1 shows a retargeting assay using AAV9 scCBH.eGFP.

[0221] [Figure 24A-1] 1 shows the results of in vitro infection tests for in vivo injection samples. [Figure 24A-2] 1 shows the results of in vitro infection tests for in vivo injection samples. [Figure 24A-3] 1 shows the results of in vitro infection tests for in vivo injection samples. [Figure 24A-4] 1 shows the results of in vitro infection tests for in vivo injection samples. [Figure 24B] 1 shows the results of in vitro infection tests for in vivo injection samples.

[0222] [Figure 25A] AAVxmTFR liver and brain (hippocampus, cortex, and cerebellum) green fluorescent protein (GFP) staining is shown for the control group (FIG. 25A) and alternative format designs. [Figure 25B]AAVxmTFR liver and brain (hippocampus, cortex, and cerebellum) green fluorescent protein (GFP) staining is shown for AAVxmTFR AF1 (FIG. 25B). [Figure 25C] AAVxmTFR liver and brain (hippocampus, cortex, and cerebellum) green fluorescent protein (GFP) staining is shown for AAVxmTFR AF3 (FIG. 25C). [Figure 25D] AAVxmTFR liver and brain (hippocampus, cortex, and cerebellum) green fluorescent protein (GFP) staining is shown for AAVxmTFR AF5 (FIG. 25D). [Figure 25E] AAVxmTFR liver and brain (hippocampus, cortex, and cerebellum) green fluorescent protein (GFP) staining is shown for AAVxmTFR AF7 (FIG. 25E). [Figure 25F] AAVxmTFR liver and brain (hippocampus, cortex, and cerebellum) green fluorescent protein (GFP) staining is shown for AAVxmTFR AF9 (FIG. 25F).

[0223] [Figure 26-1] Relative RNA expression of GFP in liver samples as determined by RT-qPCR is shown. [Figure 26-2] Relative RNA expression of GFP in liver samples as determined by RT-qPCR is shown.

[0224] [Figure 27-1] 1 shows the RNA expression of GFP in brain samples as determined by RT-qPCR. [Figure 27-2] 1 shows the RNA expression of GFP in brain samples as determined by RT-qPCR.

[0225] [Figure 28A]GFP staining in brain, heart, and liver tissues from mice administered AAV9 (Figures 28A-28B) complexed with the AAVxmTfR surrogate format AF7 at AAV vector genome (VG) to antibody (Ab) ratios (VG:Ab ratios) of 1:9 and 1:3. [Figure 28B] GFP staining in brain, heart, and liver tissues from mice administered AAV9 (Figures 28A-28B) complexed with the AAVxmTfR surrogate format AF7 at AAV vector genome (VG) to antibody (Ab) ratios (VG:Ab ratios) of 1:9 and 1:3. [Figure 28C] GFP staining in brain, heart, and liver tissues from mice administered AAV9W503A (Figures 28C and 28D) complexed with the AAVxmTfR surrogate format AF7 at AAV vector genome (VG) to antibody (Ab) ratios (VG:Ab ratios) of 1:9 and 1:3. [Figure 28D] GFP staining in brain, heart, and liver tissues from mice administered AAV9W503A (Figures 28C and 28D) complexed with the AAVxmTfR surrogate format AF7 at AAV vector genome (VG) to antibody (Ab) ratios (VG:Ab ratios) of 1:9 and 1:3.

[0226] [Figure 29A] Figure 29A shows AAVxmTfR alternative format designs AF3 and AF7. Figure 29A provides a description of the AAVxmTfR alternative format designs AF3 and AF7. Star mutations are indicated with an asterisk (*) and knob-in-hole (KiH) mutations are indicated with a triangle (e.g.,

number

[0227] [Figure 30A] Figure 30A shows AAVxCACNGI alternate format designs AF70 and AF71. Figure 30A provides a description of AAVxCACNG1 alternate format designs AF70 and AF71. The figure discloses "3xG4S" as SEQ ID NO: 1115 and "4xG4S" as SEQ ID NO: 1161. [Figure 30B] AAVxCACNGI alternative format designs AF70 and AF71 are shown. Figures 30B-30G show an example of the AAVxmTfR AF70 amino acid sequence (Figure 30B) and the corresponding nucleotide sequence (Figures 30C-30D). The figures disclose "3xG4S" as SEQ ID NO: 1115 and "4xG4S" as SEQ ID NO: 1161. [Figure 30C] AAVxCACNGI alternative format designs AF70 and AF71 are shown. Figures 30B-30G show an example of the AAVxmTfR AF70 amino acid sequence (Figure 30B) and the corresponding nucleotide sequence (Figures 30C-30D). The figures disclose "3xG4S" as SEQ ID NO: 1115 and "4xG4S" as SEQ ID NO: 1161. [Figure 30D] AAVxCACNGI alternative format designs AF70 and AF71 are shown. Figures 30B-30G show an example of the AAVxmTfR AF70 amino acid sequence (Figure 30B) and the corresponding nucleotide sequence (Figures 30C-30D). The figures disclose "3xG4S" as SEQ ID NO: 1115 and "4xG4S" as SEQ ID NO: 1161. [Figure 30E]AAVxCACNGI alternative format designs AF70 and AF71 are shown. Figures 30B-30G show an example of the AAVxmTfR AF70 amino acid sequence (Figure 30B) and corresponding nucleotide sequence (Figures 30C-30D). Figures 30E-30G show an example of the AAVxmTfR AF71 amino acid sequence (Figure 30E) and corresponding nucleotide sequence (Figures 30F-30G). The figures disclose "3xG4S" as SEQ ID NO: 1115 and "4xG4S" as SEQ ID NO: 1161. [Figure 30F] AAVxCACNGI alternative format designs AF70 and AF71 are shown. Figures 30B-30G show an example of the AAVxmTfR AF70 amino acid sequence (Figure 30B) and corresponding nucleotide sequence (Figures 30C-30D). Figures 30E-30G show an example of the AAVxmTfR AF71 amino acid sequence (Figure 30E) and corresponding nucleotide sequence (Figures 30F-30G). The figures disclose "3xG4S" as SEQ ID NO: 1115 and "4xG4S" as SEQ ID NO: 1161. [Figure 30G] AAVxCACNGI alternative format designs AF70 and AF71 are shown. Figures 30B-30G show an example of the AAVxmTfR AF70 amino acid sequence (Figure 30B) and corresponding nucleotide sequence (Figures 30C-30D). Figures 30E-30G show an example of the AAVxmTfR AF71 amino acid sequence (Figure 30E) and corresponding nucleotide sequence (Figures 30F-30G). The figures disclose "3xG4S" as SEQ ID NO: 1115 and "4xG4S" as SEQ ID NO: 1161.

[0228] [Figure 31] Figure 1 shows the enhancement of transduction of CACNG1-overexpressing 293 cells by AAVxCACNG1 bispecific antibody. GFP expression was assessed by flow cytometry and is shown as % GFP-positive cells (upper panel) or MFI of GFP-expressing cells (lower panel).

[0229] [Figure 32] An example of a study design for testing Hu37 complexed with anti-AAV x CACNG1 2x2 antibodies in D2.MDX mice is shown.

[0230] [Figure 33-1] 1 shows in vitro transduction of the complexes prepared for in vivo testing in HEK293-hCACNG1. [Figure 33-2] 1 shows in vitro transduction of the complexes prepared for in vivo testing in HEK293-hCACNG1. [Figure 33-3] 1 shows in vitro transduction of the complexes prepared for in vivo testing in HEK293-hCACNG1. [Figure 33-4] 1 shows in vitro transduction of the complexes prepared for in vivo testing in HEK293-hCACNG1.

[0231] [Figure 34A] FIG. 10 shows improved Hu37 transduction in muscle tissue when complexed with 2x2 anti-CACNG 1xAAV alternative formats. [Figure 34B] FIG. 10 shows improved Hu37 transduction in muscle tissue when complexed with 2x2 anti-CACNG 1xAAV alternative formats. [Figure 34C] FIG. 10 shows improved Hu37 transduction in muscle tissue when complexed with 2x2 anti-CACNG 1xAAV alternative formats.

[0232] [Figure 35A] 1 shows bispecific antibody enhancement of Hu37 transduction into skeletal muscle. [Figure 35B-1] 1 shows bispecific antibody enhancement of Hu37 transduction into skeletal muscle. [Figure 35B-2] 1 shows bispecific antibody enhancement of Hu37 transduction into skeletal muscle.

[0233] [Figure 36A]Figure 36A shows AAVxAsGR alternate format designs AF21 (REGN16199), AF22 (REGN16200), AF29, AF30 (REGN16204), AF32 (REGN16202), AF37, AF41, AF60A, AF61A, AF62, and AF63. Figure 36A provides a description of AAVxAsGR alternate format designs AF21 (REGN16199), AF22 (REGN16200), AF29, AF30 (REGN16204), and AF32 (REGN16202). The figure discloses "3xG4S" as SEQ ID NO: 1115 and "4xG4S" as SEQ ID NO: 1161. [Figure 36B] Figure 36B shows AAVxAsGR alternate format designs AF37, AF41, AF60A, AF61A, AF62, and AF63. Figure 36B provides a description of AAVxAsGR alternate format designs AF37, AF41, AF60A, AF61A, AF62, and AF63. The figure discloses "3xG4S" as SEQ ID NO: 1115 and "4xG4S" as SEQ ID NO: 1161.

[0234] [Figure 37A] IVIS (In Vivo Imaging Instrument, Perkin Elmer) data showing retarget...

Claims

1. An antibody, or an antigen-binding fragment thereof, wherein the antibody, or the antigen-binding fragment thereof, binds to the capsid of an adeno-associated virus (AAV) particle, and the antibody, or the antigen-binding fragment thereof, a) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 2, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; b) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 22, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; c) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 32, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, d) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 42, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; e) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 52 or SEQ ID NO: 1159, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157; f) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 62, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; g) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 71; and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; h) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 81, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; i) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 91, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, or j) An antibody, or antigen-binding fragment thereof, comprising a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 101, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, or an LCVR.

2. the antibody, or the antigen-binding fragment thereof, a) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 8, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; b) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 24, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 26, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 28, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; c) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 34, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 36, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 38, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; d) HCDR1 comprising the amino acid sequence of SEQ ID NO: 44, HCDR2 comprising the amino acid sequence of SEQ ID NO: 46, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 48, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; e) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 54, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; f) HCDR1 comprising the amino acid sequence of SEQ ID NO: 64, HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 67, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; g) HCDR1 comprising the amino acid sequence of SEQ ID NO: 73, HCDR2 comprising the amino acid sequence of SEQ ID NO: 75, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 77, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; h) HCDR1 comprising the amino acid sequence of SEQ ID NO: 83, HCDR2 comprising the amino acid sequence of SEQ ID NO: 85, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 87, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; i) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 93, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 95, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 97, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16, or j) The antibody or antigen-binding fragment of claim 1, comprising an HCDR1 having the amino acid sequence of SEQ ID NO: 103, an HCDR2 having the amino acid sequence of SEQ ID NO: 105, and an HCDR3 having the amino acid sequence of SEQ ID NO: 107, and / or an LCDR1 having the amino acid sequence of SEQ ID NO: 12, an LCDR2 having the amino acid sequence of SEQ ID NO: 14, and an LCDR3 having the amino acid sequence of SEQ ID NO:

16.

3. the antibody, or the antigen-binding fragment thereof, a) an HCVR comprising the amino acid sequence of SEQ ID NO: 2 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; b) an HCVR comprising the amino acid sequence of SEQ ID NO: 22 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; c) an HCVR comprising the amino acid sequence of SEQ ID NO: 32 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; d) an HCVR comprising the amino acid sequence of SEQ ID NO: 42 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; e) an HCVR comprising the amino acid sequence of SEQ ID NO: 52 or SEQ ID NO: 1159, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157; f) an HCVR comprising the amino acid sequence of SEQ ID NO: 62 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; g) an HCVR comprising the amino acid sequence of SEQ ID NO: 71 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; h) an HCVR comprising the amino acid sequence of SEQ ID NO: 81 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; i) an HCVR comprising the amino acid sequence of SEQ ID NO: 91, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10, or j) The antibody or antigen-binding fragment of claim 2 or 3, comprising an HCVR comprising the amino acid sequence of SEQ ID NO: 101 and / or an LCVR comprising the amino acid sequence of SEQ ID NO:

10.

4. 1. An antibody, or antigen-binding fragment thereof, which binds to a capsid of an adeno-associated virus (AAV) particle, and which binds to one or more residues in one or more viral protein 3 (VP3) polypeptides in the capsid, wherein the one or more residues are selected from those listed in Tables 18 to 26.

5. The antibody, or the antigen-binding fragment thereof, binds to a capsid of an AAV2 particle comprising the amino acid substitutions R585A and R588A, wherein the one or more residues are the following residues in the VP3 polypeptide (according to VP1 numbering): a) S264, A266, N268, H271, N382, S384, Q385, G512, R487, D494, K527, D529, K532, L538, D533, E555, N705, K706, V708, T450, Q457, and R459; b) S264, G265, A266, S267, N268, H271, N382, G383, S384, R487, K527, D528, E530, E574, Q575, K706, and S707; c) N254, L256, K258, I260, S261, Q263, Y272, E322, V323, T324, Q325, A655, A667, S668, F669, I670, T671, I332, Q545, G546, S547, E548, K556, N717, V719, T660, and F661; and / or d) The antibody or antigen-binding fragment of claim 4, selected from N254, L256, Q263, S264, V323, T324, Q325, S655, A667, S668, F669, I670, T671, G328, G546, E548, T716, and N717.

6. The antibody, or the antigen-binding fragment thereof, binds to the capsid of an AAV8 particle, and the one or more residues are the following residues in the VP3 polypeptide (according to VP1 numbering): a) N255, L257, K259, 1261, S262, N263, S266, A269, Y275, E325, V326, T327, Q328, A658, N670, S671, F672, I673, T674, Q548, N549, A550, A551, D559, E720, and T663; and / or b) The antibody or antigen-binding fragment of claim 4, selected from N255, L257, S266, E325, V326, T327, Q328, N670, S671, F672, I673, T674, N549, T719, and E720.

7. The antibody, or the antigen-binding fragment thereof, binds to the capsid of an AAV9 particle, and the one or more residues are the following residues in the VP3 polypeptide (according to VP1 numbering): a) N254, I260, N262, Y274, E324, V325, T326, D327, N328, R550, D665, N668, S669, F670, 1671, T672, Q546, G547, G549, E718, and A661; and / or b) The antibody or antigen-binding fragment of claim 4, selected from N254, L256, I260, N262, E324, V325, T326, D551, N668, S669, F670, T672, G330, and E718.

8. the antibody, or the antigen-binding fragment thereof, 1) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 32, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; 2) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 52 or SEQ ID NO: 1159, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157; 3) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 71, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, or 4) The antibody or antigen-binding fragment of any one of claims 4 to 7, comprising a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 81, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO:

10.

9. the antibody, or the antigen-binding fragment thereof, 1) HCDR1 comprising the amino acid sequence of SEQ ID NO: 34, HCDR2 comprising the amino acid sequence of SEQ ID NO: 36, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 38, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; 2) HCDR1 comprising the amino acid sequence of SEQ ID NO: 54, HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; 3) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 73, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 75, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 77, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16, or 4) The antibody or antigen-binding fragment of claim 8, comprising an HCDR1 having the amino acid sequence of SEQ ID NO: 83, an HCDR2 having the amino acid sequence of SEQ ID NO: 85, and an HCDR3 having the amino acid sequence of SEQ ID NO: 87, and / or an LCDR1 having the amino acid sequence of SEQ ID NO: 12, an LCDR2 having the amino acid sequence of SEQ ID NO: 14, and an LCDR3 having the amino acid sequence of SEQ ID NO:

16.

10. the antibody, or the antigen-binding fragment thereof, 1) an HCVR comprising the amino acid sequence of SEQ ID NO: 32, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; 2) an HCVR comprising the amino acid sequence of SEQ ID NO: 52 or SEQ ID NO: 1159, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157; 3) an HCVR comprising the amino acid sequence of SEQ ID NO: 71 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; or 4) The antibody or antigen-binding fragment of claim 8 or 9, comprising an HCVR comprising the amino acid sequence of SEQ ID NO: 81 and / or an LCVR comprising the amino acid sequence of SEQ ID NO:

10.

11. 11. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 10, wherein the antibody or antigen-binding fragment thereof is a humanized antibody or antigen-binding fragment thereof, a human antibody or antigen-binding fragment thereof, a murine antibody or antigen-binding fragment thereof, a chimeric antibody or antigen-binding fragment thereof, a Fab fragment, a F(ab')2 fragment, a F(ab)'3 fragment, a single-chain fragment variable (scFv), a bis-scFv, an (scFv)2, a diabody, a minibody, a nanobody, a triabody, a tetrabody, a disulfide-stabilized Fv protein (dsFv), a single domain antibody (sdAb), an Ig NAR, a single heavy chain antibody, a bispecific antibody, a triabody, or a chemically modified derivative thereof.

12. 12. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof comprises an IgG1 constant region, an IgG2 constant region, an IgG3 constant region, or an IgG4 constant region, or a variant thereof.

13. 13. The antibody or antigen-binding fragment thereof of claim 12, wherein the antibody or antigen-binding fragment thereof comprises an IgG1 constant region, or a variant thereof.

14. 14. The antibody or antigen-binding fragment of claim 13, wherein the IgG1 constant region comprises the amino acid sequence of SEQ ID NO: 259 or SEQ ID NO: 1164.

15. 13. The antibody or antigen-binding fragment thereof of claim 12, wherein the antibody or antigen-binding fragment thereof comprises an IgG4 constant region, or a variant thereof.

16. 16. The antibody or antigen-binding fragment of claim 15, wherein the IgG4 variant comprises a hinge domain modified to reduce binding to Fcγ receptors.

17. 17. The antibody or antigen-binding fragment of claim 16, wherein the IgG4 constant region comprises the amino acid sequence of SEQ ID NO:

261.

18. The antibody or antigen-binding fragment of any one of claims 1 to 11, wherein the antigen-binding fragment is a Fab fragment.

19. The antibody or antigen-binding fragment of any one of claims 1 to 11, wherein the antigen-binding fragment is an scFv fragment.

20. The antibody, or the antigen-binding fragment thereof, has a cytoplasmic affinity of about 1.5 x 10 as measured in a surface plasmon resonance assay. －６ Dissociation constant (K Ｄ 20. The antibody or antigen-binding fragment of any one of claims 1 to 19, which binds to AAV2 at the nucleotide sequence (SEQ ID NO: 1).

21. The antibody, or the antigen-binding fragment thereof, has a dissociation constant (K) of less than about 20 nM as measured in a surface plasmon resonance assay. Ｄ 21. The antibody or antigen-binding fragment of claim 20, which binds to AAV2 at the SEQ ID NO:

1.

22. 22. The antibody or antigen-binding fragment of any one of claims 1 to 21, wherein the capsid comprises one or more wild-type AAV capsid polypeptides.

23. 22. The antibody or antigen-binding fragment of any one of claims 1 to 21, wherein the capsid comprises one or more non-wild-type AAV capsid polypeptides.

24. 24. The antibody or antigen-binding fragment of any one of claims 1 to 23, wherein binding of the antibody or antigen-binding fragment thereof to the AAV particle capsid does not neutralize the AAV particle.

25. An antibody or antigen-binding fragment thereof that binds to the same epitope as the antibody or antigen-binding fragment of any one of claims 1 to 24.

26. An antibody, or an antigen-binding fragment thereof, that competes with the antibody or antigen-binding fragment of any one of claims 1 to 24 for binding to the capsid of an adeno-associated virus (AAV) particle.

27. A pharmaceutical composition comprising the antibody or antigen-binding fragment of any one of claims 1 to 26 and a pharmaceutically acceptable carrier or excipient.

28. A multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: i) a first antigen-binding domain that binds to the capsid of an adeno-associated virus (AAV) particle; and ii) a second antigen-binding arm that binds to a molecule on a cell surface, wherein said first antigen-binding domain comprises: a) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 2, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; b) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 22, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; c) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 32, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, d) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 42, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; e) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 52 or SEQ ID NO: 1159, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157; f) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 62, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; g) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 71; and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; h) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 81, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; i) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 91, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, or j) A multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising a second antigen-binding arm comprising a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3, and comprising the amino acid sequence of SEQ ID NO: 101, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3, and comprising the amino acid sequence of SEQ ID NO:

10.

29. the first antigen-binding domain comprises: a) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 8, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; b) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 24, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 26, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 28, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; c) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 34, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 36, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 38, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; d) HCDR1 comprising the amino acid sequence of SEQ ID NO: 44, HCDR2 comprising the amino acid sequence of SEQ ID NO: 46, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 48, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; e) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 54, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; f) HCDR1 comprising the amino acid sequence of SEQ ID NO: 64, HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 67, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; g) HCDR1 comprising the amino acid sequence of SEQ ID NO: 73, HCDR2 comprising the amino acid sequence of SEQ ID NO: 75, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 77, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; h) HCDR1 comprising the amino acid sequence of SEQ ID NO: 83, HCDR2 comprising the amino acid sequence of SEQ ID NO: 85, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 87, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; i) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 93, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 95, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 97, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16, or j) The multispecific antibody or multispecific antigen-binding fragment of claim 28, comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO: 103, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 105, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 107, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:

16.

30. the first antigen-binding domain comprises: a) an HCVR comprising the amino acid sequence of SEQ ID NO: 2 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; b) an HCVR comprising the amino acid sequence of SEQ ID NO: 22 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; c) an HCVR comprising the amino acid sequence of SEQ ID NO: 32 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; d) an HCVR comprising the amino acid sequence of SEQ ID NO: 42 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; e) an HCVR comprising the amino acid sequence of SEQ ID NO: 52 or SEQ ID NO: 1159, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157; f) an HCVR comprising the amino acid sequence of SEQ ID NO: 62 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; g) an HCVR comprising the amino acid sequence of SEQ ID NO: 71 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; h) an HCVR comprising the amino acid sequence of SEQ ID NO: 81 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; i) an HCVR comprising the amino acid sequence of SEQ ID NO: 91, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10, or j) A multispecific antibody or multispecific antigen-binding fragment according to claim 28 or 29, comprising an HCVR comprising the amino acid sequence of SEQ ID NO: 101 and / or an LCVR comprising the amino acid sequence of SEQ ID NO:

10.

31. A multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: i) a first antigen-binding domain that binds to the capsid of an adeno-associated virus (AAV) particle; and ii) A multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising a second antigen-binding domain that binds to a molecule on a cell surface, wherein said first antigen-binding domain binds to one or more residues in one or more viral protein 3 (VP3) polypeptides in the capsid, and said one or more residues are selected from the residues listed in Tables 18 to 26.

32. the first antigen-binding domain binds to the capsid of an AAV2 particle comprising the amino acid substitutions R585A and R588A, and the one or more residues are the following residues in the VP3 polypeptide (according to VP1 numbering): a) S264, A266, N268, H271, N382, S384, Q385, G512, R487, D494, K527, K529, K532, L538, D533, E555, N705, K706, V708, T450, Q457, and R459; b) S264, G265, A266, S267, N268, H271, N382, G383, S384, R487, K527, D528, E530, Q574, Q575, K706, and S707; c) N254, L256, K258, I260, S261, Q263, Y272, E322, V323, T324, Q325, A655, A667, S668, F669, I670, T671, I332, Q545, G546, S547, E548, K556, N717, V719, T660, and F661; and / or d) The multispecific antibody or multispecific antigen-binding fragment of claim 31 , selected from N254, L256, Q263, S264, V323, T324, Q325, S655, A667, S668, F669, I670, T671, G328, G546, E548, T716, and N717.

33. wherein the first antigen-binding domain binds to the capsid of an AAV8 particle, and the one or more residues are the following residues in the VP3 polypeptide (according to VP1 numbering): e) N255, L257, K259, 1261, S262, N263, S266, A269, Y275, E325, V326, T327, Q328, A658, N670, S671, F672, I673, T674, Q548, N549, A550, A551, D559, E720, and T663; and / or f) The multispecific antibody or multispecific antigen-binding fragment of claim 31 , selected from N255, L257, S266, E325, V326, T327, Q328, N670, S671, F672, I673, T674, N549, T719, and E720.

34. wherein the first antigen-binding domain binds to the capsid of an AAV9 particle, and the one or more residues are the following residues in the VP3 polypeptide (according to VP1 numbering): g) N254, I260, N262, Y274, E324, V325, T326, D327, N328, R550, D665, N668, S669, F670, 1671, T672, Q546, G547, G549, E718, and A661, and / or h) The multispecific antibody or multispecific antigen-binding fragment of claim 31 , selected from N254, L256, 1260, N262, E324, V325, T326, D551, N668, S669, F670, T672, G330, and E718.

35. the first antigen-binding domain comprises: 1) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 32, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; 2) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 52 or SEQ ID NO: 1159, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157; 3) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 71, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, or 4) A multispecific antibody or multispecific antigen-binding fragment according to any one of claims 31 to 34, comprising a heavy chain variable region (HCVR) comprising HCDR1, HCDR2 and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 81, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2 and LCDR3 and comprising the amino acid sequence of SEQ ID NO:

10.

36. the first antigen-binding domain comprises: 1) HCDR1 comprising the amino acid sequence of SEQ ID NO: 34, HCDR2 comprising the amino acid sequence of SEQ ID NO: 36, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 38, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; 2) HCDR1 comprising the amino acid sequence of SEQ ID NO: 54, HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; 3) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 73, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 75, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 77, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16, or 4) The multispecific antibody or multispecific antigen-binding fragment of claim 35, comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO: 83, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 85, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 87, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:

16.

37. the first antigen-binding domain comprises: 1) an HCVR comprising the amino acid sequence of SEQ ID NO: 32, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; 2) an HCVR comprising the amino acid sequence of SEQ ID NO: 52 or SEQ ID NO: 1159, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157; 3) an HCVR comprising the amino acid sequence of SEQ ID NO: 71 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; or 4) A multispecific antibody or multispecific antigen-binding fragment according to claim 35 or 36, comprising an HCVR comprising the amino acid sequence of SEQ ID NO: 81 and / or an LCVR comprising the amino acid sequence of SEQ ID NO:

10.

38. 38. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 28 to 37, wherein the molecule on the cell surface is asialoglycoprotein receptor 1 (ASGR1), transferrin receptor (TfR), or calcium voltage-gated channel accessory subunit gamma 1 (CACNG1).

39. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 28 to 38, wherein the molecule on the cell surface is ASGR1.

40. the second antigen-binding domain that binds to ASGR1 is a) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 220 or SEQ ID NO: 1239, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157, or b) a HCVR comprising HCDR1, HCDR2, and HCDR3 contained within a HCVR comprising the amino acid sequence of SEQ ID NO: 230, and / or a LCVR comprising LCDR1, LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO:

10.

41. the second antigen-binding domain that binds to ASGR1 is a) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 222, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 224, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 226, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16, or b) A multispecific antibody or multispecific antigen-binding fragment according to claim 39 or 40, comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO: 232, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 234, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 236, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:

16.

42. the second antigen-binding domain that binds to ASGR1 is a) an HCVR comprising the amino acid sequence of SEQ ID NO: 220 or SEQ ID NO: 1239, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157, or b) a HCVR comprising the amino acid sequence of SEQ ID NO: 230 and / or a LCVR comprising the amino acid sequence of SEQ ID NO:

10.

43. 39. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 28 to 38, wherein the molecule on the cell surface is TfR.

44. the second antigen-binding domain that binds to TfR is 1) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 270 or SEQ ID NO: 271, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 276; 2) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 281 or SEQ ID NO: 282, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 287; 3) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 292 or SEQ ID NO: 293, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 298; 4) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 303, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 308 or SEQ ID NO: 309; 5) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 314, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 319 or SEQ ID NO: 320; 6) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 325 or SEQ ID NO: 326, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 331 or SEQ ID NO: 332; 7) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 337 or SEQ ID NO: 338, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 343 or SEQ ID NO: 344; 8) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 349 or SEQ ID NO: 350, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 355 or SEQ ID NO: 356; 9) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 361, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 366; 10) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 371 or SEQ ID NO: 372, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 377; 11) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 382, ​​and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 387; 12) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 392 or SEQ ID NO: 393, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 398 or SEQ ID NO: 399; 13) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 404, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 409; 14) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 414, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 419; 15) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 424 or SEQ ID NO: 425, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 430 or SEQ ID NO: 431; 16) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 436, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 441; 17) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 446 or SEQ ID NO: 447, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 452; 18) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 457, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 462; 19) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 467 or SEQ ID NO: 468, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 473 or SEQ ID NO: 474; 20) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 479 or SEQ ID NO: 480, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 485; 21) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 490 or SEQ ID NO: 491, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 496; 22) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 501, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 506; 23) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 511, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 516; 24) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 521, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 526; 25) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 531, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 536; 26) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 541 or SEQ ID NO: 542, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 547; 27) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 552, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 557; 28) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 562, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 567; 29) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 572, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 577; 30) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 582, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 587; 31) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 592 or SEQ ID NO: 593, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 598 or SEQ ID NO: 599; 32) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 604, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 609 or SEQ ID NO: 610; or 33) The multispecific antibody or multispecific antigen-binding fragment of claim 43, comprising an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1119, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 1127.

45. the second antigen-binding domain that binds to TfR is 1) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 272, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 273, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 274, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 277, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 278, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 279; 2) HCDR1 comprising the amino acid sequence of SEQ ID NO: 283, HCDR2 comprising the amino acid sequence of SEQ ID NO: 284, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 285, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 288, LCDR2 comprising the amino acid sequence of SEQ ID NO: 289, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 290; 3) HCDR1 comprising the amino acid sequence of SEQ ID NO: 294, HCDR2 comprising the amino acid sequence of SEQ ID NO: 295, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 296, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 299, LCDR2 comprising the amino acid sequence of SEQ ID NO: 300, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 301; 4) HCDR1 comprising the amino acid sequence of SEQ ID NO: 304, HCDR2 comprising the amino acid sequence of SEQ ID NO: 305, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 306, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 310, LCDR2 comprising the amino acid sequence of SEQ ID NO: 311, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 312; 5) HCDR1 comprising the amino acid sequence of SEQ ID NO: 315, HCDR2 comprising the amino acid sequence of SEQ ID NO: 316, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 317, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 321, LCDR2 comprising the amino acid sequence of SEQ ID NO: 322, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 323; 6) HCDR1 comprising the amino acid sequence of SEQ ID NO: 327, HCDR2 comprising the amino acid sequence of SEQ ID NO: 328, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 329, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 333, LCDR2 comprising the amino acid sequence of SEQ ID NO: 334, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 335; 7) HCDR1 comprising the amino acid sequence of SEQ ID NO: 339, HCDR2 comprising the amino acid sequence of SEQ ID NO: 340, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 341, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 345, LCDR2 comprising the amino acid sequence of SEQ ID NO: 346, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 347; 8) HCDR1 comprising the amino acid sequence of SEQ ID NO: 351, HCDR2 comprising the amino acid sequence of SEQ ID NO: 352, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 353, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 357, LCDR2 comprising the amino acid sequence of SEQ ID NO: 358, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 359; 9) HCDR1 comprising the amino acid sequence of SEQ ID NO: 362, HCDR2 comprising the amino acid sequence of SEQ ID NO: 363, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 364, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 367, LCDR2 comprising the amino acid sequence of SEQ ID NO: 368, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 369; 10) HCDR1 comprising the amino acid sequence of SEQ ID NO: 373, HCDR2 comprising the amino acid sequence of SEQ ID NO: 374, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 375, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 378, LCDR2 comprising the amino acid sequence of SEQ ID NO: 379, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 380; 11) HCDR1 comprising the amino acid sequence of SEQ ID NO: 383, HCDR2 comprising the amino acid sequence of SEQ ID NO: 384, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 385, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 388, LCDR2 comprising the amino acid sequence of SEQ ID NO: 389, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 390; 12) HCDR1 comprising the amino acid sequence of SEQ ID NO: 394, HCDR2 comprising the amino acid sequence of SEQ ID NO: 395, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 396, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 400, LCDR2 comprising the amino acid sequence of SEQ ID NO: 401, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 402; 13) HCDR1 comprising the amino acid sequence of SEQ ID NO: 405, HCDR2 comprising the amino acid sequence of SEQ ID NO: 406, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 407, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 410, LCDR2 comprising the amino acid sequence of SEQ ID NO: 411, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 412; 14) HCDR1 comprising the amino acid sequence of SEQ ID NO: 415, HCDR2 comprising the amino acid sequence of SEQ ID NO: 416, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 417, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 420, LCDR2 comprising the amino acid sequence of SEQ ID NO: 421, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 422; 15) HCDR1 comprising the amino acid sequence of SEQ ID NO: 426, HCDR2 comprising the amino acid sequence of SEQ ID NO: 427, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 428, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 432, LCDR2 comprising the amino acid sequence of SEQ ID NO: 433, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 434; 16) HCDR1 comprising the amino acid sequence of SEQ ID NO: 437, HCDR2 comprising the amino acid sequence of SEQ ID NO: 438, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 439, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 442, LCDR2 comprising the amino acid sequence of SEQ ID NO: 443, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 444; 17) HCDR1 comprising the amino acid sequence of SEQ ID NO: 448, HCDR2 comprising the amino acid sequence of SEQ ID NO: 449, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 450, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 453, LCDR2 comprising the amino acid sequence of SEQ ID NO: 454, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 455; 18) HCDR1 comprising the amino acid sequence of SEQ ID NO: 458, HCDR2 comprising the amino acid sequence of SEQ ID NO: 459, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 460, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 463, LCDR2 comprising the amino acid sequence of SEQ ID NO: 464, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 465; 19) HCDR1 comprising the amino acid sequence of SEQ ID NO: 469, HCDR2 comprising the amino acid sequence of SEQ ID NO: 470, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 471, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 475, LCDR2 comprising the amino acid sequence of SEQ ID NO: 476, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 477; 20) HCDR1 comprising the amino acid sequence of SEQ ID NO: 481, HCDR2 comprising the amino acid sequence of SEQ ID NO: 482, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 483; and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 486, LCDR2 comprising the amino acid sequence of SEQ ID NO: 487, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 488; 21) HCDR1 comprising the amino acid sequence of SEQ ID NO: 492, HCDR2 comprising the amino acid sequence of SEQ ID NO: 493, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 494; and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 497, LCDR2 comprising the amino acid sequence of SEQ ID NO: 498, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 499; 22) HCDR1 comprising the amino acid sequence of SEQ ID NO: 502, HCDR2 comprising the amino acid sequence of SEQ ID NO: 503, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 504; and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 507, LCDR2 comprising the amino acid sequence of SEQ ID NO: 508, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 509; 23) HCDR1 comprising the amino acid sequence of SEQ ID NO: 512, HCDR2 comprising the amino acid sequence of SEQ ID NO: 513, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 514, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 517, LCDR2 comprising the amino acid sequence of SEQ ID NO: 518, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 519; 24) HCDR1 comprising the amino acid sequence of SEQ ID NO: 522, HCDR2 comprising the amino acid sequence of SEQ ID NO: 523, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 524; and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 527, LCDR2 comprising the amino acid sequence of SEQ ID NO: 528, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 529; 25) HCDR1 comprising the amino acid sequence of SEQ ID NO: 532, HCDR2 comprising the amino acid sequence of SEQ ID NO: 533, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 534, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 537, LCDR2 comprising the amino acid sequence of SEQ ID NO: 538, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 539; 26) HCDR1 comprising the amino acid sequence of SEQ ID NO: 543, HCDR2 comprising the amino acid sequence of SEQ ID NO: 544, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 545; and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 548, LCDR2 comprising the amino acid sequence of SEQ ID NO: 549, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 550; 27) HCDR1 comprising the amino acid sequence of SEQ ID NO: 553, HCDR2 comprising the amino acid sequence of SEQ ID NO: 554, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 555; and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 558, LCDR2 comprising the amino acid sequence of SEQ ID NO: 559, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 560; 28) HCDR1 comprising the amino acid sequence of SEQ ID NO: 563, HCDR2 comprising the amino acid sequence of SEQ ID NO: 564, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 565; and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 568, LCDR2 comprising the amino acid sequence of SEQ ID NO: 569, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 570; 29) HCDR1 comprising the amino acid sequence of SEQ ID NO: 573, HCDR2 comprising the amino acid sequence of SEQ ID NO: 574, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 575; and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 578, LCDR2 comprising the amino acid sequence of SEQ ID NO: 579, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 580; 30) HCDR1 comprising the amino acid sequence of SEQ ID NO: 583, HCDR2 comprising the amino acid sequence of SEQ ID NO: 584, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 585, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 588, LCDR2 comprising the amino acid sequence of SEQ ID NO: 589, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 590; 31) HCDR1 comprising the amino acid sequence of SEQ ID NO: 594, HCDR2 comprising the amino acid sequence of SEQ ID NO: 595, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 596, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 600, LCDR2 comprising the amino acid sequence of SEQ ID NO: 601, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 602; 32) HCDR1 comprising the amino acid sequence of SEQ ID NO: 605, HCDR2 comprising the amino acid sequence of SEQ ID NO: 606, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 607, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 611, LCDR2 comprising the amino acid sequence of SEQ ID NO: 612, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 613, or 33) The multispecific antibody or multispecific antigen-binding fragment of claim 43 or 44, comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO: 1121, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 1123, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 1125, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 1129, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 1131, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 1133.

46. the second antigen-binding domain that binds to TfR is 1) an HCVR comprising the amino acid sequence of SEQ ID NO: 270 or SEQ ID NO: 271, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 276; 2) an HCVR comprising the amino acid sequence of SEQ ID NO: 281 or SEQ ID NO: 282, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 287; 3) an HCVR comprising the amino acid sequence of SEQ ID NO: 292 or SEQ ID NO: 293, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 298; 4) an HCVR comprising the amino acid sequence of SEQ ID NO: 303, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 308 or SEQ ID NO: 309; 5) an HCVR comprising the amino acid sequence of SEQ ID NO: 314, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 319 or SEQ ID NO: 320; 6) an HCVR comprising the amino acid sequence of SEQ ID NO: 325 or SEQ ID NO: 326, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 331 or SEQ ID NO: 332; 7) HCVR comprising the amino acid sequence of SEQ ID NO: 337 or SEQ ID NO: 338, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 343 or SEQ ID NO: 344; 8) an HCVR comprising the amino acid sequence of SEQ ID NO: 349 or SEQ ID NO: 350, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 355 or SEQ ID NO: 356; 9) HCVR comprising the amino acid sequence of SEQ ID NO: 361 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 366; 10) HCVR comprising the amino acid sequence of SEQ ID NO: 371 or SEQ ID NO: 372, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 377; 11) HCVR comprising the amino acid sequence of SEQ ID NO: 382 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 387; 12) HCVR comprising the amino acid sequence of SEQ ID NO: 392 or SEQ ID NO: 393, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 398 or SEQ ID NO: 399; 13) HCVR comprising the amino acid sequence of SEQ ID NO: 404 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 409; 14) HCVR comprising the amino acid sequence of SEQ ID NO: 414 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 419; 15) HCVR comprising the amino acid sequence of SEQ ID NO: 424 or SEQ ID NO: 425, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 430 or SEQ ID NO: 431; 16) HCVR comprising the amino acid sequence of SEQ ID NO: 436 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 441; 17) HCVR comprising the amino acid sequence of SEQ ID NO: 446 or SEQ ID NO: 447, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 452; 18) HCVR comprising the amino acid sequence of SEQ ID NO: 457 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 462; 19) HCVR comprising the amino acid sequence of SEQ ID NO: 467 or SEQ ID NO: 468, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 473 or SEQ ID NO: 474; 20) HCVR comprising the amino acid sequence of SEQ ID NO: 479 or SEQ ID NO: 480, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 485; 21) HCVR comprising the amino acid sequence of SEQ ID NO: 490 or SEQ ID NO: 491, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 496; 22) HCVR comprising the amino acid sequence of SEQ ID NO: 501 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 506; 23) HCVR comprising the amino acid sequence of SEQ ID NO: 511 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 516; 24) HCVR comprising the amino acid sequence of SEQ ID NO: 521 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 526; 25) HCVR comprising the amino acid sequence of SEQ ID NO: 531 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 536; 26) HCVR comprising the amino acid sequence of SEQ ID NO: 541 or SEQ ID NO: 542, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 547; 27) HCVR comprising the amino acid sequence of SEQ ID NO: 552 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 557; 28) HCVR comprising the amino acid sequence of SEQ ID NO: 562 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 567; 29) HCVR comprising the amino acid sequence of SEQ ID NO: 572 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 577; 30) HCVR comprising the amino acid sequence of SEQ ID NO: 582 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 587; 31) HCVR comprising the amino acid sequence of SEQ ID NO: 592 or SEQ ID NO: 593, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 598 or SEQ ID NO: 599; 32) an HCVR comprising the amino acid sequence of SEQ ID NO: 604, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 609 or SEQ ID NO: 610; or 33) The multispecific antibody or multispecific antigen-binding fragment thereof according to any one of claims 43 to 45, comprising an HCVR comprising the amino acid sequence of SEQ ID NO: 1119 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 1127.

47. 39. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 28 to 38, wherein the molecule on the cell surface is CACNG1.

48. the second antigen-binding domain that binds to CACNG1, 1) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 615, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 623; 2) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 635, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 643; 3) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 655, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 663; 4) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 675, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 683; 5) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 695, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 703; 6) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 715, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 723; 7) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 735, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 743; 8) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 755, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 763; 9) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 775, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 783; 10) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 795, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 803; 11) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 815, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 823; 12) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 835, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 843; 13) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 855, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 863; 14) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 875, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 883; 15) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 895, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 903; 16) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 915, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 923; 17) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 935, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 943; 18) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 955, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 963; 19) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1181, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 1189; or 20) The multispecific antibody or multispecific antigen-binding fragment of claim 47, comprising an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1205, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 1213.

49. the second antigen-binding domain that binds to CACNG1, 1) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 617, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 619, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 621, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 625, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 627, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 629; 2) HCDR1 comprising the amino acid sequence of SEQ ID NO: 637, HCDR2 comprising the amino acid sequence of SEQ ID NO: 639, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 641, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 645, LCDR2 comprising the amino acid sequence of SEQ ID NO: 647, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 649; 3) HCDR1 comprising the amino acid sequence of SEQ ID NO: 657, HCDR2 comprising the amino acid sequence of SEQ ID NO: 659, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 661, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 665, LCDR2 comprising the amino acid sequence of SEQ ID NO: 667, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 669; 4) HCDR1 comprising the amino acid sequence of SEQ ID NO: 677, HCDR2 comprising the amino acid sequence of SEQ ID NO: 679, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 681, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 685, LCDR2 comprising the amino acid sequence of SEQ ID NO: 687, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 689; 5) HCDR1 comprising the amino acid sequence of SEQ ID NO: 697, HCDR2 comprising the amino acid sequence of SEQ ID NO: 699, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 701, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 705, LCDR2 comprising the amino acid sequence of SEQ ID NO: 707, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 709; 6) HCDR1 comprising the amino acid sequence of SEQ ID NO: 717, HCDR2 comprising the amino acid sequence of SEQ ID NO: 719, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 721, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 725, LCDR2 comprising the amino acid sequence of SEQ ID NO: 727, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 729; 7) HCDR1 comprising the amino acid sequence of SEQ ID NO: 737, HCDR2 comprising the amino acid sequence of SEQ ID NO: 739, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 741, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 745, LCDR2 comprising the amino acid sequence of SEQ ID NO: 747, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 749; 8) HCDR1 comprising the amino acid sequence of SEQ ID NO: 757, HCDR2 comprising the amino acid sequence of SEQ ID NO: 759, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 761, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 765, LCDR2 comprising the amino acid sequence of SEQ ID NO: 767, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 769; 9) HCDR1 comprising the amino acid sequence of SEQ ID NO: 777, HCDR2 comprising the amino acid sequence of SEQ ID NO: 779, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 781, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 785, LCDR2 comprising the amino acid sequence of SEQ ID NO: 787, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 789; 10) HCDR1 comprising the amino acid sequence of SEQ ID NO: 797, HCDR2 comprising the amino acid sequence of SEQ ID NO: 799, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 801, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 805, LCDR2 comprising the amino acid sequence of SEQ ID NO: 807, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 809; 11) HCDR1 comprising the amino acid sequence of SEQ ID NO: 817, HCDR2 comprising the amino acid sequence of SEQ ID NO: 819, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 821, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 825, LCDR2 comprising the amino acid sequence of SEQ ID NO: 827, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 829; 12) HCDR1 comprising the amino acid sequence of SEQ ID NO: 837, HCDR2 comprising the amino acid sequence of SEQ ID NO: 839, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 841, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 845, LCDR2 comprising the amino acid sequence of SEQ ID NO: 847, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 849; 13) HCDR1 comprising the amino acid sequence of SEQ ID NO: 857, HCDR2 comprising the amino acid sequence of SEQ ID NO: 859, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 861, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 865, LCDR2 comprising the amino acid sequence of SEQ ID NO: 867, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 869; 14) HCDR1 comprising the amino acid sequence of SEQ ID NO: 877, HCDR2 comprising the amino acid sequence of SEQ ID NO: 879, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 881, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 885, LCDR2 comprising the amino acid sequence of SEQ ID NO: 887, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 889; 15) HCDR1 comprising the amino acid sequence of SEQ ID NO: 897, HCDR2 comprising the amino acid sequence of SEQ ID NO: 899, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 901, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 905, LCDR2 comprising the amino acid sequence of SEQ ID NO: 907, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 909; 16) HCDR1 comprising the amino acid sequence of SEQ ID NO: 917, HCDR2 comprising the amino acid sequence of SEQ ID NO: 919, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 921, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 925, LCDR2 comprising the amino acid sequence of SEQ ID NO: 927, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 929; 17) HCDR1 comprising the amino acid sequence of SEQ ID NO: 937, HCDR2 comprising the amino acid sequence of SEQ ID NO: 939, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 941, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 945, LCDR2 comprising the amino acid sequence of SEQ ID NO: 947, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 949; 18) HCDR1 comprising the amino acid sequence of SEQ ID NO: 957, HCDR2 comprising the amino acid sequence of SEQ ID NO: 959, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 961, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 965, LCDR2 comprising the amino acid sequence of SEQ ID NO: 967, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 969; 19) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1183, HCDR2 comprising the amino acid sequence of SEQ ID NO: 1185, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 1187, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1191, LCDR2 comprising the amino acid sequence of SEQ ID NO: 1193, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 1195, or 20) The multispecific antibody or multispecific antigen-binding fragment of claim 47 or 48, comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO: 1207, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 1209, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 1211, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 1215, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 1217, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 1219.

50. the second antigen-binding domain that binds to CACNG1, 1) an HCVR comprising the amino acid sequence of SEQ ID NO: 615, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 623; 2) an HCVR comprising the amino acid sequence of SEQ ID NO: 635, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 643; 3) an HCVR comprising the amino acid sequence of SEQ ID NO: 655, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 663; 4) an HCVR comprising the amino acid sequence of SEQ ID NO: 675, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 683; 5) an HCVR comprising the amino acid sequence of SEQ ID NO: 695 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 703; 6) an HCVR comprising the amino acid sequence of SEQ ID NO: 715, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 723; 7) HCVR comprising the amino acid sequence of SEQ ID NO: 735, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 743; 8) HCVR comprising the amino acid sequence of SEQ ID NO: 755 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 763; 9) HCVR comprising the amino acid sequence of SEQ ID NO: 775 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 783; 10) HCVR comprising the amino acid sequence of SEQ ID NO: 795 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 803; 11) HCVR comprising the amino acid sequence of SEQ ID NO: 815 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 823; 12) HCVR comprising the amino acid sequence of SEQ ID NO: 835 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 843; 13) HCVR comprising the amino acid sequence of SEQ ID NO: 855 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 863; 14) HCVR comprising the amino acid sequence of SEQ ID NO: 875 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 883; 15) HCVR comprising the amino acid sequence of SEQ ID NO: 895 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 903; 16) HCVR comprising the amino acid sequence of SEQ ID NO: 915 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 923; 17) HCVR comprising the amino acid sequence of SEQ ID NO: 935 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 943; 18) HCVR comprising the amino acid sequence of SEQ ID NO: 955 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 963; 19) HCVR comprising the amino acid sequence of SEQ ID NO: 1181 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 1189; or 20) The multispecific antibody or multispecific antigen-binding fragment thereof according to any one of claims 47 to 49, comprising an HCVR comprising the amino acid sequence of SEQ ID NO: 1205 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 1213.

51. A multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, from N-terminal to C-terminal, (i) a first heavy chain region of a first Fab ("Fab1") operably linked to (ii) a second heavy chain region of a second Fab ("Fab2"); b) a second polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1, wherein Fab1 comprises a first antigen-binding domain (“ABD1”); and c) a third polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form Fab2, wherein Fab2 comprises a second antigen-binding domain ("ABD2"), wherein ABD1 or ABD2 binds to the capsid of an adeno-associated virus (AAV) particle, and the other of ABD1 or ABD2 binds to a molecule on the surface of a cell, or a multispecific antigen-binding fragment thereof.

52. 52. The multispecific antibody or multispecific antigen-binding fragment of claim 51 , wherein ABD1 binds to the capsid of an adeno-associated virus (AAV) particle and ABD2 binds to a molecule on the surface of said cell.

53. 52. The multispecific antibody or multispecific antigen-binding fragment of claim 51 , wherein ABD2 binds to the capsid of an adeno-associated virus (AAV) particle and ABD1 binds to a molecule on the surface of said cell.

54. 54. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 51 to 53, wherein the first heavy chain region is linked to the second heavy chain region via a linker.

55. A multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, in an N-terminal to C-terminal direction, a first scFv comprising: (i) a first antigen binding domain (“ABD1”) operably linked to (ii) an Fc domain; b) a second polypeptide chain of (i) a first heavy chain region of a first Fab (“Fab1”) operably linked, in an N-terminal to C-terminal direction, to (ii) an Fc domain; c) a third polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1, wherein Fab1 comprises a second antigen-binding domain ("ABD2"), wherein the third polypeptide chain, ABD1 or ABD2, binds to the capsid of an adeno-associated virus (AAV) particle, and the other of ABD1 or ABD2 binds to a molecule on the surface of a cell, or a multispecific antigen-binding fragment thereof.

56. 56. The multispecific antibody or multispecific antigen-binding fragment of claim 55, wherein ABD1 binds to the capsid of an adeno-associated virus (AAV) particle and ABD2 binds to a molecule on the surface of said cell.

57. 56. The multispecific antibody or multispecific antigen-binding fragment of claim 55, wherein ABD2 binds to the capsid of an adeno-associated virus (AAV) particle and ABD1 binds to a molecule on the surface of said cell.

58. 58. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 55 to 57, wherein the first scFv and / or the first heavy chain region is linked to the Fc domain via a linker.

59. The ABD1 or ABD2 that binds to the capsid of an AAV particle is a) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 2, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; b) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 22, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; c) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 32, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, d) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 42, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; e) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 52 or SEQ ID NO: 1159, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157; f) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 62, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; g) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 71; and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; h) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 81, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; i) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 91, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, and / or j) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2 and HCDR3, and which comprises the amino acid sequence of SEQ ID NO: 101; and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2 and LCDR3, and which comprises the amino acid sequence of SEQ ID NO:

10.

60. The ABD1 or ABD2 is a) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 8, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; b) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 24, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 26, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 28, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; c) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 34, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 36, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 38, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; d) HCDR1 comprising the amino acid sequence of SEQ ID NO: 44, HCDR2 comprising the amino acid sequence of SEQ ID NO: 46, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 48, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; e) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 54, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; f) HCDR1 comprising the amino acid sequence of SEQ ID NO: 64, HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 67, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; g) HCDR1 comprising the amino acid sequence of SEQ ID NO: 73, HCDR2 comprising the amino acid sequence of SEQ ID NO: 75, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 77, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; h) HCDR1 comprising the amino acid sequence of SEQ ID NO: 83, HCDR2 comprising the amino acid sequence of SEQ ID NO: 85, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 87, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; i) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 93, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 95, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 97, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16, and / or j) The multispecific antibody or multispecific antigen-binding fragment of claim 59, which binds to the capsid of an AAV particle comprising HCDR1 comprising the amino acid sequence of SEQ ID NO: 103, HCDR2 comprising the amino acid sequence of SEQ ID NO: 105, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 107, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO:

16.

61. The ABD1 or ABD2 is a) an HCVR comprising the amino acid sequence of SEQ ID NO: 2 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; b) an HCVR comprising the amino acid sequence of SEQ ID NO: 22 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; c) an HCVR comprising the amino acid sequence of SEQ ID NO: 32 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; d) an HCVR comprising the amino acid sequence of SEQ ID NO: 42 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; e) an HCVR comprising the amino acid sequence of SEQ ID NO: 52 or SEQ ID NO: 1159, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157; f) an HCVR comprising the amino acid sequence of SEQ ID NO: 62 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; g) an HCVR comprising the amino acid sequence of SEQ ID NO: 71 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; h) an HCVR comprising the amino acid sequence of SEQ ID NO: 81 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; i) an HCVR comprising the amino acid sequence of SEQ ID NO: 91, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10, and / or j) A multispecific antibody or multispecific antigen-binding fragment according to claim 59 or 60, which binds to the capsid of an AAV particle comprising an HCVR comprising the amino acid sequence of SEQ ID NO: 101 and / or an LCVR comprising the amino acid sequence of SEQ ID NO:

10.

62. 62. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 51 to 61, wherein the molecule on the cell surface is asialoglycoprotein receptor 1 (ASGR1), transferrin receptor (TfR), or calcium voltage-gated channel accessory subunit gamma 1 (CACNG1).

63. 63. The multispecific antibody or multispecific antigen-binding fragment of claim 62, wherein the molecule on the cell surface is ASGR1.

64. The other of ABD1 and ABD2 that bind to ASGR1 is a) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 220 or SEQ ID NO: 1239, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157, or b) a HCVR comprising HCDR1, HCDR2, and HCDR3 contained within a HCVR comprising the amino acid sequence of SEQ ID NO: 230, and / or a LCVR comprising LCDR1, LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO:

10.

65. The other of ABD1 and ABD2 that bind to ASGR1 is a) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 222, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 224, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 226, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16, or b) A multispecific antibody or multispecific antigen-binding fragment according to claim 63 or 64, comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO: 232, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 234, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 236, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:

16.

66. The other of ABD1 and ABD2 that bind to ASGR1 is a) an HCVR comprising the amino acid sequence of SEQ ID NO: 220 or SEQ ID NO: 1239, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10 or 1157, or b) a HCVR comprising the amino acid sequence of SEQ ID NO: 230 and / or a LCVR comprising the amino acid sequence of SEQ ID NO:

10.

67. 63. The multispecific antibody or multispecific antigen-binding fragment of claim 62, wherein the molecule on the cell surface is TfR.

68. The other of ABD1 and ABD2 that bind to TfR is 1) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 270 or SEQ ID NO: 271, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 276; 2) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 281 or SEQ ID NO: 282, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 287; 3) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 292 or SEQ ID NO: 293, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 298; 4) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 303, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 308 or SEQ ID NO: 309; 5) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 314, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 319 or SEQ ID NO: 320; 6) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 325 or SEQ ID NO: 326, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 331 or SEQ ID NO: 332; 7) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 337 or SEQ ID NO: 338, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 343 or SEQ ID NO: 344; 8) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 349 or SEQ ID NO: 350, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 355 or SEQ ID NO: 356; 9) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 361, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 366; 10) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 371 or SEQ ID NO: 372, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 377; 11) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 382, ​​and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 387; 12) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 392 or SEQ ID NO: 393, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 398 or SEQ ID NO: 399; 13) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 404, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 409; 14) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 414, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 419; 15) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 424 or SEQ ID NO: 425, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 430 or SEQ ID NO: 431; 16) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 436, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 441; 17) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 446 or SEQ ID NO: 447, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 452; 18) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 457, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 462; 19) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 467 or SEQ ID NO: 468, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 473 or SEQ ID NO: 474; 20) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 479 or SEQ ID NO: 480, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 485; 21) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 490 or SEQ ID NO: 491, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 496; 22) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 501, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 506; 23) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 511, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 516; 24) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 521, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 526; 25) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 531, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 536; 26) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 541 or SEQ ID NO: 542, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 547; 27) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 552, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 557; 28) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 562, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 567; 29) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 572, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 577; 30) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 582, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 587; 31) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 592 or SEQ ID NO: 593, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 598 or SEQ ID NO: 599; 32) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 604, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 609 or SEQ ID NO: 610; or 33) The multispecific antibody or multispecific antigen-binding fragment of claim 67, comprising an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1119, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 1127.

69. The other of ABD1 and ABD2 that bind to TfR is 1) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 272, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 273, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 274, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 277, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 278, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 279; 2) HCDR1 comprising the amino acid sequence of SEQ ID NO: 283, HCDR2 comprising the amino acid sequence of SEQ ID NO: 284, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 285, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 288, LCDR2 comprising the amino acid sequence of SEQ ID NO: 289, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 290; 3) HCDR1 comprising the amino acid sequence of SEQ ID NO: 294, HCDR2 comprising the amino acid sequence of SEQ ID NO: 295, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 296, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 299, LCDR2 comprising the amino acid sequence of SEQ ID NO: 300, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 301; 4) HCDR1 comprising the amino acid sequence of SEQ ID NO: 304, HCDR2 comprising the amino acid sequence of SEQ ID NO: 305, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 306, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 310, LCDR2 comprising the amino acid sequence of SEQ ID NO: 311, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 312; 5) HCDR1 comprising the amino acid sequence of SEQ ID NO: 315, HCDR2 comprising the amino acid sequence of SEQ ID NO: 316, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 317, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 321, LCDR2 comprising the amino acid sequence of SEQ ID NO: 322, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 323; 6) HCDR1 comprising the amino acid sequence of SEQ ID NO: 327, HCDR2 comprising the amino acid sequence of SEQ ID NO: 328, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 329, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 333, LCDR2 comprising the amino acid sequence of SEQ ID NO: 334, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 335; 7) HCDR1 comprising the amino acid sequence of SEQ ID NO: 339, HCDR2 comprising the amino acid sequence of SEQ ID NO: 340, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 341, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 345, LCDR2 comprising the amino acid sequence of SEQ ID NO: 346, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 347; 8) HCDR1 comprising the amino acid sequence of SEQ ID NO: 351, HCDR2 comprising the amino acid sequence of SEQ ID NO: 352, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 353, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 357, LCDR2 comprising the amino acid sequence of SEQ ID NO: 358, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 359; 9) HCDR1 comprising the amino acid sequence of SEQ ID NO: 362, HCDR2 comprising the amino acid sequence of SEQ ID NO: 363, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 364, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 367, LCDR2 comprising the amino acid sequence of SEQ ID NO: 368, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 369; 10) HCDR1 comprising the amino acid sequence of SEQ ID NO: 373, HCDR2 comprising the amino acid sequence of SEQ ID NO: 374, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 375, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 378, LCDR2 comprising the amino acid sequence of SEQ ID NO: 379, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 380; 11) HCDR1 comprising the amino acid sequence of SEQ ID NO: 383, HCDR2 comprising the amino acid sequence of SEQ ID NO: 384, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 385, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 388, LCDR2 comprising the amino acid sequence of SEQ ID NO: 389, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 390; 12) HCDR1 comprising the amino acid sequence of SEQ ID NO: 394, HCDR2 comprising the amino acid sequence of SEQ ID NO: 395, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 396, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 400, LCDR2 comprising the amino acid sequence of SEQ ID NO: 401, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 402; 13) HCDR1 comprising the amino acid sequence of SEQ ID NO: 405, HCDR2 comprising the amino acid sequence of SEQ ID NO: 406, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 407, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 410, LCDR2 comprising the amino acid sequence of SEQ ID NO: 411, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 412; 14) HCDR1 comprising the amino acid sequence of SEQ ID NO: 415, HCDR2 comprising the amino acid sequence of SEQ ID NO: 416, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 417, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 420, LCDR2 comprising the amino acid sequence of SEQ ID NO: 421, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 422; 15) HCDR1 comprising the amino acid sequence of SEQ ID NO: 426, HCDR2 comprising the amino acid sequence of SEQ ID NO: 427, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 428, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 432, LCDR2 comprising the amino acid sequence of SEQ ID NO: 433, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 434; 16) HCDR1 comprising the amino acid sequence of SEQ ID NO: 437, HCDR2 comprising the amino acid sequence of SEQ ID NO: 438, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 439, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 442, LCDR2 comprising the amino acid sequence of SEQ ID NO: 443, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 444; 17) HCDR1 comprising the amino acid sequence of SEQ ID NO: 448, HCDR2 comprising the amino acid sequence of SEQ ID NO: 449, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 450, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 453, LCDR2 comprising the amino acid sequence of SEQ ID NO: 454, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 455; 18) HCDR1 comprising the amino acid sequence of SEQ ID NO: 458, HCDR2 comprising the amino acid sequence of SEQ ID NO: 459, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 460, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 463, LCDR2 comprising the amino acid sequence of SEQ ID NO: 464, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 465; 19) HCDR1 comprising the amino acid sequence of SEQ ID NO: 469, HCDR2 comprising the amino acid sequence of SEQ ID NO: 470, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 471, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 475, LCDR2 comprising the amino acid sequence of SEQ ID NO: 476, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 477; 20) HCDR1 comprising the amino acid sequence of SEQ ID NO: 481, HCDR2 comprising the amino acid sequence of SEQ ID NO: 482, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 483; and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 486, LCDR2 comprising the amino acid sequence of SEQ ID NO: 487, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 488; 21) HCDR1 comprising the amino acid sequence of SEQ ID NO: 492, HCDR2 comprising the amino acid sequence of SEQ ID NO: 493, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 494; and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 497, LCDR2 comprising the amino acid sequence of SEQ ID NO: 498, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 499; 22) HCDR1 comprising the amino acid sequence of SEQ ID NO: 502, HCDR2 comprising the amino acid sequence of SEQ ID NO: 503, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 504; and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 507, LCDR2 comprising the amino acid sequence of SEQ ID NO: 508, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 509; 23) HCDR1 comprising the amino acid sequence of SEQ ID NO: 512, HCDR2 comprising the amino acid sequence of SEQ ID NO: 513, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 514, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 517, LCDR2 comprising the amino acid sequence of SEQ ID NO: 518, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 519; 24) HCDR1 comprising the amino acid sequence of SEQ ID NO: 522, HCDR2 comprising the amino acid sequence of SEQ ID NO: 523, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 524; and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 527, LCDR2 comprising the amino acid sequence of SEQ ID NO: 528, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 529; 25) HCDR1 comprising the amino acid sequence of SEQ ID NO: 532, HCDR2 comprising the amino acid sequence of SEQ ID NO: 533, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 534, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 537, LCDR2 comprising the amino acid sequence of SEQ ID NO: 538, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 539; 26) HCDR1 comprising the amino acid sequence of SEQ ID NO: 543, HCDR2 comprising the amino acid sequence of SEQ ID NO: 544, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 545; and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 548, LCDR2 comprising the amino acid sequence of SEQ ID NO: 549, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 550; 27) HCDR1 comprising the amino acid sequence of SEQ ID NO: 553, HCDR2 comprising the amino acid sequence of SEQ ID NO: 554, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 555; and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 558, LCDR2 comprising the amino acid sequence of SEQ ID NO: 559, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 560; 28) HCDR1 comprising the amino acid sequence of SEQ ID NO: 563, HCDR2 comprising the amino acid sequence of SEQ ID NO: 564, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 565; and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 568, LCDR2 comprising the amino acid sequence of SEQ ID NO: 569, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 570; 29) HCDR1 comprising the amino acid sequence of SEQ ID NO: 573, HCDR2 comprising the amino acid sequence of SEQ ID NO: 574, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 575; and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 578, LCDR2 comprising the amino acid sequence of SEQ ID NO: 579, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 580; 30) HCDR1 comprising the amino acid sequence of SEQ ID NO: 583, HCDR2 comprising the amino acid sequence of SEQ ID NO: 584, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 585, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 588, LCDR2 comprising the amino acid sequence of SEQ ID NO: 589, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 590; 31) HCDR1 comprising the amino acid sequence of SEQ ID NO: 594, HCDR2 comprising the amino acid sequence of SEQ ID NO: 595, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 596, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 600, LCDR2 comprising the amino acid sequence of SEQ ID NO: 601, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 602; 32) HCDR1 comprising the amino acid sequence of SEQ ID NO: 605, HCDR2 comprising the amino acid sequence of SEQ ID NO: 606, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 607, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 611, LCDR2 comprising the amino acid sequence of SEQ ID NO: 612, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 613, or 33) The multispecific antibody or multispecific antigen-binding fragment of claim 67 or 68, comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO: 1121, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 1123, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 1125, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 1129, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 1131, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 1133.

70. The other of ABD1 and ABD2 that bind to TfR is 1) an HCVR comprising the amino acid sequence of SEQ ID NO: 270 or SEQ ID NO: 271, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 276; 2) an HCVR comprising the amino acid sequence of SEQ ID NO: 281 or SEQ ID NO: 282, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 287; 3) an HCVR comprising the amino acid sequence of SEQ ID NO: 292 or SEQ ID NO: 293, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 298; 4) an HCVR comprising the amino acid sequence of SEQ ID NO: 303, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 308 or SEQ ID NO: 309; 5) an HCVR comprising the amino acid sequence of SEQ ID NO: 314, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 319 or SEQ ID NO: 320; 6) an HCVR comprising the amino acid sequence of SEQ ID NO: 325 or SEQ ID NO: 326, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 331 or SEQ ID NO: 332; 7) HCVR comprising the amino acid sequence of SEQ ID NO: 337 or SEQ ID NO: 338, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 343 or SEQ ID NO: 344; 8) an HCVR comprising the amino acid sequence of SEQ ID NO: 349 or SEQ ID NO: 350, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 355 or SEQ ID NO: 356; 9) HCVR comprising the amino acid sequence of SEQ ID NO: 361 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 366; 10) HCVR comprising the amino acid sequence of SEQ ID NO: 371 or SEQ ID NO: 372, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 377; 11) HCVR comprising the amino acid sequence of SEQ ID NO: 382 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 387; 12) HCVR comprising the amino acid sequence of SEQ ID NO: 392 or SEQ ID NO: 393, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 398 or SEQ ID NO: 399; 13) HCVR comprising the amino acid sequence of SEQ ID NO: 404 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 409; 14) HCVR comprising the amino acid sequence of SEQ ID NO: 414 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 419; 15) HCVR comprising the amino acid sequence of SEQ ID NO: 424 or SEQ ID NO: 425, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 430 or SEQ ID NO: 431; 16) HCVR comprising the amino acid sequence of SEQ ID NO: 436 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 441; 17) HCVR comprising the amino acid sequence of SEQ ID NO: 446 or SEQ ID NO: 447, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 452; 18) HCVR comprising the amino acid sequence of SEQ ID NO: 457 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 462; 19) HCVR comprising the amino acid sequence of SEQ ID NO: 467 or SEQ ID NO: 468, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 473 or SEQ ID NO: 474; 20) HCVR comprising the amino acid sequence of SEQ ID NO: 479 or SEQ ID NO: 480, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 485; 21) HCVR comprising the amino acid sequence of SEQ ID NO: 490 or SEQ ID NO: 491, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 496; 22) HCVR comprising the amino acid sequence of SEQ ID NO: 501 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 506; 23) HCVR comprising the amino acid sequence of SEQ ID NO: 511 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 516; 24) HCVR comprising the amino acid sequence of SEQ ID NO: 521 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 526; 25) HCVR comprising the amino acid sequence of SEQ ID NO: 531 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 536; 26) HCVR comprising the amino acid sequence of SEQ ID NO: 541 or SEQ ID NO: 542, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 547; 27) HCVR comprising the amino acid sequence of SEQ ID NO: 552 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 557; 28) HCVR comprising the amino acid sequence of SEQ ID NO: 562 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 567; 29) HCVR comprising the amino acid sequence of SEQ ID NO: 572 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 577; 30) HCVR comprising the amino acid sequence of SEQ ID NO: 582 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 587; 31) HCVR comprising the amino acid sequence of SEQ ID NO: 592 or SEQ ID NO: 593, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 598 or SEQ ID NO: 599; 32) an HCVR comprising the amino acid sequence of SEQ ID NO: 604, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 609 or SEQ ID NO: 610; or 33) The multispecific antibody or multispecific antigen-binding fragment thereof according to any one of claims 67 to 69, comprising an HCVR comprising the amino acid sequence of SEQ ID NO: 1119 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 1127.

71. 63. The multispecific antibody or multispecific antigen-binding fragment of claim 62, wherein the molecule on the cell surface is CACNG1.

72. The other of ABD1 and ABD2 that binds to CACNG1 is 1) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 615, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 623; 2) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 635, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 643; 3) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 655, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 663; 4) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 675, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 683; 5) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 695, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 703; 6) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 715, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 723; 7) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 735, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 743; 8) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 755, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 763; 9) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 775, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 783; 10) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 795, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 803; 11) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 815, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 823; 12) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 835, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 843; 13) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 855, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 863; 14) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 875, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 883; 15) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 895, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 903; 16) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 915, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 923; 17) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 935, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 943; 18) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 955, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 963; 19) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1181, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 1189; or 20) The multispecific antibody or multispecific antigen-binding fragment of claim 71, comprising an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1205, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 1213.

73. The other of ABD1 and ABD2 that binds to CACNG1 is 1) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 617, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 619, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 621, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 625, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 627, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 629; 2) HCDR1 comprising the amino acid sequence of SEQ ID NO: 637, HCDR2 comprising the amino acid sequence of SEQ ID NO: 639, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 641, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 645, LCDR2 comprising the amino acid sequence of SEQ ID NO: 647, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 649; 3) HCDR1 comprising the amino acid sequence of SEQ ID NO: 657, HCDR2 comprising the amino acid sequence of SEQ ID NO: 659, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 661, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 665, LCDR2 comprising the amino acid sequence of SEQ ID NO: 667, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 669; 4) HCDR1 comprising the amino acid sequence of SEQ ID NO: 677, HCDR2 comprising the amino acid sequence of SEQ ID NO: 679, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 681, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 685, LCDR2 comprising the amino acid sequence of SEQ ID NO: 687, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 689; 5) HCDR1 comprising the amino acid sequence of SEQ ID NO: 697, HCDR2 comprising the amino acid sequence of SEQ ID NO: 699, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 701, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 705, LCDR2 comprising the amino acid sequence of SEQ ID NO: 707, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 709; 6) HCDR1 comprising the amino acid sequence of SEQ ID NO: 717, HCDR2 comprising the amino acid sequence of SEQ ID NO: 719, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 721, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 725, LCDR2 comprising the amino acid sequence of SEQ ID NO: 727, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 729; 7) HCDR1 comprising the amino acid sequence of SEQ ID NO: 737, HCDR2 comprising the amino acid sequence of SEQ ID NO: 739, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 741, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 745, LCDR2 comprising the amino acid sequence of SEQ ID NO: 747, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 749; 8) HCDR1 comprising the amino acid sequence of SEQ ID NO: 757, HCDR2 comprising the amino acid sequence of SEQ ID NO: 759, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 761, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 765, LCDR2 comprising the amino acid sequence of SEQ ID NO: 767, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 769; 9) HCDR1 comprising the amino acid sequence of SEQ ID NO: 777, HCDR2 comprising the amino acid sequence of SEQ ID NO: 779, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 781, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 785, LCDR2 comprising the amino acid sequence of SEQ ID NO: 787, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 789; 10) HCDR1 comprising the amino acid sequence of SEQ ID NO: 797, HCDR2 comprising the amino acid sequence of SEQ ID NO: 799, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 801, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 805, LCDR2 comprising the amino acid sequence of SEQ ID NO: 807, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 809; 11) HCDR1 comprising the amino acid sequence of SEQ ID NO: 817, HCDR2 comprising the amino acid sequence of SEQ ID NO: 819, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 821, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 825, LCDR2 comprising the amino acid sequence of SEQ ID NO: 827, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 829; 12) HCDR1 comprising the amino acid sequence of SEQ ID NO: 837, HCDR2 comprising the amino acid sequence of SEQ ID NO: 839, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 841, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 845, LCDR2 comprising the amino acid sequence of SEQ ID NO: 847, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 849; 13) HCDR1 comprising the amino acid sequence of SEQ ID NO: 857, HCDR2 comprising the amino acid sequence of SEQ ID NO: 859, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 861, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 865, LCDR2 comprising the amino acid sequence of SEQ ID NO: 867, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 869; 14) HCDR1 comprising the amino acid sequence of SEQ ID NO: 877, HCDR2 comprising the amino acid sequence of SEQ ID NO: 879, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 881, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 885, LCDR2 comprising the amino acid sequence of SEQ ID NO: 887, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 889; 15) HCDR1 comprising the amino acid sequence of SEQ ID NO: 897, HCDR2 comprising the amino acid sequence of SEQ ID NO: 899, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 901, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 905, LCDR2 comprising the amino acid sequence of SEQ ID NO: 907, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 909; 16) HCDR1 comprising the amino acid sequence of SEQ ID NO: 917, HCDR2 comprising the amino acid sequence of SEQ ID NO: 919, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 921, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 925, LCDR2 comprising the amino acid sequence of SEQ ID NO: 927, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 929; 17) HCDR1 comprising the amino acid sequence of SEQ ID NO: 937, HCDR2 comprising the amino acid sequence of SEQ ID NO: 939, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 941, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 945, LCDR2 comprising the amino acid sequence of SEQ ID NO: 947, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 949; 18) HCDR1 comprising the amino acid sequence of SEQ ID NO: 957, HCDR2 comprising the amino acid sequence of SEQ ID NO: 959, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 961, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 965, LCDR2 comprising the amino acid sequence of SEQ ID NO: 967, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 969; 19) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1183, HCDR2 comprising the amino acid sequence of SEQ ID NO: 1185, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 1187, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1191, LCDR2 comprising the amino acid sequence of SEQ ID NO: 1193, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 1195, or 20) The multispecific antibody or multispecific antigen-binding fragment of claim 71 or 72, comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO: 1207, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 1209, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 1211, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 1215, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 1217, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 1219.

74. The other of ABD1 and ABD2 that binds to CACNG1 is 1) an HCVR comprising the amino acid sequence of SEQ ID NO: 615, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 623; 2) an HCVR comprising the amino acid sequence of SEQ ID NO: 635, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 643; 3) an HCVR comprising the amino acid sequence of SEQ ID NO: 655, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 663; 4) an HCVR comprising the amino acid sequence of SEQ ID NO: 675, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 683; 5) an HCVR comprising the amino acid sequence of SEQ ID NO: 695 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 703; 6) an HCVR comprising the amino acid sequence of SEQ ID NO: 715, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 723; 7) HCVR comprising the amino acid sequence of SEQ ID NO: 735, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 743; 8) HCVR comprising the amino acid sequence of SEQ ID NO: 755 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 763; 9) HCVR comprising the amino acid sequence of SEQ ID NO: 775 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 783; 10) HCVR comprising the amino acid sequence of SEQ ID NO: 795 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 803; 11) HCVR comprising the amino acid sequence of SEQ ID NO: 815 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 823; 12) HCVR comprising the amino acid sequence of SEQ ID NO: 835 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 843; 13) HCVR comprising the amino acid sequence of SEQ ID NO: 855 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 863; 14) HCVR comprising the amino acid sequence of SEQ ID NO: 875 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 883; 15) HCVR comprising the amino acid sequence of SEQ ID NO: 895 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 903; 16) HCVR comprising the amino acid sequence of SEQ ID NO: 915 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 923; 17) HCVR comprising the amino acid sequence of SEQ ID NO: 935 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 943; 18) HCVR comprising the amino acid sequence of SEQ ID NO: 955 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 963; 19) HCVR comprising the amino acid sequence of SEQ ID NO: 1181 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 1189; or 20) The multispecific antibody or multispecific antigen-binding fragment thereof according to any one of claims 71 to 73, comprising an HCVR comprising the amino acid sequence of SEQ ID NO: 1205 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 1213.

75. A multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, in an N-terminal to C-terminal direction, (i) a scFv comprising a first antigen binding domain (“ABD1”) operably linked to (ii) a first heavy chain region of a first Fab (Tab1″), wherein said first heavy chain region is operably linked to (iii) an Fc domain; b) a second polypeptide chain comprising, in an N-terminal to C-terminal direction: (i) a second heavy chain region of a second Fab (Tab2') operably linked to (ii) an Fc domain; c) a third polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1, wherein Fab1 comprises a second antigen-binding domain (“ABD2”); and d) a fourth polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form Fab2, wherein Fab2 comprises a third antigen-binding domain ("ABD3"), wherein at least one of ABD1, ABD2, and ABD3 binds to the capsid of an adeno-associated virus (AAV) particle, and one or more others of ABD1, ABD2, and ABD3 binds to a molecule on the surface of a cell.

76. 76. The multispecific antibody or multispecific antigen-binding fragment of claim 75, wherein two of ABD1, ABD2, and ABD3 bind to the capsid of an AAV particle, and one of ABD1, ABD2, and ABD3 binds to a molecule on the cell surface.

77. 77. The multispecific antibody or multispecific antigen-binding fragment of claim 76, wherein ABD2 and ABD3 bind to the capsid of an AAV particle and ABD1 binds to a molecule on the cell surface.

78. 77. The multispecific antibody or multispecific antigen-binding fragment of claim 76, wherein ABD1 and ABD3 bind to the capsid of an AAV particle and ABD2 binds to a molecule on the cell surface.

79. 79. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 43 to 78, wherein the scFv is linked to the first heavy chain region via a linker.

80. A multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, from N-terminal to C-terminal, (i) a first heavy chain region of a first Fab (“Fab1”) operably linked to (ii) an Fc domain, said Fc domain being operably linked to an scFv comprising (iii) a first antigen binding domain (“ABD1”); b) a second polypeptide chain comprising, in N-terminal to C-terminal direction: (i) a second heavy chain region of a second Fab (“Fab2”) operably linked to (ii) an Fc domain; c) a third polypeptide chain comprising a first light chain that pairs with said first heavy chain region to form Fab1, wherein Fab1 comprises a second antigen-binding domain ("ABD2"); and d) a fourth polypeptide chain comprising a second light chain that pairs with said second heavy chain region to form Fab2, wherein Fab2 comprises a third antigen-binding domain ("ABD3"); wherein at least one of ABD1, ABD2, and ABD3 binds to the capsid of an adeno-associated virus (AAV) particle, and one or more others of ABD1, ABD2, and ABD3 bind to a molecule on the surface of a cell.

81. 81. The multispecific antibody or multispecific antigen-binding fragment of claim 80, wherein two of ABD1, ABD2, and ABD3 bind to the capsid of an AAV particle, and one of ABD1, ABD2, and ABD3 binds to a molecule on the cell surface.

82. 82. The multispecific antibody or multispecific antigen-binding fragment of claim 81 , wherein ABD2 and ABD3 bind to the capsid of an AAV particle and ABD1 binds to a molecule on the cell surface.

83. 82. The multispecific antibody or multispecific antigen-binding fragment of claim 81 , wherein ABD1 and ABD2 bind to the capsid of an AAV particle and ABD3 binds to a molecule on the cell surface.

84. 84. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 80 to 83, wherein the scFv is linked to the Fc domain via a linker.

85. A multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, from N-terminal to C-terminal, (i) a first heavy chain region of a first Fab ("Fab1") operably linked to (ii) a second heavy chain region of a second Fab ("Fab2"), wherein said second heavy chain region of Fab2 is operably linked to (iii) an Fc domain; b) a second polypeptide chain comprising, in N-terminal to C-terminal direction: (i) a third heavy chain region of a third Fab (“Tab3”) operably linked to (ii) an Fc domain; c) a third polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1, wherein Fab1 comprises a first antigen-binding domain (“ABD1”); d) a fourth polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form Fab2, wherein Fab2 comprises a second antigen binding domain (“ABD2”); and e) a fifth polypeptide chain comprising a third light chain that pairs with the third heavy chain region to form Fab3, wherein Fab3 comprises a third antigen-binding domain (“ABD3”); A multispecific antibody, or a multispecific antigen-binding fragment thereof, wherein at least one of ABD1, ABD2, and ABD3 binds to the capsid of an adeno-associated virus (AAV) particle, and one or more others of ABD1, ABD2, and ABD3 bind to a molecule on the cell surface.

86. 86. The multispecific antibody or multispecific antigen-binding fragment of claim 85, wherein two of ABD1, ABD2, and ABD3 bind to the capsid of an AAV particle, and one of ABD1, ABD2, and ABD3 binds to a molecule on the cell surface.

87. 87. The multispecific antibody or multispecific antigen-binding fragment of claim 86, wherein ABD2 and ABD3 bind to the capsid of an AAV particle and ABD1 binds to a molecule on the cell surface.

88. 87. The multispecific antibody or multispecific antigen-binding fragment of claim 86, wherein ABD1 and ABD3 bind to the capsid of an AAV particle and ABD2 binds to a molecule on the cell surface.

89. 89. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 85 to 88, wherein the first heavy chain region is linked to the second heavy chain region via a linker.

90. A multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, from N-terminal to C-terminal, (i) a first heavy chain region of a first Fab (“Fab1”) operably linked to (ii) an Fc domain, said Fc domain being operably linked to (iii) a second heavy chain region of a second Fab (“Fab2”); b) a second polypeptide chain comprising, in N-terminal to C-terminal direction: (i) a third heavy chain region of a third Fab (“Fab3”) operably linked to (ii) an Fc domain; c) a third polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1, wherein Fab1 comprises a first antigen-binding domain (“ABD1”); d) a fourth polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form Fab2, wherein Fab2 comprises a second antigen binding domain (“ABD2”); and e) A multispecific antibody, or multispecific antigen-binding fragment thereof, comprising a fifth polypeptide chain comprising a third light chain that pairs with the third heavy chain region to form Fab3, wherein Fab3 comprises a third antigen-binding domain ("ABD3"), wherein at least one of ABD1, ABD2, and ABD3 binds to the capsid of an adeno-associated virus (AAV) particle, and one or more others of ABD1, ABD2, and ABD3 bind to a molecule on the surface of a cell.

91. 91. The multispecific antibody or multispecific antigen-binding fragment of claim 90, wherein two of ABD1, ABD2, and ABD3 bind to the capsid of an AAV particle, and one of ABD1, ABD2, and ABD3 binds to a molecule on the cell surface.

92. 92. The multispecific antibody or multispecific antigen-binding fragment of claim 91 , wherein ABD1 and ABD3 bind to the capsid of an AAV particle and ABD2 binds to a molecule on the cell surface.

93. 92. The multispecific antibody or multispecific antigen-binding fragment of claim 91 , wherein ABD1 and ABD2 bind to the capsid of an AAV particle and ABD3 binds to a molecule on the cell surface.

94. 94. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 90 to 93, wherein the second heavy chain region is linked to the Fc domain via a linker.

95. A multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, from N-terminal to C-terminal, (i) a first heavy chain region of a first Fab (“Fab1”), operably linked to (ii) an scFv comprising a first antigen binding domain (“ABD1”), said scFv being operably linked to (iii) an Fc domain; b) a second polypeptide chain comprising, in N-terminal to C-terminal direction: (i) a second heavy chain region of a second Fab (“Fab2”) operably linked to (ii) an Fc domain; c) a third polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1, wherein Fab1 comprises a second antigen-binding domain ("ABD2"); and d) a fourth polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form Fab2, wherein Fab2 comprises a third antigen-binding domain ("ABD3"); wherein at least one of ABD1, ABD2, and ABD3 binds to the capsid of an adeno-associated virus (AAV) particle, and one or more others of ABD1, ABD2, and ABD3 bind to a molecule on the surface of a cell.

96. 96. The multispecific antibody or multispecific antigen-binding fragment of claim 95, wherein two of ABD1, ABD2, and ABD3 bind to the capsid of an AAV particle, and one of ABD1, ABD2, and ABD3 binds to a molecule on the cell surface.

97. 97. The multispecific antibody or multispecific antigen-binding fragment of claim 96, wherein ABD2 and ABD3 bind to the capsid of an AAV particle and ABD1 binds to a molecule on the cell surface.

98. 97. The multispecific antibody or multispecific antigen-binding fragment of claim 96, wherein ABD1 and ABD2 bind to the capsid of an AAV particle and ABD3 binds to a molecule on the cell surface.

99. 99. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 95 to 98, wherein the scFv is linked to the first heavy chain region via a linker.

100. A multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, from N-terminal to C-terminal, (i) a first heavy chain region of a first Fab (“Fab1”) operably linked to (ii) an Fc domain, said Fc domain being operably linked to (iii) a second heavy chain region of a second Fab (“Fab2”); b) a second polypeptide chain comprising, in an N-terminal to C-terminal direction, an scFv comprising: (i) a first antigen binding domain (“ABD1”) operably linked to (ii) an Fc domain; c) a third polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1, wherein Fab1 comprises a second antigen-binding domain (“ABD2”); and d) a fourth polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form Fab2, wherein Fab2 comprises a third antigen-binding domain (“ABD3”); A multispecific antibody, or a multispecific antigen-binding fragment thereof, wherein at least one of ABD1, ABD2, and ABD3 binds to the capsid of an adeno-associated virus (AAV) particle, and one or more others of ABD1, ABD2, and ABD3 bind to a molecule on the cell surface.

101. The multispecific antibody or multispecific antigen-binding fragment of claim 100, wherein two of ABD1, ABD2, and ABD3 bind to the capsid of an AAV particle, and one of ABD1, ABD2, and ABD3 binds to a molecule on the cell surface.

102. 102. The multispecific antibody or multispecific antigen-binding fragment of claim 101, wherein ABD2 and ABD3 bind to the capsid of an AAV particle and ABD1 binds to a molecule on the cell surface.

103. The multispecific antibody or multispecific antigen-binding fragment of claim 101, wherein ABD1 and ABD2 bind to the capsid of an AAV particle and ABD3 binds to a molecule on the cell surface.

104. 104. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 100 to 103, wherein the second heavy chain region is linked to the Fc domain via a linker.

105. a) a first polypeptide chain comprising, from N-terminal to C-terminal, (i) a first heavy chain region of a first Fab ("Fab1") operably linked to (ii) a second heavy chain region of a second Fab ("Fab2"), said second heavy chain region being operably linked to (iii) a third heavy chain region of a third Fab ("Fab3"); b) a second polypeptide chain comprising a first light chain region that pairs with a first heavy chain region to form Fab1, wherein Fab1 comprises a first antigen-binding domain (“ABD1”); c) a third polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form Fab2, wherein Fab2 comprises a second antigen binding domain (“ABD2”); d) a fourth polypeptide chain comprising a fifth polypeptide chain comprising a third light chain that pairs with said third heavy chain region to form Fab3, wherein Fab3 comprises a third antigen-binding domain ("ABD3"), wherein at least one of ABD1, ABD2, and ABD3 binds to the capsid of an adeno-associated virus (AAV) particle, and one or more others of ABD1, ABD2, and ABD3 binds to a molecule on the surface of a cell.

106. The multispecific antibody or multispecific antigen-binding fragment of claim 105, wherein two of ABD1, ABD2, and ABD3 bind to the capsid of an AAV particle, and one of ABD1, ABD2, and ABD3 binds to a molecule on the cell surface.

107. 107. The multispecific antibody or multispecific antigen-binding fragment of claim 106, wherein ABD2 and ABD3 bind to the capsid of an AAV particle and ABD1 binds to a molecule on the cell surface.

108. The multispecific antibody or multispecific antigen-binding fragment of claim 106, wherein ABD1 and ABD3 bind to the capsid of an AAV particle and ABD2 binds to a molecule on the cell surface.

109. 109. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 105 to 108, wherein the first heavy chain region is operably linked to the second heavy chain region and / or the second heavy chain region is operably linked to the third heavy chain region via a linker.

110. At least one of ABD1, ABD2, and ABD3 that binds to the capsid of an AAV particle is a) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 2, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; b) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 22, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; c) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 32, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, d) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 42, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; e) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 52 or SEQ ID NO: 1159, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157; f) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 62, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; g) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 71; and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; h) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 81, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; i) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 91, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, and / or j) A multispecific antibody or multispecific antigen-binding fragment according to any one of claims 75 to 109, comprising a heavy chain variable region (HCVR) comprising HCDR1, HCDR2 and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 101, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2 and LCDR3 and comprising the amino acid sequence of SEQ ID NO:

10.

111. At least one of ABD1, ABD2, and ABD3 that binds to the capsid of an AAV particle is a) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 8, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; b) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 24, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 26, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 28, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; c) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 34, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 36, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 38, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; d) HCDR1 comprising the amino acid sequence of SEQ ID NO: 44, HCDR2 comprising the amino acid sequence of SEQ ID NO: 46, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 48, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; e) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 54, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; f) HCDR1 comprising the amino acid sequence of SEQ ID NO: 64, HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 67, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; g) HCDR1 comprising the amino acid sequence of SEQ ID NO: 73, HCDR2 comprising the amino acid sequence of SEQ ID NO: 75, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 77, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; h) HCDR1 comprising the amino acid sequence of SEQ ID NO: 83, HCDR2 comprising the amino acid sequence of SEQ ID NO: 85, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 87, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; i) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 93, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 95, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 97, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16, and / or j) A multispecific antibody or multispecific antigen-binding fragment according to claim 110, comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO: 103, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 105, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 107, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:

16.

112. At least one of ABD1, ABD2, and ABD3 that binds to the capsid of an AAV particle is a) an HCVR comprising the amino acid sequence of SEQ ID NO: 2 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; b) an HCVR comprising the amino acid sequence of SEQ ID NO: 22 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; c) an HCVR comprising the amino acid sequence of SEQ ID NO: 32 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; d) an HCVR comprising the amino acid sequence of SEQ ID NO: 42 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; e) an HCVR comprising the amino acid sequence of SEQ ID NO: 52 or SEQ ID NO: 1159, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157; f) an HCVR comprising the amino acid sequence of SEQ ID NO: 62 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; g) an HCVR comprising the amino acid sequence of SEQ ID NO: 71 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; h) an HCVR comprising the amino acid sequence of SEQ ID NO: 81 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; i) an HCVR comprising the amino acid sequence of SEQ ID NO: 91, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10, and / or j) A multispecific antibody or multispecific antigen-binding fragment according to claim 110 or 111, comprising an HCVR comprising the amino acid sequence of SEQ ID NO: 101 and / or an LCVR comprising the amino acid sequence of SEQ ID NO:

10.

113. 113. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 75 to 112, wherein the molecule on the cell surface is asialoglycoprotein receptor 1 (ASGR1), transferrin receptor (TfR), or calcium voltage-gated channel accessory subunit gamma 1 (CACNG1).

114. 114. The multispecific antibody or multispecific antigen-binding fragment of claim 113, wherein the molecule on the cell surface is ASGR1.

115. one or more others of ABD1, ABD2, and ABD3 that bind to ASGR1 are selected from a group consisting of: a) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO:220 or SEQ ID NO:1239, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO:10 or SEQ ID NO:1157; or b) a HCVR comprising HCDR1, HCDR2, and HCDR3 contained within a HCVR comprising the amino acid sequence of SEQ ID NO: 230, and / or a LCVR comprising LCDR1, LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO:

10.

116. One or more other of ABD1, ABD2, and ABD3 that bind to ASGR1 a) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 222, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 224, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 226, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16, or b) A multispecific antibody or multispecific antigen-binding fragment according to claim 114 or 115, comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO: 232, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 234, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 236, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:

16.

117. One or more other of ABD1, ABD2, and ABD3 that bind to ASGR1 a) an HCVR comprising the amino acid sequence of SEQ ID NO: 220 or SEQ ID NO: 1239, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157, or b) a HCVR comprising the amino acid sequence of SEQ ID NO: 230 and / or a LCVR comprising the amino acid sequence of SEQ ID NO:

10.

118. 114. The multispecific antibody or multispecific antigen-binding fragment of claim 113, wherein the molecule on the cell surface is TfR.

119. One or more other of ABD1, ABD2, and ABD3 that bind to TfR 1) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 270 or SEQ ID NO: 271, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 276; 2) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 281 or SEQ ID NO: 282, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 287; 3) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 292 or SEQ ID NO: 293, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 298; 4) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 303, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 308 or SEQ ID NO: 309; 5) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 314, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 319 or SEQ ID NO: 320; 6) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 325 or SEQ ID NO: 326, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 331 or SEQ ID NO: 332; 7) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 337 or SEQ ID NO: 338, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 343 or SEQ ID NO: 344; 8) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 349 or SEQ ID NO: 350, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 355 or SEQ ID NO: 356; 9) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 361, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 366; 10) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 371 or SEQ ID NO: 372, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 377; 11) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 382, ​​and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 387; 12) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 392 or SEQ ID NO: 393, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 398 or SEQ ID NO: 399; 13) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 404, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 409; 14) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 414, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 419; 15) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 424 or SEQ ID NO: 425, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 430 or SEQ ID NO: 431; 16) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 436, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 441; 17) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 446 or SEQ ID NO: 447, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 452; 18) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 457, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 462; 19) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 467 or SEQ ID NO: 468, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 473 or SEQ ID NO: 474; 20) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 479 or SEQ ID NO: 480, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 485; 21) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 490 or SEQ ID NO: 491, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 496; 22) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 501, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 506; 23) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 511, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 516; 24) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 521, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 526; 25) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 531, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 536; 26) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 541 or SEQ ID NO: 542, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 547; 27) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 552, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 557; 28) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 562, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 567; 29) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 572, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 577; 30) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 582, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 587; 31) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 592 or SEQ ID NO: 593, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 598 or SEQ ID NO: 599; 32) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 604, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 609 or SEQ ID NO: 610; or 33) The multispecific antibody or multispecific antigen-binding fragment of claim 118, comprising an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1119, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 1127.

120. One or more other of ABD1, ABD2, and ABD3 that bind to TfR 1) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 272, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 273, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 274, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 277, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 278, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 279; 2) HCDR1 comprising the amino acid sequence of SEQ ID NO: 283, HCDR2 comprising the amino acid sequence of SEQ ID NO: 284, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 285, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 288, LCDR2 comprising the amino acid sequence of SEQ ID NO: 289, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 290; 3) HCDR1 comprising the amino acid sequence of SEQ ID NO: 294, HCDR2 comprising the amino acid sequence of SEQ ID NO: 295, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 296, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 299, LCDR2 comprising the amino acid sequence of SEQ ID NO: 300, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 301; 4) HCDR1 comprising the amino acid sequence of SEQ ID NO: 304, HCDR2 comprising the amino acid sequence of SEQ ID NO: 305, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 306, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 310, LCDR2 comprising the amino acid sequence of SEQ ID NO: 311, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 312; 5) HCDR1 comprising the amino acid sequence of SEQ ID NO: 315, HCDR2 comprising the amino acid sequence of SEQ ID NO: 316, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 317, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 321, LCDR2 comprising the amino acid sequence of SEQ ID NO: 322, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 323; 6) HCDR1 comprising the amino acid sequence of SEQ ID NO: 327, HCDR2 comprising the amino acid sequence of SEQ ID NO: 328, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 329, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 333, LCDR2 comprising the amino acid sequence of SEQ ID NO: 334, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 335; 7) HCDR1 comprising the amino acid sequence of SEQ ID NO: 339, HCDR2 comprising the amino acid sequence of SEQ ID NO: 340, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 341, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 345, LCDR2 comprising the amino acid sequence of SEQ ID NO: 346, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 347; 8) HCDR1 comprising the amino acid sequence of SEQ ID NO: 351, HCDR2 comprising the amino acid sequence of SEQ ID NO: 352, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 353, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 357, LCDR2 comprising the amino acid sequence of SEQ ID NO: 358, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 359; 9) HCDR1 comprising the amino acid sequence of SEQ ID NO: 362, HCDR2 comprising the amino acid sequence of SEQ ID NO: 363, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 364, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 367, LCDR2 comprising the amino acid sequence of SEQ ID NO: 368, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 369; 10) HCDR1 comprising the amino acid sequence of SEQ ID NO: 373, HCDR2 comprising the amino acid sequence of SEQ ID NO: 374, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 375, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 378, LCDR2 comprising the amino acid sequence of SEQ ID NO: 379, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 380; 11) HCDR1 comprising the amino acid sequence of SEQ ID NO: 383, HCDR2 comprising the amino acid sequence of SEQ ID NO: 384, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 385, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 388, LCDR2 comprising the amino acid sequence of SEQ ID NO: 389, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 390; 12) HCDR1 comprising the amino acid sequence of SEQ ID NO: 394, HCDR2 comprising the amino acid sequence of SEQ ID NO: 395, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 396, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 400, LCDR2 comprising the amino acid sequence of SEQ ID NO: 401, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 402; 13) HCDR1 comprising the amino acid sequence of SEQ ID NO: 405, HCDR2 comprising the amino acid sequence of SEQ ID NO: 406, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 407, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 410, LCDR2 comprising the amino acid sequence of SEQ ID NO: 411, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 412; 14) HCDR1 comprising the amino acid sequence of SEQ ID NO: 415, HCDR2 comprising the amino acid sequence of SEQ ID NO: 416, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 417, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 420, LCDR2 comprising the amino acid sequence of SEQ ID NO: 421, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 422; 15) HCDR1 comprising the amino acid sequence of SEQ ID NO: 426, HCDR2 comprising the amino acid sequence of SEQ ID NO: 427, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 428, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 432, LCDR2 comprising the amino acid sequence of SEQ ID NO: 433, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 434; 16) HCDR1 comprising the amino acid sequence of SEQ ID NO: 437, HCDR2 comprising the amino acid sequence of SEQ ID NO: 438, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 439, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 442, LCDR2 comprising the amino acid sequence of SEQ ID NO: 443, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 444; 17) HCDR1 comprising the amino acid sequence of SEQ ID NO: 448, HCDR2 comprising the amino acid sequence of SEQ ID NO: 449, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 450, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 453, LCDR2 comprising the amino acid sequence of SEQ ID NO: 454, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 455; 18) HCDR1 comprising the amino acid sequence of SEQ ID NO: 458, HCDR2 comprising the amino acid sequence of SEQ ID NO: 459, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 460, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 463, LCDR2 comprising the amino acid sequence of SEQ ID NO: 464, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 465; 19) HCDR1 comprising the amino acid sequence of SEQ ID NO: 469, HCDR2 comprising the amino acid sequence of SEQ ID NO: 470, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 471, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 475, LCDR2 comprising the amino acid sequence of SEQ ID NO: 476, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 477; 20) HCDR1 comprising the amino acid sequence of SEQ ID NO: 481, HCDR2 comprising the amino acid sequence of SEQ ID NO: 482, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 483; and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 486, LCDR2 comprising the amino acid sequence of SEQ ID NO: 487, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 488; 21) HCDR1 comprising the amino acid sequence of SEQ ID NO: 492, HCDR2 comprising the amino acid sequence of SEQ ID NO: 493, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 494; and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 497, LCDR2 comprising the amino acid sequence of SEQ ID NO: 498, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 499; 22) HCDR1 comprising the amino acid sequence of SEQ ID NO: 502, HCDR2 comprising the amino acid sequence of SEQ ID NO: 503, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 504; and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 507, LCDR2 comprising the amino acid sequence of SEQ ID NO: 508, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 509; 23) HCDR1 comprising the amino acid sequence of SEQ ID NO: 512, HCDR2 comprising the amino acid sequence of SEQ ID NO: 513, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 514, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 517, LCDR2 comprising the amino acid sequence of SEQ ID NO: 518, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 519; 24) HCDR1 comprising the amino acid sequence of SEQ ID NO: 522, HCDR2 comprising the amino acid sequence of SEQ ID NO: 523, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 524; and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 527, LCDR2 comprising the amino acid sequence of SEQ ID NO: 528, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 529; 25) HCDR1 comprising the amino acid sequence of SEQ ID NO: 532, HCDR2 comprising the amino acid sequence of SEQ ID NO: 533, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 534, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 537, LCDR2 comprising the amino acid sequence of SEQ ID NO: 538, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 539; 26) HCDR1 comprising the amino acid sequence of SEQ ID NO: 543, HCDR2 comprising the amino acid sequence of SEQ ID NO: 544, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 545; and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 548, LCDR2 comprising the amino acid sequence of SEQ ID NO: 549, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 550; 27) HCDR1 comprising the amino acid sequence of SEQ ID NO: 553, HCDR2 comprising the amino acid sequence of SEQ ID NO: 554, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 555; and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 558, LCDR2 comprising the amino acid sequence of SEQ ID NO: 559, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 560; 28) HCDR1 comprising the amino acid sequence of SEQ ID NO: 563, HCDR2 comprising the amino acid sequence of SEQ ID NO: 564, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 565; and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 568, LCDR2 comprising the amino acid sequence of SEQ ID NO: 569, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 570; 29) HCDR1 comprising the amino acid sequence of SEQ ID NO: 573, HCDR2 comprising the amino acid sequence of SEQ ID NO: 574, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 575; and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 578, LCDR2 comprising the amino acid sequence of SEQ ID NO: 579, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 580; 30) HCDR1 comprising the amino acid sequence of SEQ ID NO: 583, HCDR2 comprising the amino acid sequence of SEQ ID NO: 584, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 585, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 588, LCDR2 comprising the amino acid sequence of SEQ ID NO: 589, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 590; 31) HCDR1 comprising the amino acid sequence of SEQ ID NO: 594, HCDR2 comprising the amino acid sequence of SEQ ID NO: 595, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 596, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 600, LCDR2 comprising the amino acid sequence of SEQ ID NO: 601, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 602; 32) HCDR1 comprising the amino acid sequence of SEQ ID NO: 605, HCDR2 comprising the amino acid sequence of SEQ ID NO: 606, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 607, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 611, LCDR2 comprising the amino acid sequence of SEQ ID NO: 612, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 613, or 33) The multispecific antibody or multispecific antigen-binding fragment of claim 118 or 119, comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO: 1121, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 1123, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 1125, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 1129, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 1131, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 1133.

121. One or more other of ABD1, ABD2, and ABD3 that bind to TfR 1) an HCVR comprising the amino acid sequence of SEQ ID NO: 270 or SEQ ID NO: 271, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 276; 2) an HCVR comprising the amino acid sequence of SEQ ID NO: 281 or SEQ ID NO: 282, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 287; 3) an HCVR comprising the amino acid sequence of SEQ ID NO: 292 or SEQ ID NO: 293, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 298; 4) an HCVR comprising the amino acid sequence of SEQ ID NO: 303, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 308 or SEQ ID NO: 309; 5) an HCVR comprising the amino acid sequence of SEQ ID NO: 314, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 319 or SEQ ID NO: 320; 6) an HCVR comprising the amino acid sequence of SEQ ID NO: 325 or SEQ ID NO: 326, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 331 or SEQ ID NO: 332; 7) HCVR comprising the amino acid sequence of SEQ ID NO: 337 or SEQ ID NO: 338, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 343 or SEQ ID NO: 344; 8) an HCVR comprising the amino acid sequence of SEQ ID NO: 349 or SEQ ID NO: 350, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 355 or SEQ ID NO: 356; 9) HCVR comprising the amino acid sequence of SEQ ID NO: 361 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 366; 10) HCVR comprising the amino acid sequence of SEQ ID NO: 371 or SEQ ID NO: 372, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 377; 11) HCVR comprising the amino acid sequence of SEQ ID NO: 382 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 387; 12) HCVR comprising the amino acid sequence of SEQ ID NO: 392 or SEQ ID NO: 393, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 398 or SEQ ID NO: 399; 13) HCVR comprising the amino acid sequence of SEQ ID NO: 404 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 409; 14) HCVR comprising the amino acid sequence of SEQ ID NO: 414 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 419; 15) HCVR comprising the amino acid sequence of SEQ ID NO: 424 or SEQ ID NO: 425, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 430 or SEQ ID NO: 431; 16) HCVR comprising the amino acid sequence of SEQ ID NO: 436 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 441; 17) HCVR comprising the amino acid sequence of SEQ ID NO: 446 or SEQ ID NO: 447, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 452; 18) HCVR comprising the amino acid sequence of SEQ ID NO: 457 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 462; 19) HCVR comprising the amino acid sequence of SEQ ID NO: 467 or SEQ ID NO: 468, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 473 or SEQ ID NO: 474; 20) HCVR comprising the amino acid sequence of SEQ ID NO: 479 or SEQ ID NO: 480, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 485; 21) HCVR comprising the amino acid sequence of SEQ ID NO: 490 or SEQ ID NO: 491, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 496; 22) HCVR comprising the amino acid sequence of SEQ ID NO: 501 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 506; 23) HCVR comprising the amino acid sequence of SEQ ID NO: 511 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 516; 24) HCVR comprising the amino acid sequence of SEQ ID NO: 521 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 526; 25) HCVR comprising the amino acid sequence of SEQ ID NO: 531 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 536; 26) HCVR comprising the amino acid sequence of SEQ ID NO: 541 or SEQ ID NO: 542, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 547; 27) HCVR comprising the amino acid sequence of SEQ ID NO: 552 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 557; 28) HCVR comprising the amino acid sequence of SEQ ID NO: 562 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 567; 29) HCVR comprising the amino acid sequence of SEQ ID NO: 572 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 577; 30) HCVR comprising the amino acid sequence of SEQ ID NO: 582 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 587; 31) HCVR comprising the amino acid sequence of SEQ ID NO: 592 or SEQ ID NO: 593, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 598 or SEQ ID NO: 599; 32) an HCVR comprising the amino acid sequence of SEQ ID NO: 604, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 609 or SEQ ID NO: 610; or 33) The multispecific antibody or multispecific antigen-binding fragment thereof according to any one of claims 118 to 120, comprising an HCVR comprising the amino acid sequence of SEQ ID NO: 1119 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 1127.

122. 114. The multispecific antibody or multispecific antigen-binding fragment of claim 113, wherein the molecule on the cell surface is CACNG1.

123. One or more other of ABD1, ABD2, and ABD3 that bind to CACNG1 1) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 615, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 623; 2) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 635, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 643; 3) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 655, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 663; 4) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 675, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 683; 5) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 695, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 703; 6) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 715, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 723; 7) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 735, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 743; 8) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 755, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 763; 9) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 775, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 783; 10) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 795, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 803; 11) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 815, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 823; 12) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 835, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 843; 13) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 855, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 863; 14) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 875, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 883; 15) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 895, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 903; 16) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 915, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 923; 17) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 935, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 943; 18) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 955, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 963; 19) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1181, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 1189; or 20) The multispecific antibody or multispecific antigen-binding fragment of claim 122, comprising an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1205, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 1213.

124. One or more other of ABD1, ABD2, and ABD3 that bind to CACNG1 1) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 617, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 619, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 621, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 625, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 627, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 629; 2) HCDR1 comprising the amino acid sequence of SEQ ID NO: 637, HCDR2 comprising the amino acid sequence of SEQ ID NO: 639, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 641, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 645, LCDR2 comprising the amino acid sequence of SEQ ID NO: 647, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 649; 3) HCDR1 comprising the amino acid sequence of SEQ ID NO: 657, HCDR2 comprising the amino acid sequence of SEQ ID NO: 659, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 661, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 665, LCDR2 comprising the amino acid sequence of SEQ ID NO: 667, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 669; 4) HCDR1 comprising the amino acid sequence of SEQ ID NO: 677, HCDR2 comprising the amino acid sequence of SEQ ID NO: 679, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 681, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 685, LCDR2 comprising the amino acid sequence of SEQ ID NO: 687, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 689; 5) HCDR1 comprising the amino acid sequence of SEQ ID NO: 697, HCDR2 comprising the amino acid sequence of SEQ ID NO: 699, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 701, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 705, LCDR2 comprising the amino acid sequence of SEQ ID NO: 707, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 709; 6) HCDR1 comprising the amino acid sequence of SEQ ID NO: 717, HCDR2 comprising the amino acid sequence of SEQ ID NO: 719, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 721, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 725, LCDR2 comprising the amino acid sequence of SEQ ID NO: 727, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 729; 7) HCDR1 comprising the amino acid sequence of SEQ ID NO: 737, HCDR2 comprising the amino acid sequence of SEQ ID NO: 739, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 741, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 745, LCDR2 comprising the amino acid sequence of SEQ ID NO: 747, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 749; 8) HCDR1 comprising the amino acid sequence of SEQ ID NO: 757, HCDR2 comprising the amino acid sequence of SEQ ID NO: 759, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 761, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 765, LCDR2 comprising the amino acid sequence of SEQ ID NO: 767, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 769; 9) HCDR1 comprising the amino acid sequence of SEQ ID NO: 777, HCDR2 comprising the amino acid sequence of SEQ ID NO: 779, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 781, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 785, LCDR2 comprising the amino acid sequence of SEQ ID NO: 787, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 789; 10) HCDR1 comprising the amino acid sequence of SEQ ID NO: 797, HCDR2 comprising the amino acid sequence of SEQ ID NO: 799, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 801, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 805, LCDR2 comprising the amino acid sequence of SEQ ID NO: 807, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 809; 11) HCDR1 comprising the amino acid sequence of SEQ ID NO: 817, HCDR2 comprising the amino acid sequence of SEQ ID NO: 819, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 821, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 825, LCDR2 comprising the amino acid sequence of SEQ ID NO: 827, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 829; 12) HCDR1 comprising the amino acid sequence of SEQ ID NO: 837, HCDR2 comprising the amino acid sequence of SEQ ID NO: 839, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 841, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 845, LCDR2 comprising the amino acid sequence of SEQ ID NO: 847, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 849; 13) HCDR1 comprising the amino acid sequence of SEQ ID NO: 857, HCDR2 comprising the amino acid sequence of SEQ ID NO: 859, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 861, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 865, LCDR2 comprising the amino acid sequence of SEQ ID NO: 867, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 869; 14) HCDR1 comprising the amino acid sequence of SEQ ID NO: 877, HCDR2 comprising the amino acid sequence of SEQ ID NO: 879, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 881, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 885, LCDR2 comprising the amino acid sequence of SEQ ID NO: 887, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 889; 15) HCDR1 comprising the amino acid sequence of SEQ ID NO: 897, HCDR2 comprising the amino acid sequence of SEQ ID NO: 899, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 901, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 905, LCDR2 comprising the amino acid sequence of SEQ ID NO: 907, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 909; 16) HCDR1 comprising the amino acid sequence of SEQ ID NO: 917, HCDR2 comprising the amino acid sequence of SEQ ID NO: 919, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 921, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 925, LCDR2 comprising the amino acid sequence of SEQ ID NO: 927, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 929; 17) HCDR1 comprising the amino acid sequence of SEQ ID NO: 937, HCDR2 comprising the amino acid sequence of SEQ ID NO: 939, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 941, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 945, LCDR2 comprising the amino acid sequence of SEQ ID NO: 947, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 949; 18) HCDR1 comprising the amino acid sequence of SEQ ID NO: 957, HCDR2 comprising the amino acid sequence of SEQ ID NO: 959, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 961, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 965, LCDR2 comprising the amino acid sequence of SEQ ID NO: 967, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 969; 19) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1183, HCDR2 comprising the amino acid sequence of SEQ ID NO: 1185, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 1187, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1191, LCDR2 comprising the amino acid sequence of SEQ ID NO: 1193, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 1195, or 20) The multispecific antibody or multispecific antigen-binding fragment of claim 122 or 123, comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO: 1207, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 1209, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 1211, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 1215, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 1217, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 1219.

125. One or more other of ABD1, ABD2, and ABD3 that bind to CACNG1 1) an HCVR comprising the amino acid sequence of SEQ ID NO: 615, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 623; 2) an HCVR comprising the amino acid sequence of SEQ ID NO: 635, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 643; 3) an HCVR comprising the amino acid sequence of SEQ ID NO: 655, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 663; 4) an HCVR comprising the amino acid sequence of SEQ ID NO: 675, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 683; 5) an HCVR comprising the amino acid sequence of SEQ ID NO: 695 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 703; 6) an HCVR comprising the amino acid sequence of SEQ ID NO: 715, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 723; 7) HCVR comprising the amino acid sequence of SEQ ID NO: 735, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 743; 8) HCVR comprising the amino acid sequence of SEQ ID NO: 755 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 763; 9) HCVR comprising the amino acid sequence of SEQ ID NO: 775 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 783; 10) HCVR comprising the amino acid sequence of SEQ ID NO: 795 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 803; 11) HCVR comprising the amino acid sequence of SEQ ID NO: 815 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 823; 12) HCVR comprising the amino acid sequence of SEQ ID NO: 835 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 843; 13) HCVR comprising the amino acid sequence of SEQ ID NO: 855 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 863; 14) HCVR comprising the amino acid sequence of SEQ ID NO: 875 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 883; 15) HCVR comprising the amino acid sequence of SEQ ID NO: 895 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 903; 16) HCVR comprising the amino acid sequence of SEQ ID NO: 915 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 923; 17) HCVR comprising the amino acid sequence of SEQ ID NO: 935 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 943; 18) HCVR comprising the amino acid sequence of SEQ ID NO: 955 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 963; 19) HCVR comprising the amino acid sequence of SEQ ID NO: 1181 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 1189; or 20) The multispecific antibody or multispecific antigen-binding fragment thereof according to any one of claims 122 to 124, comprising an HCVR comprising the amino acid sequence of SEQ ID NO: 1205 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 1213.

126. A multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, from N-terminal to C-terminal, (i) a first scFv comprising a first antigen binding domain (“ABD1”) operably linked to (ii) a first heavy chain region of a first Fab (“Fab1”), wherein said first heavy chain region of Fab1 is operably linked to (iii) an Fc domain; b) a second polypeptide chain comprising, in an N-terminal to C-terminal direction: (i) a second scFv comprising a second antigen binding domain (“ABD2”) operably linked to (ii) a second heavy chain region of a second Fab (“Fab2”), wherein said second heavy chain region of Fab2 is operably linked to (iii) an Fc domain; c) a third polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1, wherein Fab1 comprises a third antigen-binding domain ("ABD3"); and d) a fourth polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form Fab2, wherein Fab2 comprises a fourth antigen-binding domain ("ABD4"); wherein at least one of ABD1, ABD2, ABD3, and ABD4 binds to the capsid of an adeno-associated virus (AAV) particle, and one or more others of ABD1, ABD2, ABD3, and ABD4 bind to a molecule on the surface of a cell.

127. 127. The multispecific antibody or multispecific antigen-binding fragment of claim 126, wherein two of ABD1, ABD2, ABD3, and ABD4 bind to the capsid of an AAV particle, and two of ABD1, ABD2, ABD3, and ABD4 bind to a molecule on the cell surface.

128. The multispecific antibody or multispecific antigen-binding fragment of claim 127, wherein ABD1 and ABD2 bind to the capsid of an AAV particle, and ABD3 and ABD4 bind to a molecule on the cell surface.

129. 128. The multispecific antibody or multispecific antigen-binding fragment of claim 127, wherein ABD3 and ABD4 bind to the capsid of an AAV particle, and ABD1 and ABD2 bind to a molecule on the cell surface.

130. 130. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 126 to 129, wherein the first scFv is linked to the first heavy chain region and / or the second scFv is linked to the second heavy chain region via a linker.

131. A multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, from N-terminal to C-terminal, (i) a first heavy chain region of a first Fab (“Fab1”) operably linked to (ii) an Fc domain, said Fc domain being operably linked to a first scFv comprising (iii) a first antigen binding domain (“ABD1”); b) a second polypeptide chain comprising, in an N-terminal to C-terminal direction, (i) a second heavy chain region of a second Fab (“Fab2”) operably linked to (ii) an Fc domain, said Fc domain being operably linked to a second scFv comprising (iii) a second antigen binding domain (“ABD2”); c) a third polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1, wherein Fab1 comprises a third antigen-binding domain (“ABD3”); d) a fourth polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form Fab2, wherein Fab2 comprises a fourth antigen-binding domain ("ABD4"), wherein at least one of ABD1, ABD2, ABD3, and ABD4 binds to the capsid of an adeno-associated virus (AAV) particle, and one or more others of ABD1, ABD2, ABD3, and ABD4 bind to a molecule on the surface of a cell.

132. 132. The multispecific antibody or multispecific antigen-binding fragment of claim 131 , wherein two of ABD1, ABD2, ABD3, and ABD4 bind to the capsid of an AAV particle, and two of ABD1, ABD2, ABD3, and ABD4 bind to a molecule on the cell surface.

133. 133. The multispecific antibody or multispecific antigen-binding fragment of claim 132, wherein ABD1 and ABD2 bind to the capsid of an AAV particle, and ABD3 and ABD4 bind to a molecule on the cell surface.

134. 133. The multispecific antibody or multispecific antigen-binding fragment of claim 132, wherein ABD3 and ABD4 bind to the capsid of an AAV particle, and ABD1 and ABD2 bind to a molecule on the cell surface.

135. 135. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 131 to 134, wherein the first scFv and / or the second scFv is linked to the Fc domain via a linker.

136. A multispecific antibody, or a multispecific antigen-binding fragment thereof, comprising: a) a first polypeptide chain comprising, from N-terminal to C-terminal, (i) a first heavy chain region of a first Fab (“Fab1”), (ii) a first heavy chain region of a second Fab (“Fab2”), operably linked to (iii) an Fc domain; b) a second polypeptide chain operably linked, in the N-terminal to C-terminal direction, (i) a third heavy chain region of a third Fab (Tab3) to (ii) a fourth heavy chain region of a fourth Fab ("Fab4"), and (iii) an Fc domain; c) a third polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form Fab1, wherein Fab1 comprises a first antigen-binding domain (“ABD1”); d) a fourth polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form Fab2, wherein Fab2 comprises a second antigen binding domain (“ADB2”); e) a fifth polypeptide chain comprising a third light chain that pairs with the third heavy chain region to form Fab3, wherein Fab3 comprises a third antigen binding domain (“ABD3”); and f) A multispecific antibody, or multispecific antigen-binding fragment thereof, comprising a sixth polypeptide chain comprising a fourth light chain that pairs with the fourth heavy chain region to form Fab4, wherein Fab4 comprises a fourth antigen-binding domain ("ABD4"), wherein at least one of ABD1, ABD2, ABD3, and ABD4 binds to the capsid of an adeno-associated virus (AAV) particle, and one or more others of ABD1, ABD2, ABD3, and ABD4 bind to a molecule on the surface of a cell.

137. 137. The multispecific antibody or multispecific antigen-binding fragment of claim 136, wherein two of ABD1, ABD2, ABD3, and ABD4 bind to the capsid of an AAV particle, and two of ABD1, ABD2, ABD3, and ABD4 bind to a molecule on the cell surface.

138. The multispecific antibody or multispecific antigen-binding fragment of claim 137, wherein ABD1 and ABD3 bind to the capsid of an AAV particle, and ABD2 and ABD4 bind to a molecule on the cell surface.

139. The multispecific antibody or multispecific antigen-binding fragment of claim 137, wherein ABD2 and ABD4 bind to the capsid of an AAV particle, and ABD1 and ABD3 bind to a molecule on the cell surface.

140. 140. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 136 to 139, wherein the first heavy chain region is operably linked to the second heavy chain region and / or the third heavy chain region is operably linked to the fourth heavy chain region via a linker.

141. At least one of ABD1, ABD2, ABD3, and ABD4 that binds to the capsid of an AAV particle is a) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 2, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; b) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 22, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; c) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 32, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, d) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 42, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; e) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 52 or SEQ ID NO: 1159, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157; f) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 62, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; g) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 71; and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; h) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 81, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10; i) a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 91, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2, and LCDR3 and comprising the amino acid sequence of SEQ ID NO: 10, and / or j) A multispecific antibody or multispecific antigen-binding fragment according to any one of claims 126 to 140, comprising a heavy chain variable region (HCVR) comprising HCDR1, HCDR2 and HCDR3 and comprising the amino acid sequence of SEQ ID NO: 101, and / or a light chain variable region (LCVR) comprising LCDR1, LCDR2 and LCDR3 and comprising the amino acid sequence of SEQ ID NO:

10.

142. At least one of ABD1, ABD2, ABD3, and ABD4 that binds to the capsid of an AAV particle is a) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 8, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; b) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 24, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 26, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 28, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; c) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 34, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 36, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 38, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; d) HCDR1 comprising the amino acid sequence of SEQ ID NO: 44, HCDR2 comprising the amino acid sequence of SEQ ID NO: 46, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 48, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; e) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 54, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; f) HCDR1 comprising the amino acid sequence of SEQ ID NO: 64, HCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 67, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; g) HCDR1 comprising the amino acid sequence of SEQ ID NO: 73, HCDR2 comprising the amino acid sequence of SEQ ID NO: 75, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 77, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; h) HCDR1 comprising the amino acid sequence of SEQ ID NO: 83, HCDR2 comprising the amino acid sequence of SEQ ID NO: 85, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 87, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; i) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 93, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 95, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 97, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16, and / or j) A multispecific antibody or multispecific antigen-binding fragment according to claim 141, comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO: 103, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 105, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 107, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:

16.

143. At least one of ABD1, ABD2, ABD3, and ABD4 that binds to the capsid of an AAV particle is a) an HCVR comprising the amino acid sequence of SEQ ID NO: 2 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; b) an HCVR comprising the amino acid sequence of SEQ ID NO: 22 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; c) an HCVR comprising the amino acid sequence of SEQ ID NO: 32 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; d) an HCVR comprising the amino acid sequence of SEQ ID NO: 42 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; e) an HCVR comprising the amino acid sequence of SEQ ID NO: 52 or SEQ ID NO: 1159, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157; f) an HCVR comprising the amino acid sequence of SEQ ID NO: 62 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; g) an HCVR comprising the amino acid sequence of SEQ ID NO: 71 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; h) an HCVR comprising the amino acid sequence of SEQ ID NO: 81 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10; i) an HCVR comprising the amino acid sequence of SEQ ID NO: 91, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10, and / or j) A multispecific antibody or multispecific antigen-binding fragment according to claim 141 or 142, comprising an HCVR comprising the amino acid sequence of SEQ ID NO: 101 and / or an LCVR comprising the amino acid sequence of SEQ ID NO:

10.

144. 144. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 126 to 143, wherein the molecule on the cell surface is asialoglycoprotein receptor 1 (ASGR1), transferrin receptor (TfR), or calcium voltage-gated channel accessory subunit gamma 1 (CACNG1).

145. 145. The multispecific antibody or multispecific antigen-binding fragment of claim 144, wherein the molecule on the cell surface is ASGR1.

146. one or more other of ABD1, ABD2, ABD3, and ABD4 that bind to ASGR1; a) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 220 or SEQ ID NO: 1239, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157, or b) a HCVR comprising HCDR1, HCDR2, and HCDR3 contained within a HCVR comprising the amino acid sequence of SEQ ID NO: 230, and / or a LCVR comprising LCDR1, LCDR2, and LCDR3 contained within a LCVR comprising the amino acid sequence of SEQ ID NO:

10.

147. one or more others of ABD1, ABD2, ABD3, and ABD4 that bind to ASGR1; a) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 222, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 224, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 226, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16, or b) A multispecific antibody or multispecific antigen-binding fragment according to claim 145 or 146, comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO: 232, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 234, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 236, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:

16.

148. one or more others of ABD1, ABD2, ABD3, and ABD4 that bind to ASGR1; a) an HCVR comprising the amino acid sequence of SEQ ID NO: 220 or SEQ ID NO: 1239, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 1157, or b) a HCVR comprising the amino acid sequence of SEQ ID NO: 230 and / or a LCVR comprising the amino acid sequence of SEQ ID NO:

10.

149. 145. The multispecific antibody or multispecific antigen-binding fragment of claim 144, wherein the molecule on the cell surface is TfR.

150. One or more other of ABD1, ABD2, ABD3, and ABD4 that bind to TfR 1) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 270 or SEQ ID NO: 271, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 276; 2) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 281 or SEQ ID NO: 282, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 287; 3) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 292 or SEQ ID NO: 293, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 298; 4) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 303, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 308 or SEQ ID NO: 309; 5) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 314, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 319 or SEQ ID NO: 320; 6) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 325 or SEQ ID NO: 326, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 331 or SEQ ID NO: 332; 7) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 337 or SEQ ID NO: 338, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 343 or SEQ ID NO: 344; 8) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 349 or SEQ ID NO: 350, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 355 or SEQ ID NO: 356; 9) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 361, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 366; 10) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 371 or SEQ ID NO: 372, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 377; 11) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 382, ​​and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 387; 12) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 392 or SEQ ID NO: 393, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 398 or SEQ ID NO: 399; 13) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 404, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 409; 14) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 414, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 419; 15) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 424 or SEQ ID NO: 425, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 430 or SEQ ID NO: 431; 16) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 436, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 441; 17) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 446 or SEQ ID NO: 447, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 452; 18) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 457, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 462; 19) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 467 or SEQ ID NO: 468, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 473 or SEQ ID NO: 474; 20) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 479 or SEQ ID NO: 480, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 485; 21) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 490 or SEQ ID NO: 491, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 496; 22) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 501, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 506; 23) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 511, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 516; 24) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 521, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 526; 25) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 531, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 536; 26) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 541 or SEQ ID NO: 542, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 547; 27) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 552, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 557; 28) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 562, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 567; 29) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 572, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 577; 30) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 582, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 587; 31) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 592 or SEQ ID NO: 593, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 598 or SEQ ID NO: 599; 32) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 604, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 609 or SEQ ID NO: 610; or 33) The multispecific antibody or multispecific antigen-binding fragment of claim 149, comprising an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1119, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 1127.

151. One or more other of ABD1, ABD2, ABD3, and ABD4 that bind to TfR 1) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 272, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 273, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 274, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 277, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 278, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 279; 2) HCDR1 comprising the amino acid sequence of SEQ ID NO: 283, HCDR2 comprising the amino acid sequence of SEQ ID NO: 284, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 285, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 288, LCDR2 comprising the amino acid sequence of SEQ ID NO: 289, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 290; 3) HCDR1 comprising the amino acid sequence of SEQ ID NO: 294, HCDR2 comprising the amino acid sequence of SEQ ID NO: 295, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 296, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 299, LCDR2 comprising the amino acid sequence of SEQ ID NO: 300, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 301; 4) HCDR1 comprising the amino acid sequence of SEQ ID NO: 304, HCDR2 comprising the amino acid sequence of SEQ ID NO: 305, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 306, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 310, LCDR2 comprising the amino acid sequence of SEQ ID NO: 311, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 312; 5) HCDR1 comprising the amino acid sequence of SEQ ID NO: 315, HCDR2 comprising the amino acid sequence of SEQ ID NO: 316, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 317, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 321, LCDR2 comprising the amino acid sequence of SEQ ID NO: 322, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 323; 6) HCDR1 comprising the amino acid sequence of SEQ ID NO: 327, HCDR2 comprising the amino acid sequence of SEQ ID NO: 328, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 329, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 333, LCDR2 comprising the amino acid sequence of SEQ ID NO: 334, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 335; 7) HCDR1 comprising the amino acid sequence of SEQ ID NO: 339, HCDR2 comprising the amino acid sequence of SEQ ID NO: 340, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 341, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 345, LCDR2 comprising the amino acid sequence of SEQ ID NO: 346, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 347; 8) HCDR1 comprising the amino acid sequence of SEQ ID NO: 351, HCDR2 comprising the amino acid sequence of SEQ ID NO: 352, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 353, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 357, LCDR2 comprising the amino acid sequence of SEQ ID NO: 358, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 359; 9) HCDR1 comprising the amino acid sequence of SEQ ID NO: 362, HCDR2 comprising the amino acid sequence of SEQ ID NO: 363, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 364, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 367, LCDR2 comprising the amino acid sequence of SEQ ID NO: 368, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 369; 10) HCDR1 comprising the amino acid sequence of SEQ ID NO: 373, HCDR2 comprising the amino acid sequence of SEQ ID NO: 374, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 375, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 378, LCDR2 comprising the amino acid sequence of SEQ ID NO: 379, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 380; 11) HCDR1 comprising the amino acid sequence of SEQ ID NO: 383, HCDR2 comprising the amino acid sequence of SEQ ID NO: 384, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 385, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 388, LCDR2 comprising the amino acid sequence of SEQ ID NO: 389, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 390; 12) HCDR1 comprising the amino acid sequence of SEQ ID NO: 394, HCDR2 comprising the amino acid sequence of SEQ ID NO: 395, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 396, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 400, LCDR2 comprising the amino acid sequence of SEQ ID NO: 401, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 402; 13) HCDR1 comprising the amino acid sequence of SEQ ID NO: 405, HCDR2 comprising the amino acid sequence of SEQ ID NO: 406, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 407, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 410, LCDR2 comprising the amino acid sequence of SEQ ID NO: 411, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 412; 14) HCDR1 comprising the amino acid sequence of SEQ ID NO: 415, HCDR2 comprising the amino acid sequence of SEQ ID NO: 416, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 417, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 420, LCDR2 comprising the amino acid sequence of SEQ ID NO: 421, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 422; 15) HCDR1 comprising the amino acid sequence of SEQ ID NO: 426, HCDR2 comprising the amino acid sequence of SEQ ID NO: 427, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 428, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 432, LCDR2 comprising the amino acid sequence of SEQ ID NO: 433, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 434; 16) HCDR1 comprising the amino acid sequence of SEQ ID NO: 437, HCDR2 comprising the amino acid sequence of SEQ ID NO: 438, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 439, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 442, LCDR2 comprising the amino acid sequence of SEQ ID NO: 443, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 444; 17) HCDR1 comprising the amino acid sequence of SEQ ID NO: 448, HCDR2 comprising the amino acid sequence of SEQ ID NO: 449, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 450, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 453, LCDR2 comprising the amino acid sequence of SEQ ID NO: 454, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 455; 18) HCDR1 comprising the amino acid sequence of SEQ ID NO: 458, HCDR2 comprising the amino acid sequence of SEQ ID NO: 459, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 460, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 463, LCDR2 comprising the amino acid sequence of SEQ ID NO: 464, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 465; 19) HCDR1 comprising the amino acid sequence of SEQ ID NO: 469, HCDR2 comprising the amino acid sequence of SEQ ID NO: 470, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 471, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 475, LCDR2 comprising the amino acid sequence of SEQ ID NO: 476, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 477; 20) HCDR1 comprising the amino acid sequence of SEQ ID NO: 481, HCDR2 comprising the amino acid sequence of SEQ ID NO: 482, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 483; and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 486, LCDR2 comprising the amino acid sequence of SEQ ID NO: 487, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 488; 21) HCDR1 comprising the amino acid sequence of SEQ ID NO: 492, HCDR2 comprising the amino acid sequence of SEQ ID NO: 493, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 494; and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 497, LCDR2 comprising the amino acid sequence of SEQ ID NO: 498, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 499; 22) HCDR1 comprising the amino acid sequence of SEQ ID NO: 502, HCDR2 comprising the amino acid sequence of SEQ ID NO: 503, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 504; and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 507, LCDR2 comprising the amino acid sequence of SEQ ID NO: 508, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 509; 23) HCDR1 comprising the amino acid sequence of SEQ ID NO: 512, HCDR2 comprising the amino acid sequence of SEQ ID NO: 513, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 514, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 517, LCDR2 comprising the amino acid sequence of SEQ ID NO: 518, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 519; 24) HCDR1 comprising the amino acid sequence of SEQ ID NO: 522, HCDR2 comprising the amino acid sequence of SEQ ID NO: 523, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 524; and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 527, LCDR2 comprising the amino acid sequence of SEQ ID NO: 528, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 529; 25) HCDR1 comprising the amino acid sequence of SEQ ID NO: 532, HCDR2 comprising the amino acid sequence of SEQ ID NO: 533, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 534, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 537, LCDR2 comprising the amino acid sequence of SEQ ID NO: 538, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 539; 26) HCDR1 comprising the amino acid sequence of SEQ ID NO: 543, HCDR2 comprising the amino acid sequence of SEQ ID NO: 544, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 545; and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 548, LCDR2 comprising the amino acid sequence of SEQ ID NO: 549, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 550; 27) HCDR1 comprising the amino acid sequence of SEQ ID NO: 553, HCDR2 comprising the amino acid sequence of SEQ ID NO: 554, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 555; and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 558, LCDR2 comprising the amino acid sequence of SEQ ID NO: 559, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 560; 28) HCDR1 comprising the amino acid sequence of SEQ ID NO: 563, HCDR2 comprising the amino acid sequence of SEQ ID NO: 564, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 565; and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 568, LCDR2 comprising the amino acid sequence of SEQ ID NO: 569, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 570; 29) HCDR1 comprising the amino acid sequence of SEQ ID NO: 573, HCDR2 comprising the amino acid sequence of SEQ ID NO: 574, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 575; and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 578, LCDR2 comprising the amino acid sequence of SEQ ID NO: 579, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 580; 30) HCDR1 comprising the amino acid sequence of SEQ ID NO: 583, HCDR2 comprising the amino acid sequence of SEQ ID NO: 584, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 585, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 588, LCDR2 comprising the amino acid sequence of SEQ ID NO: 589, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 590; 31) HCDR1 comprising the amino acid sequence of SEQ ID NO: 594, HCDR2 comprising the amino acid sequence of SEQ ID NO: 595, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 596, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 600, LCDR2 comprising the amino acid sequence of SEQ ID NO: 601, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 602; 32) HCDR1 comprising the amino acid sequence of SEQ ID NO: 605, HCDR2 comprising the amino acid sequence of SEQ ID NO: 606, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 607, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 611, LCDR2 comprising the amino acid sequence of SEQ ID NO: 612, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 613, or 33) The multispecific antibody or multispecific antigen-binding fragment of claim 149 or 150, comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO: 1121, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 1123, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 1125, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 1129, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 1131, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 1133.

152. One or more other of ABD1, ABD2, ABD3, and ABD4 that bind to TfR 1) an HCVR comprising the amino acid sequence of SEQ ID NO: 270 or SEQ ID NO: 271, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 276; 2) an HCVR comprising the amino acid sequence of SEQ ID NO: 281 or SEQ ID NO: 282, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 287; 3) an HCVR comprising the amino acid sequence of SEQ ID NO: 292 or SEQ ID NO: 293, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 298; 4) an HCVR comprising the amino acid sequence of SEQ ID NO: 303, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 308 or SEQ ID NO: 309; 5) an HCVR comprising the amino acid sequence of SEQ ID NO: 314, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 319 or SEQ ID NO: 320; 6) an HCVR comprising the amino acid sequence of SEQ ID NO: 325 or SEQ ID NO: 326, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 331 or SEQ ID NO: 332; 7) HCVR comprising the amino acid sequence of SEQ ID NO: 337 or SEQ ID NO: 338, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 343 or SEQ ID NO: 344; 8) an HCVR comprising the amino acid sequence of SEQ ID NO: 349 or SEQ ID NO: 350, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 355 or SEQ ID NO: 356; 9) HCVR comprising the amino acid sequence of SEQ ID NO: 361 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 366; 10) HCVR comprising the amino acid sequence of SEQ ID NO: 371 or SEQ ID NO: 372, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 377; 11) HCVR comprising the amino acid sequence of SEQ ID NO: 382 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 387; 12) HCVR comprising the amino acid sequence of SEQ ID NO: 392 or SEQ ID NO: 393, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 398 or SEQ ID NO: 399; 13) HCVR comprising the amino acid sequence of SEQ ID NO: 404 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 409; 14) HCVR comprising the amino acid sequence of SEQ ID NO: 414 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 419; 15) HCVR comprising the amino acid sequence of SEQ ID NO: 424 or SEQ ID NO: 425, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 430 or SEQ ID NO: 431; 16) HCVR comprising the amino acid sequence of SEQ ID NO: 436 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 441; 17) HCVR comprising the amino acid sequence of SEQ ID NO: 446 or SEQ ID NO: 447, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 452; 18) HCVR comprising the amino acid sequence of SEQ ID NO: 457 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 462; 19) HCVR comprising the amino acid sequence of SEQ ID NO: 467 or SEQ ID NO: 468, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 473 or SEQ ID NO: 474; 20) HCVR comprising the amino acid sequence of SEQ ID NO: 479 or SEQ ID NO: 480, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 485; 21) HCVR comprising the amino acid sequence of SEQ ID NO: 490 or SEQ ID NO: 491, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 496; 22) HCVR comprising the amino acid sequence of SEQ ID NO: 501 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 506; 23) HCVR comprising the amino acid sequence of SEQ ID NO: 511 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 516; 24) HCVR comprising the amino acid sequence of SEQ ID NO: 521 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 526; 25) HCVR comprising the amino acid sequence of SEQ ID NO: 531 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 536; 26) HCVR comprising the amino acid sequence of SEQ ID NO: 541 or SEQ ID NO: 542, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 547; 27) HCVR comprising the amino acid sequence of SEQ ID NO: 552 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 557; 28) HCVR comprising the amino acid sequence of SEQ ID NO: 562 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 567; 29) HCVR comprising the amino acid sequence of SEQ ID NO: 572 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 577; 30) HCVR comprising the amino acid sequence of SEQ ID NO: 582 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 587; 31) HCVR comprising the amino acid sequence of SEQ ID NO: 592 or SEQ ID NO: 593, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 598 or SEQ ID NO: 599; 32) an HCVR comprising the amino acid sequence of SEQ ID NO: 604, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 609 or SEQ ID NO: 610; or 33) The multispecific antibody or multispecific antigen-binding fragment thereof according to any one of claims 149 to 151, comprising an HCVR comprising the amino acid sequence of SEQ ID NO: 1119 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 1127.

153. 145. The multispecific antibody or multispecific antigen-binding fragment of claim 144, wherein the molecule on the cell surface is CACNG1.

154. one or more others of ABD1, ABD2, ABD3, and ABD4 that bind to CACNG1; 1) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 615, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 623; 2) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 635, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 643; 3) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 655, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 663; 4) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 675, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 683; 5) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 695, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 703; 6) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 715, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 723; 7) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 735, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 743; 8) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 755, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 763; 9) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 775, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 783; 10) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 795, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 803; 11) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 815, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 823; 12) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 835, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 843; 13) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 855, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 863; 14) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 875, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 883; 15) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 895, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 903; 16) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 915, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 923; 17) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 935, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 943; 18) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 955, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 963; 19) an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1181, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 1189; or 20) The multispecific antibody or multispecific antigen-binding fragment of claim 153, comprising an HCVR comprising HCDR1, HCDR2, and HCDR3 contained within an HCVR comprising the amino acid sequence of SEQ ID NO: 1205, and / or an LCVR comprising LCDR1, LCDR2, and LCDR3 contained within an LCVR comprising the amino acid sequence of SEQ ID NO: 1213.

155. one or more others of ABD1, ABD2, ABD3, and ABD4 that bind to CACNG1; 1) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 617, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 619, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 621, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 625, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 627, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 629; 2) HCDR1 comprising the amino acid sequence of SEQ ID NO: 637, HCDR2 comprising the amino acid sequence of SEQ ID NO: 639, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 641, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 645, LCDR2 comprising the amino acid sequence of SEQ ID NO: 647, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 649; 3) HCDR1 comprising the amino acid sequence of SEQ ID NO: 657, HCDR2 comprising the amino acid sequence of SEQ ID NO: 659, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 661, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 665, LCDR2 comprising the amino acid sequence of SEQ ID NO: 667, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 669; 4) HCDR1 comprising the amino acid sequence of SEQ ID NO: 677, HCDR2 comprising the amino acid sequence of SEQ ID NO: 679, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 681, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 685, LCDR2 comprising the amino acid sequence of SEQ ID NO: 687, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 689; 5) HCDR1 comprising the amino acid sequence of SEQ ID NO: 697, HCDR2 comprising the amino acid sequence of SEQ ID NO: 699, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 701, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 705, LCDR2 comprising the amino acid sequence of SEQ ID NO: 707, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 709; 6) HCDR1 comprising the amino acid sequence of SEQ ID NO: 717, HCDR2 comprising the amino acid sequence of SEQ ID NO: 719, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 721, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 725, LCDR2 comprising the amino acid sequence of SEQ ID NO: 727, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 729; 7) HCDR1 comprising the amino acid sequence of SEQ ID NO: 737, HCDR2 comprising the amino acid sequence of SEQ ID NO: 739, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 741, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 745, LCDR2 comprising the amino acid sequence of SEQ ID NO: 747, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 749; 8) HCDR1 comprising the amino acid sequence of SEQ ID NO: 757, HCDR2 comprising the amino acid sequence of SEQ ID NO: 759, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 761, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 765, LCDR2 comprising the amino acid sequence of SEQ ID NO: 767, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 769; 9) HCDR1 comprising the amino acid sequence of SEQ ID NO: 777, HCDR2 comprising the amino acid sequence of SEQ ID NO: 779, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 781, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 785, LCDR2 comprising the amino acid sequence of SEQ ID NO: 787, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 789; 10) HCDR1 comprising the amino acid sequence of SEQ ID NO: 797, HCDR2 comprising the amino acid sequence of SEQ ID NO: 799, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 801, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 805, LCDR2 comprising the amino acid sequence of SEQ ID NO: 807, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 809; 11) HCDR1 comprising the amino acid sequence of SEQ ID NO: 817, HCDR2 comprising the amino acid sequence of SEQ ID NO: 819, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 821, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 825, LCDR2 comprising the amino acid sequence of SEQ ID NO: 827, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 829; 12) HCDR1 comprising the amino acid sequence of SEQ ID NO: 837, HCDR2 comprising the amino acid sequence of SEQ ID NO: 839, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 841, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 845, LCDR2 comprising the amino acid sequence of SEQ ID NO: 847, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 849; 13) HCDR1 comprising the amino acid sequence of SEQ ID NO: 857, HCDR2 comprising the amino acid sequence of SEQ ID NO: 859, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 861, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 865, LCDR2 comprising the amino acid sequence of SEQ ID NO: 867, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 869; 14) HCDR1 comprising the amino acid sequence of SEQ ID NO: 877, HCDR2 comprising the amino acid sequence of SEQ ID NO: 879, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 881, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 885, LCDR2 comprising the amino acid sequence of SEQ ID NO: 887, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 889; 15) HCDR1 comprising the amino acid sequence of SEQ ID NO: 897, HCDR2 comprising the amino acid sequence of SEQ ID NO: 899, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 901, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 905, LCDR2 comprising the amino acid sequence of SEQ ID NO: 907, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 909; 16) HCDR1 comprising the amino acid sequence of SEQ ID NO: 917, HCDR2 comprising the amino acid sequence of SEQ ID NO: 919, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 921, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 925, LCDR2 comprising the amino acid sequence of SEQ ID NO: 927, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 929; 17) HCDR1 comprising the amino acid sequence of SEQ ID NO: 937, HCDR2 comprising the amino acid sequence of SEQ ID NO: 939, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 941, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 945, LCDR2 comprising the amino acid sequence of SEQ ID NO: 947, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 949; 18) HCDR1 comprising the amino acid sequence of SEQ ID NO: 957, HCDR2 comprising the amino acid sequence of SEQ ID NO: 959, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 961, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 965, LCDR2 comprising the amino acid sequence of SEQ ID NO: 967, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 969; 19) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1183, HCDR2 comprising the amino acid sequence of SEQ ID NO: 1185, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 1187, and / or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1191, LCDR2 comprising the amino acid sequence of SEQ ID NO: 1193, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 1195, or 20) The multispecific antibody or multispecific antigen-binding fragment of claim 153 or 154, comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO: 1207, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 1209, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 1211, and / or an LCDR1 comprising the amino acid sequence of SEQ ID NO: 1215, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 1217, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 1219.

156. one or more others of ABD1, ABD2, ABD3, and ABD4 that bind to CACNG1; 1) an HCVR comprising the amino acid sequence of SEQ ID NO: 615, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 623; 2) an HCVR comprising the amino acid sequence of SEQ ID NO: 635, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 643; 3) an HCVR comprising the amino acid sequence of SEQ ID NO: 655, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 663; 4) an HCVR comprising the amino acid sequence of SEQ ID NO: 675, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 683; 5) an HCVR comprising the amino acid sequence of SEQ ID NO: 695 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 703; 6) an HCVR comprising the amino acid sequence of SEQ ID NO: 715, and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 723; 7) HCVR comprising the amino acid sequence of SEQ ID NO: 735, and / or LCVR comprising the amino acid sequence of SEQ ID NO: 743; 8) HCVR comprising the amino acid sequence of SEQ ID NO: 755 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 763; 9) HCVR comprising the amino acid sequence of SEQ ID NO: 775 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 783; 10) HCVR comprising the amino acid sequence of SEQ ID NO: 795 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 803; 11) HCVR comprising the amino acid sequence of SEQ ID NO: 815 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 823; 12) HCVR comprising the amino acid sequence of SEQ ID NO: 835 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 843; 13) HCVR comprising the amino acid sequence of SEQ ID NO: 855 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 863; 14) HCVR comprising the amino acid sequence of SEQ ID NO: 875 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 883; 15) HCVR comprising the amino acid sequence of SEQ ID NO: 895 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 903; 16) HCVR comprising the amino acid sequence of SEQ ID NO: 915 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 923; 17) HCVR comprising the amino acid sequence of SEQ ID NO: 935 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 943; 18) HCVR comprising the amino acid sequence of SEQ ID NO: 955 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 963; 19) HCVR comprising the amino acid sequence of SEQ ID NO: 1181 and / or LCVR comprising the amino acid sequence of SEQ ID NO: 1189; or 20) The multispecific antibody or multispecific antigen-binding fragment thereof according to any one of claims 153 to 155, comprising an HCVR comprising the amino acid sequence of SEQ ID NO: 1205 and / or an LCVR comprising the amino acid sequence of SEQ ID NO: 1213.

157. The linker is (a) at least 5 amino acids in length, at least 6 amino acids in length, or at least 7 amino acids in length, and optionally (b) the multispecific antibody or multispecific antigen-binding fragment of any one of claims 54, 58, 79, 84, 89, 94, 99, 104, 109, 130, 135, and 140, which is up to 30 amino acids in length, up to 40 amino acids in length, up to 50 amino acids in length, or up to 60 amino acids in length.

158. The linker is (a) 5 to 50 amino acids in length; (b) 5 to 45 amino acids in length; (c) 5 to 40 amino acids in length; (d) 5 to 35 amino acids in length; (e) 5 to 30 amino acids in length; (f) 5 to 25 amino acids in length, or (g) the multispecific antibody or multispecific antigen-binding fragment of claim 157, which is between 5 and 20 amino acids in length.

159. The linker is (a) a length of 6 to 50 amino acids; (b) 6 to 45 amino acids in length; (c) 6 to 40 amino acids in length; (d) 6 amino acids to 35 amino acids in length; (e) a length of 6 amino acids to 30 amino acids; (f) 6 to 25 amino acids in length, or (g) the multispecific antibody or multispecific antigen-binding fragment of claim 157, which is between 6 and 20 amino acids in length.

160. The linker is (a) 7 to 40 amino acids in length; (b) 7 to 35 amino acids in length; (c) 7 to 30 amino acids in length; (d) 7 to 25 amino acids in length; (e) the multispecific antibody or multispecific antigen-binding fragment of claim 157, which is between 7 and 20 amino acids in length.

161. 158. The multispecific antibody or multispecific antigen-binding fragment of claim 157, wherein the linker is between 5 and 25 amino acids in length.

162. 158. The multispecific antibody or multispecific antigen-binding fragment of claim 157, wherein the linker is between 10 and 60 amino acids in length.

163. 158. The multispecific antibody or multispecific antigen-binding fragment of claim 157, wherein the linker is between 20 and 50 amino acids in length.

164. 158. The multispecific antibody or multispecific antigen-binding fragment of claim 157, wherein the linker is 25 to 35 amino acids in length.

165. The linker is G ｎ S (SEQ ID NO: 239) or SG ｎ (SEQ ID NO: 240), wherein n is an integer between 1 and 10.

166. 166. The multispecific antibody or multispecific antigen-binding fragment of claim 165, wherein the linker is or comprises a multimer of G4S (SEQ ID NO: 242).

167. 165. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 157 to 164, wherein the linker is or comprises two consecutive glycines (2Gly), three consecutive glycines (3Gly), four consecutive glycines (4Gly (SEQ ID NO: 243)), five consecutive glycines (5Gly (SEQ ID NO: 244)), six consecutive glycines (6Gly (SEQ ID NO: 245)), seven consecutive glycines (7Gly (SEQ ID NO: 246)), eight consecutive glycines (8Gly (SEQ ID NO: 247)) or nine consecutive glycines (9Gly (SEQ ID NO: 248)).

168. 168. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 51 to 167, wherein one or more of the light chains is a universal light chain.

169. 168. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 51 to 167, wherein the light chain constant region (CL) and the first heavy chain constant region (CH1) of one or more Fabs are in a CrossmAb configuration.

170. 170. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 28 to 169, comprising an Fc heterodimer.

171. 171. The multispecific antibody or multispecific antigen-binding fragment of claim 170, wherein the Fc domain in the Fc heterodimer comprises a knob-in-hole mutation compared to the wild-type Fc domain.

172. 172. The multispecific antibody or multispecific antigen-binding fragment of claim 171, wherein one Fc domain in the Fc heterodimer comprises the amino acid substitutions S354C and T366W (according to EU numbering) compared to the wild-type Fc domain, and the other Fc domain in the Fc heterodimer comprises the amino acid substitutions Y349C, T366S, L368A, and Y407V (according to EU numbering) compared to the wild-type Fc domain.

173. 173. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 170 to 172, wherein at least one Fc domain in the Fc heterodimer comprises a star mutation compared to the wild-type Fc domain.

174. 174. The multispecific antibody or multispecific antigen-binding fragment of claim 173, wherein one Fc domain in the Fc heterodimer comprises the amino acid mutations H435R and / or Y436F (according to EU numbering) compared to the wild-type Fc domain.

175. 175. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 28 to 174, wherein the capsid comprises one or more wild-type AAV capsid polypeptides.

176. 175. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 28 to 174, wherein the capsid comprises one or more non-wild-type AAV capsid polypeptides.

177. 177. The multispecific antibody or multispecific antigen-binding fragment of any one of claims 28 to 176, which is a bispecific antibody or bispecific antigen-binding fragment thereof.

178. 178. A pharmaceutical composition comprising the multispecific antibody or multispecific antigen-binding fragment of any one of claims 28 to 177 and a pharmaceutically acceptable carrier or excipient.

179. A molecular complex comprising an AAV particle bound to one or more antibodies and / or antigen-binding fragments of any one of claims 1 to 26.

180. 180. The molecular complex of claim 179, wherein the AAV particle comprises one or more mutations in one or more AAV capsid proteins that inhibit the natural tropism of the AAV particle.

181. 181. A pharmaceutical composition comprising the molecular conjugate of claim 179 or 180 and a pharmaceutically acceptable carrier or excipient.

182. A method for preparing a molecular complex described in claim 179 or 180, comprising incubating the AAV particles in the presence of the one or more antibodies and / or antigen-binding fragments under conditions that allow specific binding of the one or more antibodies and / or antigen-binding fragments to the AAV particle capsid.

183. 178. A molecular complex comprising an AAV particle bound to one or more multispecific antibodies and / or multispecific antigen-binding fragments of any one of claims 28 to 177.

184. The molecular complex of claim 183, wherein the AAV particle comprises one or more mutations in one or more AAV capsid proteins that inhibit the natural tropism of the AAV particle.

185. 185. A pharmaceutical composition comprising the molecular conjugate of claim 183 or 184 and a pharmaceutically acceptable carrier or excipient.

186. 185. A method for preparing a molecular complex of claim 183 or 184, comprising incubating the AAV particles in the presence of the one or more multispecific antibodies and / or multispecific antigen-binding fragments under conditions that allow specific binding of the one or more multispecific antibodies and / or multispecific antigen-binding fragments to the AAV particle capsid.

187. 186. A method for targeting AAV particles to cells expressing a molecule on the cell surface, comprising contacting the cells with the molecular complex of claim 183 or the pharmaceutical composition of claim 185, wherein the molecular complex comprises one or more multispecific antibodies and / or multispecific antigen-binding fragments that bind to the molecule on the cell surface.

188. 186. A method for delivering a polynucleotide to a cell expressing a molecule on the cell surface, comprising contacting the cell with the molecular complex of claim 183 or the pharmaceutical composition of claim 185, wherein the molecular complex comprises AAV particles comprising the polynucleotide and bound to one or more multispecific antibodies and / or multispecific antigen-binding fragments that bind to the molecule on the cell surface.

189. The method of claim 187 or claim 188, wherein the cell is in a subject and the molecular complex is administered to the subject.

190. 190. The method of any one of claims 187 to 189, wherein the AAV particles do not target the cells in the absence of the one or more multispecific antibodies and / or multispecific antigen-binding fragments.

Images